Delivery Systems for Controlled Drug Release

Drug delivery systems with hydrazone, amide, and ester bonds provide controlled release of therapeutic agents, addressing stability and targeting issues in existing systems to enhance efficacy and reduce side effects.

JP7595098B2Active Publication Date: 2024-12-05ラドレックス コーポレイション
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2023004453
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2015-12-01
Filing Date
2023-01-16
Publication Date
2024-12-05
Estimated Expiration
2036-06-17

AI Technical Summary

Technical Problem

Existing drug delivery systems face challenges in achieving controlled release of therapeutic agents at target sites while minimizing systemic side effects, particularly for drugs with narrow therapeutic windows like cancer therapeutics, due to issues with stability and targeted drug release mechanisms.

Method used

The development of drug delivery systems incorporating hydrazone, amide, carbamate, and ester bonds that are cleaved enzymatically and/or hydrolytically to control the release of therapeutic agents, utilizing acidic environments and enzymatic processes for precise drug release.

Benefits of technology

This approach enables targeted and controlled release of therapeutic agents, enhancing efficacy at tumor sites while reducing systemic side effects by ensuring stability in the bloodstream and selective drug delivery.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

To provide a delivery system for controlled drug release. [Solution] The present invention provides compounds having the structure of Formula (I), or pharmaceutically acceptable salts, hydrates, solvates, or isomers thereof, for the controlled delivery and release of drugs. The present invention relates to drug delivery systems containing hydrazone moieties that are cleaved in a controlled manner in an acidic environment to provide controlled release of a therapeutic agent. The present invention relates to drug delivery systems containing amide, carbamate, and / or ester bonds that are cleaved enzymatically and / or hydrolytically, for example, by esterases or amidases, to provide controlled release of a therapeutic agent. TIFF2023052413000206.tif55128
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] Related Applications This application claims the benefit of and priority from U.S. Provisional Patent Application Nos. 62 / 182,219, filed June 19, 2015, 62 / 261,213, filed November 30, 2015, and 62 / 261,563, filed December 1, 2015. Each of the foregoing applications is incorporated herein by reference in its entirety. [Background technology]

[0002] 2. Background of the Invention Many drugs, especially cancer therapeutics, have a narrow therapeutic window and their side effects limit their beneficial effects. Systemic administration of such drugs often limits the therapeutic effect because the doses required to induce a stronger effect result in side effects that are not tolerated by the patient. This is especially crucial in the case of drugs with high potential cytotoxicity, such as cytostatic, virostatic or immunosuppressive agents. Numerous research efforts have examined the delivery of specific drugs at specific sites of action. Often this approach results in higher concentrations of the drug at the site of action than can be achieved by systemic administration, while limiting side effects.

[0003] Drug delivery in oncology is of particular interest due to the narrow therapeutic window of drugs used in such indications. Numerous research efforts have focused on conjugating anticancer drugs to a wide range of low and high molecular weight carriers, including sugars, growth factors, vitamins, peptides, antibodies, polysaccharides, lectins, serum proteins, and synthetic polymers. In most such drug delivery systems, the drug is attached to the carrier via a spacer that incorporates a predetermined cutoff point at which the attached drug can be released at the cellular target site. (Kratz et al., ChemMedChem, 3:20-53 (2008)). Conjugates are known in which cytostatic drugs are attached to serum proteins, primarily specific carrier molecules such as human serum albumin and human serum transferin, and then administered. In some cases, the conjugates contain a therapeutically active substance and, upon administration, transport the therapeutically active substance to the target site where it is released (U.S. Patent No. 7,387,771). In other cases, conjugates comprising a therapeutically active agent, a spacer molecule, and a protein-binding molecule that transports the therapeutically active agent to a target site where it is released, upon administration, covalently bind to circulating serum albumin (U.S. Pat. No. 7,387,771). In still other cases, antibody-drug conjugates (ADCs) can transport drugs to a target site for localized release (Kratz et al., ChemMedChem, 3:20-53 (2008); Panowski et al., mAbs, 6:34-45 (2014); Chari et al., J. Med. Chem. 2007, 14:111-112 (2013)). , Angewandte Chem. Int. Ed., Vol. 53, pp. 3796-3827 (2014)). However, when designing a drug delivery system, a proper balance should be struck to be able to controllably release the drug while preserving the targeting properties of the drug carrier. The drug delivery construct should have sufficient stability in the bloodstream and be able to effectively release the drug at the tumor site by enzymatic cleavage, reduction, or in a pH-dependent manner (Kratz et al., ChemMedChem, 3:20-53 (2008)). For example, gemcitabine (Gemzar®) is an anticancer nucleoside chemotherapeutic agent that is widely used to treat solid tumors. Unfortunately, its recommended dose of about 1000 mg / m 2 Approximately 90% of gemcitabine is inactivated by cytidine deaminase to inactive uridine metabolites and excreted in the urine. A further disadvantage that causes chemotherapy resistance is the low expression level of human equilibrative nucleoside transporter 1 (hENT1) on the cell surface of cancer cells, thus preventing substantial uptake of gemcitabine. Therefore, there remains a need for efficient drug delivery and release systems to achieve more effective controlled delivery and release of drugs. [Prior art documents] [Patent documents]

[0004] [Patent Document 1] U.S. Pat. No. 7,387,771 [Non-patent literature]

[0005] [Non-Patent Document 1] Kratz et al., ChemMedChem, 3:20-53 (2008) [Non-Patent Document 2] Panowski et al., mAbs, 6, 34-45 (2014) [Non-Patent Document 3] Chari et al., Angewandte Chem. Int. Ed., vol. 53, pp. 3796-3827 (2014) Summary of the Invention [Means for solving the problem]

[0006] Summary of the Invention The present invention provides a delivery system for the effective controlled delivery and release of therapeutic agents. The present invention relates to drug delivery systems that include hydrazone moieties that are cleaved in a controlled manner in an acidic environment to provide controlled release of a therapeutic agent. The present invention relates to drug delivery systems that include amide, carbamate, and / or ester bonds that are cleaved enzymatically and / or hydrolytically, e.g., by esterases or amidases, to provide controlled release of a therapeutic agent. In some embodiments, the present invention relates to drug delivery systems that include amide bonds that are cleaved enzymatically and / or hydrolytically, e.g., by esterases or amidases, to provide controlled release of a therapeutic agent. In other embodiments, the present invention relates to drug delivery systems that include carbamate bonds that are enzymatically and / or hydrolytically cleaved. In yet other embodiments, the present invention relates to drug delivery systems that include ester bonds that are enzymatically and / or hydrolytically cleaved.

[0007] The present invention relates to a drug delivery system comprising (i) a hydrazone moiety that is cleaved in a controlled manner in an acidic environment to provide controlled release of a therapeutic agent, and optionally (ii) an amide bond, a carbamate bond, and / or an ester bond that is cleaved enzymatically and / or hydrolytically, for example, by an esterase or an amidase to provide controlled release of a therapeutic agent. In some embodiments, the present invention relates to a drug delivery system comprising (i) a hydrazone moiety that is cleaved in a controlled manner in an acidic environment to provide controlled release of a therapeutic agent, and optionally (ii) an amide bond that is cleaved enzymatically and / or hydrolytically, for example, by an esterase or an amidase to provide controlled release of a therapeutic agent. In some embodiments, the present invention relates to a drug delivery system comprising (i) a hydrazone moiety that is cleaved in a controlled manner in an acidic environment to provide controlled release of a therapeutic agent, and optionally (ii) a carbamate bond that is cleaved enzymatically and / or hydrolytically, for example, by an esterase or an amidase to provide controlled release of a therapeutic agent. In some embodiments, the present invention relates to a drug delivery system comprising (i) a hydrazone moiety that is cleaved in a controlled manner in an acidic environment to provide controlled release of a therapeutic agent, and optionally (ii) an ester bond that is enzymatically and / or hydrolytically cleaved to provide controlled release of a therapeutic agent. In some embodiments, the present invention relates to a drug delivery system comprising (i) a hydrazone moiety that is cleaved in a controlled manner in an acidic environment to provide controlled release of a therapeutic agent, and optionally (ii) an amide bond that is selectively cleaved by carboxylesterase 1 and / or 2 to provide controlled release of a therapeutic agent. In some embodiments, the present invention relates to a drug delivery system comprising (i) a hydrazone moiety that is cleaved in a controlled manner in an acidic environment to provide controlled release of a therapeutic agent, and optionally (ii) an amide bond that is selectively cleaved by carboxylesterase 2 to provide controlled release of a therapeutic agent.

[0008] The present invention relates to a compound having a structure represented by formula (I): [ka] or a pharma- ceutically acceptable salt, hydrate, solvate or isomer thereof. [In the formula, Drugs include cytostatics, cytotoxics, cytokines, immunosuppressants, antirheumatics, anti-inflammatory drugs, antibiotics, analgesics, virostatics, anti-inflammatory drugs, antifungal (antimicotic) drugs, transcription factors, and the like. a ligand for a polypeptide, a polypeptide that is selected from the group consisting of a polypeptide that is a polypeptide of the present invention, a polypeptide that is a polypeptide of the present invention, a polypeptide that is a polypeptide of the present invention, a polypeptide that is a polypeptide of the present invention, a polypeptide that is a polypeptide of the present invention, a polypeptide that is a polypeptide of the present invention, The spacer is absent or [ka] and n is 0 or 1, X is an optionally substituted C1-C 18 Alkyl (C1-C 18 up to 6 carbon atoms of the alkyl are each independently replaced with -OCHCH-; optionally substituted C1-C 18 Alkyl-NH-C(O)-R-(the above C1 to C 18 up to 6 carbon atoms of the alkyl are each independently replaced with -OCHCH-; optionally substituted C1-C 18 Alkyl-C(O)-NH-R5-(C1 to C 18 optionally substituted aryl; optionally substituted heteroaryl; and optionally substituted cycloalkyl; R5 is selected from the group consisting of optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted cycloalkyl; Y is selected from the group consisting of absent or optionally substituted C1-C6 alkyl, -NH-C(O)-, -C(O)-NH-, -C(O)-O-, and -OC(O)-; R1 is absent or optionally substituted C1-C 18 Alkyl (C1-C 18 up to 6 carbon atoms of the alkyl are each independently replaced with -OCHCH-; optionally substituted C1-C 18 Alkyl-NH-C(O)R-(the above C1 to C 18 up to 6 carbon atoms of alkyl are each independently replaced with -OCHCH-; and optionally substituted C1-C 18 Alkyl-C(O)-NH-R5-(C1 to C 18 Optionally, alkyl up to 6 carbon atoms are each independently replaced with -OCHCH-; or R1 is a naturally occurring or non-naturally occurring amino acid; Or R1 is of the following formula: [ka] It has [ka] does not exist or [ka] is selected from the group consisting of R is [ka] (M1=Mg 2+ , 2Na + , 2K + , 2H + , 2NH4 + ),or [ka] (M2=Na + , K + , H + , NH4 + ) and R2 is -H, optionally substituted C1-C 12 selected from the group consisting of alkyl, optionally substituted aryl, and optionally substituted heteroaryl; Z1, Z2, Z3 and Z4 are each independently selected from the group consisting of -H, an electron-withdrawing group, and a water-soluble group; PBG is a protein binding group selected from the group consisting of an optionally substituted maleimide group, an optionally substituted haloacetamide group, an optionally substituted haloacetate group, an optionally substituted pyridylthio group, an optionally substituted isothiocyanate group, an optionally substituted vinylcarbonyl group, an optionally substituted aziridine group, an optionally substituted disulfide group, an optionally substituted acetylene group, an optionally substituted N-hydroxysuccinimide ester group, a derivatized antibody of an antibody or fragment thereof, and a derivatized fragment thereof; When the spacer is absent, the drug is linked to the nitrogen adjacent to the spacer by a double bond; At least one of Z1, Z2, Z3 and Z4 is an electron withdrawing group.

[0009] In some embodiments, PBG is an optionally substituted maleimide group, an optionally substituted haloacetamide group, an optionally substituted haloacetate group, an optionally substituted pyridylthio group, an optionally substituted isothiocyanate group, an optionally substituted vinylcarbonyl group, an optionally substituted aziridine group, an optionally substituted disulfide group, an optionally substituted acetylene group. and an optionally substituted N-hydroxysuccinimide ester group.

[0010] In some embodiments, PBG is associated with an antibody or a fragment thereof. In some embodiments, PBG is covalently bound to an antibody or a fragment thereof. In some embodiments, PBG is associated with albumin. In other embodiments, PBG is covalently bound to endogenous or exogenous albumin. In other embodiments, PBG is covalently bound to cysteine-34 of endogenous or exogenous albumin.

[0011] The present invention relates to a compound having a structure represented by formula (I): [ka] or a pharma- ceutically acceptable salt, hydrate, solvate or isomer thereof. [In the formula, the drug is selected from the group consisting of cytostatic agents, cytotoxic agents, cytokines, immunosuppressants, antirheumatic agents, anti-inflammatory agents, antibiotics, analgesics, virostatic agents, anti-inflammatory agents, antifungal agents, transcription factor inhibitors, cell cycle modulators, MDR modulators, proteasome or protease inhibitors, apoptosis modulators, enzyme inhibitors, signal transduction inhibitors, protease inhibitors, angiogenesis inhibitors, hormones or hormone derivatives, antibodies or fragments thereof, therapeutically or diagnostically active peptides, radioactive substances, luminescent substances, light absorbing substances, and derivatives of any of the foregoing; The spacer is absent or [ka] and n is 0 or 1, X is an optionally substituted C1-C 18 Alkyl (C1-C 18 up to 6 carbon atoms of the alkyl are each independently replaced with -OCHCH-; optionally substituted C1-C 18 Alkyl-NH-C(O)-R-(the above C1 to C 18up to 6 carbon atoms of the alkyl are each independently replaced with -OCHCH-; optionally substituted C1-C 18 Alkyl-C(O)-NH-R5-(C1 to C 18 optionally substituted aryl; optionally substituted heteroaryl; and optionally substituted cycloalkyl; R5 is selected from the group consisting of optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted cycloalkyl; Y is selected from the group consisting of absent or optionally substituted C1-C6 alkyl, -NH-C(O)-, -C(O)-NH-, -C(O)-O-, and -OC(O)-; R1 is absent or optionally substituted C1-C 18 Alkyl (C1-C 18 up to 6 carbon atoms of the alkyl are each independently replaced with -OCHCH-; optionally substituted C1-C 18 Alkyl-NH-C(O)R-(the above C1 to C 18 up to 6 carbon atoms of alkyl are each independently replaced with -OCHCH-; and optionally substituted C1-C 18 Alkyl-C(O)-NH-R5-(C1 to C 18 optionally up to 6 carbon atoms of alkyl are each independently replaced with -OCHCH-; R2 is -H, optionally substituted C1-C 12 selected from the group consisting of alkyl, optionally substituted aryl, and optionally substituted heteroaryl; Z1, Z2, Z3 and Z4 are each independently selected from the group consisting of -H or an electron withdrawing group; PBG is a protein binding group selected from the group consisting of optionally substituted maleimide groups, optionally substituted haloacetamide groups, optionally substituted haloacetate groups, optionally substituted pyridylthio groups, optionally substituted isothiocyanate groups, optionally substituted vinylcarbonyl groups, optionally substituted aziridine groups, optionally substituted disulfide groups, optionally substituted acetylene groups, optionally substituted N-hydroxysuccinimide ester groups, and antibodies or fragments thereof; When the spacer is absent, the drug is linked to the nitrogen adjacent to the spacer by a double bond; At least one of Z1, Z2, Z3 and Z4 is an electron withdrawing group.

[0012] In some embodiments, PBG is a protein binding group selected from the group consisting of an optionally substituted maleimide group, an optionally substituted haloacetamide group, an optionally substituted haloacetate group, an optionally substituted pyridylthio group, an optionally substituted isothiocyanate group, an optionally substituted vinylcarbonyl group, an optionally substituted aziridine group, an optionally substituted disulfide group, an optionally substituted acetylene group, and an optionally substituted N-hydroxysuccinimide ester group.

[0013] In some embodiments, PBG is associated with an antibody or a fragment thereof. In some embodiments, PBG is covalently bound to an antibody or a fragment thereof. In some embodiments, PBG is associated with albumin. In other embodiments, PBG is covalently bound to endogenous or exogenous albumin. In other embodiments, PBG is covalently bound to cysteine-34 of endogenous or exogenous albumin.

[0014] In certain embodiments, the present invention provides a compound represented by formula (II): [ka] or a pharma- ceutically acceptable salt, hydrate, solvate or isomer thereof. [wherein the drug, PBG, Y, R1, Z1, Z2, Z3 and Z4 are as defined for compounds of formula (I)].

[0015] In certain embodiments, the present invention provides a compound having a structure represented by formula (III): [ka] or a pharma- ceutically acceptable salt, hydrate, solvate or isomer thereof. wherein the drug, the spacer, PBG, Y, R1, Z2, Z3 and Z4 are as defined for compounds of formula (I); Z1 is an electron-withdrawing group.

[0016] In certain embodiments, the present invention provides a compound having a structure represented by formula (IV): [ka] or a pharma- ceutically acceptable salt, hydrate, solvate or isomer thereof. [In the formula, the drug, PBG, Y, R1, Z2, Z3 and Z4 are each independently selected from the group consisting of the compounds of formula (I). As defined, Z1 is an electron-withdrawing group.

[0017] In certain embodiments, the present invention provides a compound having a structure represented by formula (V): [ka] or a pharma- ceutically acceptable salt, hydrate, solvate or isomer thereof. [Wherein, drug, PBG, n, Y, R1, R 2、 Z1, Z2, Z3 and Z4 are as defined for compounds of formula (I).

[0018] In certain embodiments, the present invention provides a compound having a structure represented by formula (VI): [ka] or a pharma- ceutically acceptable salt, hydrate, solvate or isomer thereof. [In the formula, M is a pyrimidine or purine group containing at least one primary or secondary amino group and optionally containing one or more substituents selected from halogen; X1 and X2 are each independently selected from the group consisting of -H, -OH, C1-C6 alkyl, halogen, and -N3; X3 and X4 are each independently selected from the group consisting of absent, -H, -OH, C1-C6 alkyl, halogen, and -N3, wherever valence is possible; R' is -R3 or -CH2R3; R3 at each occurrence is independently selected from the group consisting of -OH, -CH3, -OP(O)(OH)2, -P(O)(OH)OP(O)(OH)2, -OP(O)(OH)OP(O)(OH)OP(O)(OH)2, -OP(O)(OH)(NH2), amino acids, acyl groups, and pharma- ceutically acceptable salts thereof, wherein the salts are selected from the group consisting of an alkali metal ion, an acyl group, and pharma- ceutically acceptable salts thereof. l ion), alkaline metal ion, ammonium, or alkyl-substituted ammonium ion; X, n, Z1, Z2, Z3, Z4, Y, R1, R2 and PBG are as defined for compounds of formula (V).

[0019] In certain embodiments, the present invention provides a compound having a structure represented by formula (VI): [ka] or a pharma- ceutically acceptable salt, hydrate, solvate or isomer thereof, wherein M is a pyrimidine or purine group containing at least one primary or secondary amino group; X1 and X2 are each independently selected from the group consisting of -H, -OH, C1-C6 alkyl, halogen, and -N3; X3 and X4 are each independently selected from the group consisting of absent, -H, -OH, C1-C6 alkyl, halogen, and -N3, wherever valence is possible; R3 is selected from -OH, -OP(O)(OH), -P(O)(OH)OP(O)(OH), -OP(O)(OH)OP(O)(OH)OP(O)(OH), -OP(O)(OH)(NH), amino acids, acyl groups, and pharma- ceutically acceptable salts thereof, the salts of which contain an alkali metal ion, an alkaline metal ion, ammonium, or an alkyl-substituted ammonium ion; X, n, Z1, Z2, Z3, Z4, Y, R1, R2 and PBG are as defined for compounds of formula (V).

[0020] In certain embodiments, the present invention provides a compound having a structure represented by formula (VII): [ka] or a pharma- ceutically acceptable salt, hydrate, solvate or isomer thereof. [wherein R' is -R3 or -CH2R3, and X, X1, X2, X3, X4, n, Y, R1, R2, R3, Z1, Z2, Z3, Z4 and PBG are as defined for compounds of formula (VI)].

[0021] In certain embodiments, the present invention provides a compound having a structure represented by formula (VII): [ka] or a pharma- ceutically acceptable salt, hydrate, solvate or isomer thereof. [wherein X, X1, X2, X3, X4, n, Y, R1, R2, R3, Z1, Z2, Z3, Z4 and PBG are as defined for compounds of formula (V)].

[0022] In certain embodiments, the present invention provides a compound having a structure represented by formula (VIII): [ka] or a pharma- ceutically acceptable salt, hydrate, solvate or isomer thereof, wherein Z1 is an electron withdrawing group; The drug, X, n, R2, PBG, Y, R1, Z2, Z3 and Z4 are as defined for compounds of formula (V).

[0023] In certain embodiments, the present invention provides a compound having a structure represented by formula (IX): [ka] or a pharma- ceutically acceptable salt, hydrate, solvate or isomer thereof. [In the formula, M is a pyrimidine or purine group containing at least one primary or secondary amino group and optionally containing one or more substituents selected from halogen; X1 and X2 are each independently selected from the group consisting of -H, -OH, C1-C6 alkyl, halogen, and -N3; X3 and X4 are each independently selected from the group consisting of absent, -H, -OH, C1-C6 alkyl, halogen, and -N3, wherever valence is possible; R' is -R3 or -CH2R3; R3, at each occurrence, is independently selected from the group consisting of -OH, -CH3, -OP(O)(OH)2, -P(O)(OH)OP(O)(OH)2, -OP(O)(OH)OP(O)(OH)OP(O)(OH)2, -OP(O)(OH)(NH2), an amino acid, an acyl group, and pharma- ceutically acceptable salts thereof, the salts of which contain an alkali metal ion, an alkaline metal ion, ammonium, or an alkyl substituted ammonium ion; X, n, Y, Z1, Z2, Z3, Z4, R1, R2 and PBG are as defined for compounds of formula (VIII).

[0024] In certain embodiments, the present invention provides a compound having a structure represented by formula (IX): [ka] or a pharma- ceutically acceptable salt, hydrate, solvate or isomer thereof, wherein M is a pyrimidine or purine group containing at least one primary or secondary amino group; X1 and X2 are each independently selected from the group consisting of -H, -OH, C1-C6 alkyl, halogen, and -N3; X3 and X4 are each independently selected from the group consisting of absent, -H, -OH, C1-C6 alkyl, halogen, and -N3, wherever valence is possible; R3 is selected from -OH, -OP(O)(OH), -P(O)(OH)OP(O)(OH), -OP(O)(OH)OP(O)(OH)OP(O)(OH), -OP(O)(OH)(NH), amino acids, acyl groups, and pharma- ceutically acceptable salts thereof, the salts of which contain an alkali metal ion, an alkaline metal ion, ammonium, or an alkyl-substituted ammonium ion; X, n, Y, Z1, Z2, Z3, Z4, R1, R2 and PBG are as defined for compounds of formula (VIII).

[0025] In some embodiments, X1, X2, X3, and X4 are each independently selected from the group consisting of -H, -OH, -CH3, -F, -Cl, -Br, -I, and -N3.

[0026] In certain embodiments, the present invention provides a compound having a structure represented by formula (X): [ka] or a pharma- ceutically acceptable salt, hydrate, solvate or isomer thereof. [wherein R' is -R3 or -CH2R3, and X1, X2, X3, X4, R3, X, n, Y, Z1, Z2, Z3, Z4, R1 and R2 are as defined for compounds of formula (IX)].

[0027] In certain embodiments, the present invention provides a compound having a structure represented by formula (X): [ka] or a pharma- ceutically acceptable salt, hydrate, solvate or isomer thereof. [wherein X1, X2, X3, X4, R3, X, n, Y, Z1, Z2, Z3, Z4, R1 and R2 are as defined for compounds of formula (IX)].

[0028] In some embodiments, the agent is an N-nitrosourea; doxorubicin, 2-pyrrole pyrrolinoanthracycline, morpholinoanthracycline, diacetoxyalkyl anthracycline, Lacycline (diacetatoxyalkylanthracycline), daunorubicin, epirubicin, Darubicin, nemorubicin, PNU-159682, mitoxantrone; amethanthrone; chlorambucil, bendamustine, melphalan, oxazaphosphorine; 5-fluorouracil, 5'-deoxy-5-fluorocytidine, 2'-deoxy-5-fluoridine, cytarabine, cladribine, fludarabine, pentostatin, gemcitabine, 4-amino-1-(((2S,3R ,4S,5R)-3,4-dihydroxy-5-methyltetrahydrofuran-2-yl)methyl)-5-fluoropyrimidin-2(1H)-one, thioguanine; methotrexate, raltitrexed, pemetrexed, previtrexed; paclitaxel, docetaxel; topotecan, irinotecan, SN-38, 10-hydroxycamptothecin, GG211, lurtotecan, 9- Aminocamptothecin, camptothecin, 7-formylcamptothecin, 7-acetylcamptothecin, 9-formylcamptothecin, 9-acetylcamptothecin, 9-formyl-10-hydroxycamptothecin, 10-formylcamptothecin, 10-acetylcamptothecin, 7-butyl-10-aminocamptothecin, 7-butyl-9-amino-10,11-methylenedioxocamptothecin; vinblastine, vincristine, vindesine, vinorelbine; calicheamicin; maytansine, maytansinol; auristatins (auristatin D, auristatin E, auristatin F, monomethylauristatin D, monomethylauristatin E, monomethylauristatin F, monomethylauristatin F methyl ester, auristatin PYE auristatin PHE, the related natural product dolastatin 10, and derivatives thereof; amatoxins, including, but not limited to, α-amanitin, β-amanitin, γ-amanitin, ε-amanitin, amanin, amaninamide, amanulin, and amanullinic acid and derivatives thereof; including but not limited to); duocarmycin A, duocarmycin B1, duocarmycin B2, duocarmycin C, duocarmycin SA, CC1065, adozelesin, bizelesin, carzelesin; eribulin; trabectedin; pyrrolobenzodiazepines, anthramycin, tomaycin, sibiromycin, DC-81, DSB-120; epothilones; bleomycin; dactinomycin; plicamycin, mitomycin C, and cis-configured platinum(II) complexes; or derivatives of any of the foregoing. is selected from the group consisting of:

[0029] In some embodiments, the agent is N-nitrosoureas; doxorubicin, 2-pyrrolepyrrolinoanthracyclines, morpholinoanthracyclines, diacetoxyalkylanthracyclines, daunorubicin, epirubicin, idarubicin, nemorubicin, PNU-159682, mitoxantrone; amethanthrone; chlorambucil, bendamustine, melphalan, oxazaphosphorines; 5-fluorouracil, 2'-deoxy-5-fluoridine, cytarabine, cladribine, fludarabine, pentostatin, gemcitabine, 4-amino-1-(((2S,3R,4S,5R)-3,4-dihydroxy-5-methyltetrahydrofuran-2-yl)methyl)-5-fluoropyrimidin-2(1H)-one, thioguanine; methotrexate, raltitrexed, pemetrexed, previtrexed; paclitaxel, docetaxel; topotecan, irinotecan, SN-38, 10-hydroxycamptothecin, GG211, lurtotecan, 9-aminocamptothecin, camptothecin, 7-formylcamptothecin, 9-formylcamptothecin, 9-formyl-10-hydroxycamptothecin, 7-butyl-10-aminocamptothecin, 7-butyl-9-amino-10,11,-methylenedioxocamptothecin; vinblastine, vincristine, vindesine, vinorelbine; calicheamicin; maytansinoids; auristatins; epothilones; bleomycin, dactinomycin, plicamycin, mitomycin C, and cis-configured platinum(II) complexes; or derivatives of any of the foregoing.

[0030] In some embodiments, Z1, Z2, Z3, and Z4 are each independently -H, halogen, In some embodiments, Z1, Z2, Z3, and Z4 are each independently selected from the group consisting of -H, -Cl, -Br, -I, -F, -C(O)OH, -NO2, -CF3, and -CN. In some embodiments, Z1, Z2, Z3, and Z4 are each independently selected from the group consisting of -H, -Cl, -F, -NO2, and -CF3. In some embodiments, Z1, Z2, Z3, and Z4 are each independently selected from the group consisting of -OP(O)(OH), -P(O)(OH)OP(O)(OH), -OP(O)(OH)OP(O)(OH)OP(O)(OH), -OP(O)(OH)(NH), -P(O)(OH), -SO3H, and pharma- ceutically acceptable salts thereof. In some embodiments, at least one of Z1, Z2, Z3, and Z4 is not -H.

[0031] In some embodiments, Z1, Z2, Z3, and Z4 are each independently selected from the group consisting of -H, halogen, -C(O)OH, -C(O)O-C1-C6 alkyl, -NO2, haloalkyl, -S(O)2-C1-C6 alkyl, and -CN. In some embodiments, Z1, Z2, Z3, and Z4 are each independently selected from the group consisting of -H, -Cl, -Br, -I, -F, -C(O)OH, -NO2, -CF3, and -CN. In some embodiments, Z1, Z2, Z3, and Z4 are each independently selected from the group consisting of -H, -Cl, -F, -NO2, and -CF3. In some embodiments, at least one of Z1, Z2, Z3, and Z4 is not -H.

[0032] In some embodiments, Z1 is selected from the group consisting of halogen, -C(O)OH, -C(O)O-C1-C6 alkyl, -NO2, haloalkyl, -S(O)2-C1-C6 alkyl, and -CN, and Z2, Z3, and Z4 are each independently selected from the group consisting of -H, halogen, -C(O)OH, -C(O)O-C1-C6 alkyl, -NO2, haloalkyl, -S(O)2-C1-C6 alkyl, and -CN. In some embodiments, Z1 is selected from the group consisting of -Cl, -Br, -I, -F, -C(O)OH, -NO2, -CF3, and -CN, and Z2, Z3, and Z4 are each independently selected from the group consisting of -H, -Cl, -Br, -I, -F, -C(O)OH, -NO2, -CF3, and -CN. In some embodiments, Z1 is selected from the group consisting of -Cl, -F, and -NO2, and Z2, Z3, and Z4 are each independently selected from the group consisting of -H, -Cl, -F, -NO2, and -CF3.

[0033] In some embodiments, the compounds of the present invention [ka] The part is [ka] is selected from the group consisting of:

[0034] In some embodiments, the compounds of the present invention [ka] The part is [ka] is selected from the group consisting of:

[0035] In some embodiments, Y is -C(O)-NH-. In some embodiments, Y is -C(O)-O-. In some embodiments, Y is absent.

[0036] In some embodiments, R1 is an optionally substituted C1-C 18 Alkyl (C1-C 18 up to 6 carbon atoms of the alkyl are each independently replaced with -OCHCH-; optionally substituted C1-C 18 Alkyl-NH-C(O)-R-(the above C1 to C 18 up to 6 carbon atoms of alkyl are each independently replaced with -OCHCH-; and optionally substituted C1-C 18 Alkyl-C(O)-NH-R5-(C1 to C 18 Optionally up to 6 carbon atoms of alkyl are each independently replaced with -OCH2CH2-.

[0037] In some embodiments, R is [ka] is selected from the group consisting of:

[0038] In some embodiments, R1 is absent.

[0039] In some embodiments, PBG is an optionally substituted maleimide group. In some embodiments, PBG is [ka] It is.

[0040] In some embodiments, the compounds of the present invention [ka] The part is [ka] [ka] [ka] [ka] is selected from the group consisting of:

[0041] In some embodiments, the spacer is [ka] where n is 0 or 1 and X is an optionally substituted C1-C 18 Alkyl (C1-C 18 optionally substituted aryl; optionally substituted heteroaryl; and optionally substituted cycloalkyl, wherein R2 is as defined for formula I.

[0042] In some embodiments, the spacer is [ka] where R2 is -H, optionally substituted C1-C 12alkyl, optionally substituted aryl, and optionally substituted heteroaryl, and W1, W2, W3, and W4 are each independently selected from the group consisting of -H, halogen, -C(O)OH, -C(O)O-C1-C6 alkyl, -NO2, haloalkyl, -S(O)2-C1-C6 alkyl, and -CN. In some embodiments, W1, W2, W3, and W4 are each independently selected from the group consisting of -H, -Cl, -Br, -I, -F, -C(O)OH, -NO2, -CF3, and -CN. In some embodiments, W1, W2, W3, and W4 are each independently selected from the group consisting of -H, -Cl, -F, -NO2, and -CF3. In some embodiments, W1, W2, W3, and W4 are each independently selected from the group consisting of a phenoxy group, a primary, secondary, or tertiary amine group, an ether group, a phenol group, an amide group, an ester group, an alkyl group, a substituted alkyl group, a phenyl group, and a vinyl group. In some embodiments, W1, W2, W3, and W4 are each independently selected from the group consisting of -OP(O)(OH), -P(O)(OH)OP(O)(OH), -OP(O)(OH)OP(O)(OH), -OP(O)(OH)(NH), -P(O)(OH), -SOH, and pharma- ceutically acceptable salts thereof. In some embodiments, at least one of W1, W2, W3, and W4 is not -H.

[0043] In some embodiments, W1 is selected from the group consisting of halogen, -C(O)OH, -C(O)O-C1-C6 alkyl, -NO2, haloalkyl, -S(O)2-C1-C6 alkyl, and -CN, and W2, W3, and W4 are each independently selected from the group consisting of -H, halogen, -C(O)OH, -C(O)O-C1-C6 alkyl, -NO2, haloalkyl, -S(O)2-C1-C6 alkyl, and -CN. In some embodiments, W1 is selected from the group consisting of -Cl, -Br, -I, -F, -C(O)OH, -NO2, -CF3, and -CN, and W2, W3, and W4 are each independently selected from the group consisting of -H, -Cl, -Br, -I, -F, -C(O)OH, -NO2, -CF3, and -CN. In some embodiments, W1 is selected from the group consisting of -Cl, -F, and -NO2. and Z2, Z3 and Z4 are each independently selected from the group consisting of -H, -Cl, -F, -NO2, and -CF3.

[0044] In some embodiments, the spacer is [ka] where R2 is -H, optionally substituted C1-C 12 It is selected from the group consisting of alkyl, optionally substituted aryl, and optionally substituted heteroaryl.

[0045] In some embodiments, the spacer is [ka] It is.

[0046] In some embodiments, the spacer is [ka] and m is 1, 2, 3, 4, 5, or 6.

[0047] In some embodiments, the spacer is [ka] It is.

[0048] In some embodiments, the compounds of the invention are [ka] [ka] or a pharma- ceutically acceptable salt, hydrate, solvate or isomer thereof. [In the formula, SG= [ka] and [ka] does not exist or [ka] is selected from the group consisting of R is [ka] (M1=Mg 2+ , 2Na + , 2K + , 2H + , 2NH4 + , Na + , K + , NH4 + and / or H + ),or [ka] (M2=Na + , K + , H + , and / or NH4 + ) [is].

[0049] In some embodiments, the compounds of the invention are [ka] [ka] [ka] [ka] [ka] [ka] [ka] or a pharma- ceutically acceptable salt, hydrate, solvate or isomer thereof.

[0050] In some embodiments, the agent is α-amanitin and the compound of the invention is [ka] [ka] or a pharma- ceutically acceptable salt, hydrate, solvate or isomer thereof.

[0051] In some embodiments, the drug is an auristatin or a derivative thereof, and the compound of the invention is [ka] [ka] or a pharma- ceutically acceptable salt, hydrate, solvate or isomer thereof. will be done.

[0052] In certain embodiments, the present invention provides a pharmaceutical composition comprising a compound disclosed herein and a pharma- ceutically acceptable carrier.

[0053] In certain embodiments, the present invention provides a method of treating a disease or condition selected from the group consisting of cancer, a viral disease, an autoimmune disease, an acute or chronic inflammatory disease, and a disease caused by a bacteria, fungus or other microorganism, comprising administering to a patient in need thereof a therapeutically effective amount of a compound described herein or a pharmaceutical composition described herein.

[0054] In some embodiments, the present invention provides compounds and compositions for use as pharmaceuticals. In some embodiments, the present invention provides compounds and compositions for use in treating a disease or condition selected from the group consisting of cancer, viral diseases, autoimmune diseases, acute or chronic inflammatory diseases, and diseases caused by bacteria, fungi or other microorganisms.

[0055] In some embodiments, the compounds disclosed herein can be used in the manufacture or preparation of a medicament for the treatment of a disease or condition selected from the group consisting of cancer, a viral disease, an autoimmune disease, an acute or chronic inflammatory disease, and a disease caused by a bacteria, fungus or other microorganism. [Brief description of the drawings]

[0056] [Figure 1] FIG. 1 shows the effect of compound 15 and gemcitabine on tumor growth in the NSLC xenograft model LXFE397.

[0057] [Diagram 2] FIG. 2 shows the effect of compound 15 and gemcitabine on tumor growth in the NSLC xenograft model LXFE397.

[0058] [Diagram 3]FIG. 3 shows the effect of compound 15 and gemcitabine on body weight change in the human non-small cell carcinoma xenograft model LXFE937.

[0059] [Figure 4] FIG. 4 shows the effect of compound 15 and gemcitabine on tumor growth in an ovarian cancer OVXF899 xenograft model.

[0060] [Diagram 5] FIG. 5 shows the effect of compound 15 and gemcitabine on body weight change in a human ovarian cancer OVXF899 xenograft model.

[0061] [Figure 6] Figures 6(A) and 6(B) are scatter plots of individual tumor volumes following treatment with compound 15 or gemcitabine in an ovarian cancer OVXF899 xenograft model. Figure 6(A) shows the absolute tumor volume on day 0, and Figure 6(B) shows the absolute tumor volume on day 67.

[0062] [Figure 7] FIG. 7 shows the effect of compound 15 and gemcitabine on tumor growth in a pancreatic cancer Panc11159 xenograft model.

[0063] [Figure 8] FIG. 8 shows the effect of compound 15 and gemcitabine on body weight change in a pancreatic cancer Panc11159 xenograft model. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0064] Detailed Description of the Invention Unless otherwise defined herein, scientific and technical terms used in this application have the meanings commonly understood by those of ordinary skill in the art. In general, the nomenclature used in connection with, and techniques of, chemistry, molecular biology, cell and cancer biology, immunology, microbiology, pharmacology, and protein and nucleic acid chemistry described herein are those well known and commonly used in the art.

[0065] All publications, patents and published patent applications mentioned in this application are specifically incorporated herein by reference.In the event of any discrepancy, this specification, including the specific definitions herein, shall prevail.Unless otherwise specified, it should be understood that each embodiment of the present invention can be used alone or in combination with any one or more other embodiments of the present invention.

[0066] Throughout this specification, the term "comprise" or variations such as "comprises" or "comprising" are understood to mean the inclusion of a stated integer (or component) or group of integers (or components), but not the exclusion of any other integer (or component) or group of integers (or components).

[0067] Throughout this application, when a compound or composition is described as having, including, or comprising certain components, it is also contemplated that such compound or composition can consist essentially of or consist of the recited components. Similarly, when a method or process is described as having, including, or comprising certain process steps, the process can also consist essentially of or consist of the recited process steps. Furthermore, the order of steps or the order for performing certain actions is not critical so long as the compounds, compositions, and methods described herein remain operable. Furthermore, two or more steps or actions can be performed simultaneously.

[0068] The singular forms "a," "an," and "the" include plurals unless the context clearly dictates otherwise.

[0069] The term "including" is used to mean "including but not limited to." "Including" and "including but not limited to" are used interchangeably.

[0070] The term "or," as used herein, should be understood to mean "and / or" unless context clearly indicates otherwise.

[0071] The terms "drug", "pharmaceutical agent", "therapeutic agent" or "therapeutically active substance" are used to mean any compound that produces a pharmacological effect by itself or following its transformation in the organism in question, and thus also includes derivatives resulting from these transformations. The pharmacological effect of the drug of the composition according to the invention may be only a single effect, e.g. a cytostatic effect, or a broad pharmacological action, e.g. a simultaneous immunosuppressive effect and an anti-inflammatory effect.

[0072] The term "anthracycline" refers to a class of antineoplastic antibiotics that have an anthracenedione (also called anthraquinone or dioxoanthracene) structural unit. For example, the term "anthracycline" specifically refers to doxorubicin, daunorubicin, epirubicin, idarubicin, nemorubicin, valrubicin, pirarubicin, zorubicin, zolbizin ... The anthracyclines are intended to individually include cyclosporine, aclarubicin, 2-pyrrolepyrrolinoanthracyclines, morpholinoanthracyclines, diacetoxyalkylanthracyclines, PNU-159682, carminomycin, mitoxantrone, and amethantrone.

[0073] The terms "patient", "subject" or "individual" are used interchangeably and refer to either a human or a non-human animal. These terms include mammals, such as humans, primates, livestock animals (e.g., cows, pigs), companion animals (e.g., dogs, cats) and rodents (e.g., mice and rats). In certain embodiments, the patient or subject is a human patient or subject, e.g., a human patient having a condition requiring treatment.

[0074] The term "pharmaceutical composition" refers to a composition suitable for pharmaceutical use in animal subjects, including humans and mammals, for example in combination with one or more pharma- ceutically acceptable carriers, excipients, or solvents. Such compositions may also contain excipients, fillers, salts, buffers, stabilizers, solubilizers, and other materials known in the art. In certain embodiments, pharmaceutical compositions include compositions that contain active ingredient(s) and inactive ingredient(s) that make up the excipients, carriers, or excipients, as well as any product that results directly or indirectly from the combination, complexation, or aggregation of any two or more of the ingredients, or from the dissociation of one or more of the ingredients, or from one or more other types of reaction or interaction of the ingredients. Thus, pharmaceutical compositions of the present disclosure include any composition created by mixing a compound of the present disclosure and one or more pharma- ceutically acceptable excipient(s), carrier(s), and / or excipient(s).

[0075] The term "pharmaceutically acceptable carrier" refers to a non-toxic carrier that can be administered to a patient together with a therapeutically effective substance of the present invention and does not destroy the pharmaceutical activity of the agent. The term "additive" refers to an additional substance in a formulation or composition that is not a pharmaceutically active ingredient. In certain embodiments, a "pharmaceutically acceptable" substance is suitable for use in contact with an animal or human cell, tissue, or organ without undue toxicity, irritation, allergic response, immunogenicity, or other adverse reaction, in an amount that is used in a dosage form according to an administration schedule and that is consistent with a reasonable benefit-to-loss ratio. In certain embodiments, a "pharmaceutically acceptable" substance that is a component of a pharmaceutical composition is also compatible with the other component(s) of the composition. In certain embodiments, the terms "pharmaceutically acceptable additive", "pharmaceutically acceptable carrier" and "pharmaceutically acceptable excipient" include pharmaceutically acceptable inactive ingredients, materials, compositions, and vehicles, such as, but not limited to, liquid fillers, solid fillers, excipients, excipients, carriers, solvents, and encapsulating materials. Carriers, excipients, and additives also include all pharma- ceutically acceptable dispersion media, coatings, buffers, isotonic agents, stabilizers, absorption delaying agents, antimicrobial agents, antibacterial agents, antifungal agents, adjuvants, and the like. Except insofar as any conventional additive, carrier, or excipient is incompatible with the active ingredient, the present disclosure encompasses the use of conventional additives, carriers, and excipients in pharmaceutical compositions. See, e.g., Remington: The Science and Practice of Pharmacy, 21st ed., Lippincott Williams & Wilkins (Philadelphia, Pennsylvania, 2005); Handbook of Pharmaceutical Excipients, Vol. 5th ed., Rowe et al., The Pharmaceutical Press and the American Pharmaceutical Association (2005); Handbook of Pharmaceutical Additives, 3rd ed., Ash and Ash, eds., Gower Publishing Co. (2007); and Pharmaceutical Preformulation and Formulation, Gibson, ed., CRC Press LLC (Boca Raton, Florida, 2004).

[0076] The term "pharmacologically effective amount," "therapeutically effective amount," or "therapeutically effective dose" refers to an amount effective to treat a disease in a patient, e.g., an amount effective to effect a beneficial and / or desired change in the overall health of a patient suffering from a disease (e.g., cancer), treating, curing, inhibiting, ameliorating, etc., a physiological response or condition. A full therapeutic effect may not necessarily be achieved by administration of a single dose. It may not occur at all, but only after a series of doses have been administered. Thus, a therapeutically effective amount may be administered in one or multiple doses. The exact effective amount required for a subject will depend, for example, on the size, health and age of the subject, the nature and extent of the disease, the treatment or combination of treatments selected for administration, and the mode of administration. Those skilled in the art can easily determine the effective amount for a given situation by routine experimentation. Those skilled in the art will recognize that cancer treatment includes, but is not limited to, killing cancer cells, preventing the growth of new cancer cells, causing tumor regression (reducing tumor size), causing a reduction in metastasis, improving the patient's vital functions, improving the patient's well-being, reducing pain, improving appetite, improving the patient's weight, and any combination thereof. The term "pharmaceutical effective amount", "therapeutically effective amount" or "therapeutically effective dose" refers to the amount required to improve the patient's clinical symptoms. The methods of cancer treatment or treatment described herein should not be construed as a "cure" of cancer or otherwise limited to a "cure" of cancer.

[0077] As used herein, the term "treat" or "treatment" includes reversing, reducing, or arresting symptoms, clinical signs, and underlying pathology of a condition in a manner that improves or stabilizes the subject's condition. As used herein, and as is well understood in the art, "treatment" is an approach to obtain beneficial or desired results, including clinical results. Beneficial or desired clinical results may include, but are not limited to, alleviation, amelioration, or slowing of progression of one or more symptoms or conditions associated with a condition (e.g., cancer), whether detectable or undetectable, reduction in the extent of disease, stabilization (i.e., not worsening) of disease, delay or slowing of disease progression, amelioration or palliation of disease symptoms, and remission (whether partial or total). "Treatment" may also mean prolonging survival compared to the expected survival in the absence of treatment. Exemplary beneficial clinical results are described herein.

[0078] "Administering" a substance, compound, or agent to a subject or "administration" of them to a subject can be performed using one of a variety of methods known to those skilled in the art. For example, a compound or agent can be administered intravenously, intraarterially, intradermally, intramuscularly, intraperitoneally, subcutaneously, ocularly, sublingually, orally (by ingestion), intranasally (by inhalation), intraspinally, intracerebrally, and transdermally (by absorption, e.g., through a skin tract). A compound or agent can also be suitably introduced by a rechargeable or biodegradable polymeric device, or other device, such as a patch and pump, or a formulation that provides an extended, slow or controlled release of the compound or agent. Administration can also be performed, for example, once, multiple times, and / or over one or more extended periods of time. In some embodiments, administration includes both direct administration, including self-administration, and indirect administration, including the act of prescribing a drug. For example, as used herein, a physician who instructs a patient to self-administer a drug or to have a drug administered by another person and / or by a person who provides the patient with a drug prescription is considered to administer the drug to the patient. When a method is part of a therapeutic regimen involving more than one drug or treatment modality, the present disclosure contemplates that the drugs can be administered at the same or different times and by the same or different administration routes.The appropriate method of administering a substance, compound or drug to a subject depends on, for example, the age of the subject, whether the subject is active or inactive at the time of administration, whether the subject has cognitive impairment at the time of administration, the degree of functional impairment, and the chemical and biological properties (e.g., solubility, digestibility, bioavailability, stability and toxicity) of the compound or drug.

[0079] The term "substituted" refers to moieties having substituents replacing a hydrogen on one or more carbons of the compound backbone. "Substituted" or "substituted with" refers to any substitution that is in accordance with the available valence of the substituted atom and the substituent, and that the substitution may result in, for example, a rearrangement, a ring structure, or the like. It is understood that the implicit condition is that the resulting compound is stable and not spontaneously transformed by addition, elimination, or the like. As used herein, the term "substituted" includes all permissible substituents of organic compounds. In one broad aspect, the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and nonaromatic substituents of organic compounds. The permissible substituents can be one or more and the same or different for appropriate organic compounds. For purposes of this invention, heteroatoms such as nitrogen can have hydrogen substituents and / or any permissible substituents of organic compounds described herein that satisfy the valence of the heteroatom. Substituents can include any of the substituents described herein, such as halogen, hydroxyl, carbonyl (e.g., carboxyl, alkoxycarbonyl, formyl, or acyl), thiocarbonyl (e.g., thioester, thioacetate, or thioformate), alkoxyl, alkylthio, acyloxy, phosphoryl, phosphate, phosphonate, amino, amido, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamide, sulfonyl, heterocyclyl, aralkyl, or an aromatic or heteroaromatic moiety.

[0080] "Optional" or "optionally" means that the situation described below may or may not occur, and thus the application includes cases where the situation occurs and where it does not occur. For example, the phrase "optionally substituted" means that a non-hydrogen substituent may or may not be present on a given atom, and thus the application includes structures where the non-hydrogen substituent is present and structures where the non-hydrogen substituent is not present.

[0081] Unless specifically stated as "unsubstituted," references to chemical moieties herein are understood to include substituted variants. For example, references to an "alkyl" group or moiety implicitly include both substituted and unsubstituted variants. Examples of substituents on a chemical moiety include, but are not limited to, halogen, hydroxyl, carbonyl (e.g., carboxyl, alkoxycarbonyl, formyl, or acyl), thiocarbonyl (e.g., thioester, thioacetate, or thioformate), alkoxyl, alkylthio, acyloxy, phosphoryl, phosphate, phosphonate, amino, amido, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamide, sulfonyl, heterocyclyl, aralkyl, or aryl or heteroaryl moieties.

[0082] The term "acyl" is art-recognized and refers to a group represented by the general formula hydrocarbyl-C(O)-, preferably alkyl-C(O)-.

[0083] The term "alkyl" refers to the radical of a saturated aliphatic group, including straight-chain and branched-chain alkyl groups. In preferred embodiments, a straight-chain or branched-chain alkyl has 30 or fewer carbon atoms in its backbone (e.g., C1-C for straight chain). 30 , C3~C for branched chains 30 ), more preferably 20 or fewer carbon atoms. In certain embodiments, the alkyl group is a lower alkyl group, such as methyl, ethyl, n-propyl, i-propyl, n-butyl, and n-pentyl. Furthermore, the term "alkyl" as used throughout the specification, examples, and claims is intended to include both "unsubstituted alkyl" and "substituted alkyl," the latter of which refers to alkyl moieties having substituents replacing a hydrogen on one or more carbons of the hydrocarbon backbone. In certain embodiments, a straight or branched chain alkyl has 30 or fewer carbon atoms in its backbone (e.g., C1-C4 for straight chain). 30 , C3~C for branched chains 30In a preferred embodiment, the chain has 10 or fewer carbons (C1 to C 10 ) atoms. In other embodiments, the chain has six or fewer carbon (C1-C6) atoms in its backbone.

[0084] Such substituents can include, for example, halogen, hydroxyl, carbonyl (e.g., carboxyl, alkoxycarbonyl, formyl, or acyl), thiocarbonyl (e.g., thioester, thioacetate, or thioformate), alkoxyl, alkylthio, acyloxy, phosphoryl, phosphate, phosphonate, amino, amido, amidine, imine, cyano, nitro, azido, sulfhydryl, alkylthio, sulfate, sulfonate, sulfamoyl, sulfonamide, sulfonyl, heterocyclyl, aralkyl, or aryl or heteroaryl moieties.

[0085] The term "amide" as used herein means [ka] In the formula, R X and R Y each independently represents hydrogen or a hydrocarbyl group, or R X and R Y together with the N atom to which they are attached complete a heterocycle having 4 to 8 atoms in the ring structure.

[0086] In some embodiments, the amide is -NH-C(O)- or -C(O)-NH-.

[0087] The terms "amine" and "amino" are art-recognized and refer to unsubstituted and substituted amines and their salts, e.g., [ka] wherein R X , R Y , and RZ each independently represents hydrogen or a hydrocarbyl group, or R X and R Y together with the N atom to which they are attached complete a heterocycle having 4 to 8 atoms in the ring structure.

[0088] The term "aryl" as used herein includes substituted or unsubstituted monocyclic aromatic groups in which each atom of the ring is carbon. Preferably, the ring is a 5-7 membered ring, more preferably a 6 membered ring. Aryl groups include phenyl, phenol, aniline, and the like. The term "aryl" also includes "polycyclyl", "polycyclic", and "polycyclic" ring systems having two or more rings, in which two or more atoms are common to two adjacent rings, e.g., the rings are "fused rings" in which at least one of the rings is aromatic, e.g., the other cyclic rings can be cycloalkyl, cycloalkenyl, cycloalkynyl, aryl. In some preferred embodiments, the polycyclic ring has two to three rings. In certain preferred embodiments, the polycyclic ring system has a bicyclic ring in which both rings are aromatic. Each of the rings of the polycyclic ring can be substituted or unsubstituted. In certain embodiments, each ring of the polycyclic ring contains 3 to 10 atoms in the ring, preferably 5 to 7 atoms. For example, aryl groups include, but are not limited to, phenyl, tolyl, anthracenyl, fluorenyl, indenyl, azulenyl, and naphthyl, as well as benzo-fused carbocyclic moieties such as 5,6,7,8-tetrahydronaphthyl, and the like.

[0089] In some embodiments, an aryl is a monocyclic aromatic group. In some embodiments, an aryl is a bicyclic aromatic group. In some embodiments, an aryl is a tricyclic aromatic group.

[0090] The term "cycloalkyl," as used herein, refers to the radical of a saturated aliphatic ring. In preferred embodiments, cycloalkyls have from 3-10 carbon atoms in their ring structure, and more preferably have 5-7 carbon atoms in the ring structure. In some embodiments, bicyclic rings can have two or more atoms in common, e.g., the rings are "fused rings." Suitable cycloalkyls include cycloheptyl, cyclohexyl, cyclopentyl, cyclobutyl, and cyclopropyl.

[0091] In some embodiments, a cycloalkyl is a monocyclic group. In some embodiments, a cycloalkyl is a bicyclic group. In some embodiments, a cycloalkyl is a tricyclic group.

[0092] The term "haloalkyl" as used herein refers to an alkyl group substituted with one or more halogens. When more than one halogen is present, the halogens may be the same or different. For example, haloalkyl groups include, but are not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, chlorodifluoromethyl, 2,2,2-trifluoroethyl, pentafluoroethyl, and the like.

[0093] The terms "halo" and "halogen" as used herein mean halogen, which includes chloro, fluoro, bromo, and iodo.

[0094] The term "heteroaryl" includes substituted or unsubstituted aromatic monocyclic ring structures, preferably 5-7 membered rings, more preferably 5-6 membered rings, whose ring structures contain at least one heteroatom (e.g., O, N, or S), preferably 1-4 or 1-3 heteroatoms, more preferably 1 or 2 heteroatoms. When two or more heteroatoms are present in a heteroaryl ring, they may be the same or different. The term "heteroaryl" also includes "polycyclyl", "polycyclic", and "polycyclic" ring systems having two or more cyclic rings, where two or more carbons are common to two adjacent rings, e.g., the rings are "fused rings" where at least one of the rings is heteroaromatic, e.g., the other cyclic rings may be cycloalkyl, cycloalkenyl, cycloalkynyl, aryl, heteroaryl, and / or heterocyclyl. In some preferred embodiments, preferred polycycles have 2-3 rings. In certain embodiments, preferred polycyclic ring systems have bicyclic rings in which both rings are aromatic. In certain embodiments, each ring of the polycyclic ring contains 3 to 10 atoms in the ring, preferably 5 to 7 atoms. For example, heteroaryl groups include, but are not limited to, pyrrole, furan, thiophene, imidazole, oxazole, thiazole, pyrazole, pyridine, pyrazine, pyridazine, quinoline, pyrimidine, indolizine, indole, indazole, benzimidazole, benzothiazole, benzofuran, benzothiophene, cinnoline, phthalazine, quinazoline, carbazole, phenoxazine, quinoline, purine, and the like.

[0095] In some embodiments, the heteroaryl is a monocyclic aromatic group. In some embodiments, the heteroaryl is a bicyclic aromatic group. In some embodiments, the heteroaryl is a tricyclic aromatic group.

[0096] The terms "heterocyclyl," "heterocycle," and "heterocyclic" refer to a substituted or unsubstituted non-aromatic ring structure, preferably a 3- to 10-membered ring, more preferably a 3- to 10-membered ring, whose ring structure includes at least one heteroatom, preferably 1 to 4 heteroatoms, and more preferably 1 or 2 heteroatoms. More preferably, it refers to a 3- to 7-membered ring. In certain embodiments, the ring structure can have a bicyclic ring. In some embodiments, the bicyclic ring can have two or more atoms in common, e.g., the rings are "fused rings." Heterocyclyl groups include, for example, piperidine, piperazine, pyrrolidine, morpholine, lactones, lactams, and the like.

[0097] The term "hydrocarbyl" as used herein refers to a group that is bonded through a carbon atom that does not have =O or =S substituents, typically has at least one carbon-hydrogen bond and a predominantly carbon backbone, but can optionally contain heteroatoms. Thus, groups such as methyl, ethoxyethyl, 2-pyridyl, and trifluoromethyl are considered hydrocarbyl for purposes of this application, but substituents such as acetyl (which has =O substituents on the connecting carbon) and ethoxy (which is connected through an oxygen rather than a carbon) are not. Hydrocarbyl groups include, but are not limited to, aryl, heteroaryl, carbocyclic, heterocyclic, alkyl, alkenyl, alkynyl, and combinations thereof.

[0098] The term "hydrazone moiety" or "hydrazone" means [ka] or [ka] The stereochemistry of the hydrazone moiety can be E or Z. The term hydrazone, as used herein, includes both the E and Z isomers.

[0099] In various places herein, substituents of the compounds of the present disclosure are disclosed in groups or ranges. The present disclosure is specifically intended to include each and every individual subcombination of the members of such groups and ranges. For example, the term "C1-C6 alkyl" is specifically intended to individually disclose methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, isobutyl, etc.

[0100] "Pharmaceutically acceptable salt" refers to salts of compounds suitable for pharmaceutical use, including, but not limited to, metal salts (e.g., sodium, potassium, magnesium, calcium, etc.), acid addition salts (e.g., mineral acids, carboxylic acids, etc.), and base addition salts (e.g., ammonia, organic amines, etc.). The acid addition salt forms of compounds occurring in their free form as bases can be obtained by treating said free base form with a suitable acid, such as inorganic acids, e.g., hydrohalic acids, e.g., hydrochloric acid or hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, etc.; or organic acids, e.g., acetic acid, hydroxyacetic acid, propanoic acid, lactic acid, pyruvic acid, malonic acid, succinic acid, maleic acid, fumaric acid, malic acid, tartaric acid, citric acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, cyclic acids, salicylic acid, p-aminosalicylic acid, pamoic acid, etc. See, e.g., WO01 / 062726. Some pharma- ceutically acceptable salts are described in Berge et al., Journal of Pharmaceutical Sciences, vol. 66:1-19 (1 The compounds containing acidic protons can be converted into their therapeutically active, non-toxic base addition salt forms, such as metal salts or amine salts, by treating with suitable organic and inorganic bases. Suitable base salt forms include, for example, ammonium salts, alkali and alkaline earth metal salts or ions, such as lithium, sodium, potassium, magnesium, calcium salts, and the like, salts with organic bases, such as N-methyl-D-glucamine, hydrabamine salts, and salts with amino acids, such as arginine, lysine, and the like. Conversely, the salt forms can be converted into free forms by treating with a suitable base or acid. The compounds and their salts may be in the form of solvates, which are included within the scope of the present disclosure. Such solvates include, for example, hydrates, alcoholates, and the like. See, for example, WO01 / 062726.

[0101] The present disclosure further provides pharmaceutical compositions comprising one or more compounds of the present disclosure together with a pharma- ceutically acceptable carrier or excipient. The compounds or pharmaceutical compositions of the present disclosure can be administered in It can be used in vitro or in vivo.

[0102] The term "isomer" as used herein includes, but is not limited to, tautomers, cis- and trans-isomers (E(entgegen), Z(zusammen)), R- and S-enantiomers (the R and S symbols are used in correspondence according to the rules set forth in Pure Appl. Chem. (1976), Vol. 45, pp. 11-30), diastereomers, (D)-isomers, (L)-isomers, stereoisomers, racemic mixtures thereof, and other mixtures thereof. All such isomers, as well as mixtures thereof, are intended to be included in the present invention. Tautomers are intended to be included within the scope of the present invention even if they are not expressly shown in the formulas set forth herein. Compounds of the Invention

[0103] The present invention relates to a compound having a structure represented by formula (I): [ka] or a pharma- ceutically acceptable salt, hydrate, solvate or isomer thereof. [In the formula, the drug is selected from the group consisting of cytostatic agents, cytotoxic agents, cytokines, immunosuppressants, antirheumatic agents, anti-inflammatory agents, antibiotics, analgesics, virostatic agents, anti-inflammatory agents, antifungal agents, transcription factor inhibitors, cell cycle modulators, MDR modulators, proteasome or protease inhibitors, apoptosis modulators, enzyme inhibitors, signal transduction inhibitors, protease inhibitors, angiogenesis inhibitors, hormones or hormone derivatives, antibodies or fragments thereof, therapeutically or diagnostically active peptides, radioactive substances, luminescent substances, light absorbing substances, and derivatives of any of the foregoing; The spacer is absent or [ka] and [ka] is selected from the group consisting of n is 0 or 1, X is an optionally substituted C1-C 18 Alkyl (C1-C 18 up to 6 carbon atoms of the alkyl are each independently replaced with -OCHCH-; optionally substituted C1-C 18 Alkyl-NH-C(O)-R-(the above C1 to C 18 up to 6 carbon atoms of the alkyl are each independently replaced with -OCHCH-; optionally substituted C1-C 18 Alkyl-C(O)-NH-R5-(C1 to C 18optionally substituted aryl; optionally substituted heteroaryl; and optionally substituted cycloalkyl; R5 is selected from the group consisting of optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted cycloalkyl; Y is selected from the group consisting of absent or optionally substituted C1-C6 alkyl, -NH-C(O)-, -C(O)-NH-, -C(O)-O-, and -OC(O)-; R1 is absent or optionally substituted C1-C 18 Alkyl (C1-C 18 up to 6 carbon atoms of the alkyl are each independently replaced with -OCHCH-; optionally substituted C1-C 18 Alkyl-NH-C(O)R-(the above C1 to C 18 up to 6 carbon atoms of alkyl are each independently replaced with -OCHCH-; and optionally substituted C1-C 18 Alkyl-C(O)-NH-R5-(C1 to C 18 optionally up to 6 carbon atoms of alkyl are each independently replaced with -OCHCH-; or R1 is a naturally occurring or non-naturally occurring amino acid; Or R1 is of the following formula: [ka] It has [ka] does not exist or [ka] is selected from the group consisting of R is [ka] (M1=Mg 2+ , 2Na + , 2K + , 2H + , 2NH4 + ),or [ka] (M2=Na + , K + , H + , NH4 + ) and R2 is -H, optionally substituted C1-C 12 selected from the group consisting of alkyl, optionally substituted aryl, and optionally substituted heteroaryl; Z1, Z2, Z3 and Z4 are each independently selected from -H, an electron withdrawing group, and / or a water soluble group; PBG is a protein binding group selected from the group consisting of an optionally substituted maleimide group, an optionally substituted haloacetamide group, an optionally substituted haloacetate group, an optionally substituted pyridylthio group, an optionally substituted isothiocyanate group, an optionally substituted vinylcarbonyl group, an optionally substituted aziridine group, an optionally substituted disulfide group, an optionally substituted acetylene group, an optionally substituted N-hydroxysuccinimide ester group, a derivatized antibody of an antibody or fragment thereof, and a derivatized fragment thereof; When the spacer is absent, the drug is linked to the nitrogen adjacent to the spacer by a double bond; At least one of Z1, Z2, Z3 and Z4 is an electron withdrawing group.

[0104] In some embodiments of the compounds described herein, PBG is a protein binding group selected from the group consisting of an optionally substituted maleimide group, an optionally substituted haloacetamide group, an optionally substituted haloacetate group, an optionally substituted pyridylthio group, an optionally substituted isothiocyanate group, an optionally substituted vinylcarbonyl group, an optionally substituted aziridine group, an optionally substituted disulfide group, an optionally substituted acetylene group, and an optionally substituted N-hydroxysuccinimide ester group.

[0105] In some embodiments, PBG is associated with an antibody or a fragment thereof. In some embodiments, PBG is covalently bound to an antibody or a fragment thereof. In some embodiments, PBG is associated with albumin. In other embodiments, PBG is covalently bound to endogenous or exogenous albumin. In other embodiments, PBG is covalently bound to cysteine-34 of endogenous or exogenous albumin.

[0106] In certain embodiments, the present invention provides a compound having a structure represented by formula (I): [ka] or a pharma- ceutically acceptable salt, hydrate, solvate or isomer thereof, wherein the agent is selected from the group consisting of a cytostatic agent, a cytotoxic agent, a cytokine, an immunosuppressant, an antirheumatic agent, an anti-inflammatory agent, an antibiotic, an analgesic, a virostatic agent, an anti-inflammatory agent, an antifungal agent, a transcription factor inhibitor, a cell cycle modulator, an MDR modulator, a proteasome or protease inhibitor, an apoptosis modulator, an enzyme inhibitor, a signal transduction inhibitor, a protease inhibitor, an angiogenesis inhibitor, a hormone or hormone derivative, an antibody or fragment thereof, a therapeutically or diagnostically active peptide, a radioactive material, a luminescent material, a light absorbing material, and a derivative of any of the foregoing; The spacer is absent or [ka] and n is 0 or 1, X is an optionally substituted C1-C 18 Alkyl (C1-C 18 up to 6 carbon atoms of the alkyl are each independently replaced with -OCHCH-; optionally substituted C1-C 18 Alkyl-NH-C(O)-R-(the above C1 to C 18 up to 6 carbon atoms of the alkyl are each independently replaced with -OCHCH-; optionally substituted C1-C 18 Alkyl-C(O)-NH-R5-(C1 to C 18 optionally substituted aryl; optionally substituted heteroaryl; and optionally substituted cycloalkyl; R5 is selected from the group consisting of optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted cycloalkyl; Y is selected from the group consisting of absent or optionally substituted C1-C6 alkyl, -NH-C(O)-, -C(O)-NH-, -C(O)-O-, and -OC(O)-; R1 is absent or optionally substituted C1-C 18 Alkyl (C1-C 18 up to 6 carbon atoms of the alkyl are each independently replaced with -OCHCH-; optionally substituted C1-C 18 Alkyl-NH-C(O)R-(the above C1 to C 18 up to 6 carbon atoms of alkyl are each independently replaced with -OCHCH-; and optionally substituted C1-C 18 Alkyl-C(O)-NH-R5-(C1 to C 18Optionally up to 6 carbon atoms of alkyl are each independently replaced with -OCH2CH2- is selected from the group R2 is -H, optionally substituted C1-C 12 selected from the group consisting of alkyl, optionally substituted aryl, and optionally substituted heteroaryl; Z1, Z2, Z3, and Z4 are each independently selected from the group consisting of -H and an electron withdrawing group; PBG is a protein binding group selected from the group consisting of optionally substituted maleimide groups, optionally substituted haloacetamide groups, optionally substituted haloacetate groups, optionally substituted pyridylthio groups, optionally substituted isothiocyanate groups, optionally substituted vinylcarbonyl groups, optionally substituted aziridine groups, optionally substituted disulfide groups, optionally substituted acetylene groups, optionally substituted N-hydroxysuccinimide ester groups and antibodies or fragments thereof; When the spacer is absent, the drug is linked to the nitrogen adjacent to the spacer by a double bond; At least one of Z1, Z2, Z3 and Z4 is an electron withdrawing group.

[0107] In some embodiments of the compounds described herein, PBG is a protein binding group selected from the group consisting of an optionally substituted maleimide group, an optionally substituted haloacetamide group, an optionally substituted haloacetate group, an optionally substituted pyridylthio group, an optionally substituted isothiocyanate group, an optionally substituted vinylcarbonyl group, an optionally substituted aziridine group, an optionally substituted disulfide group, an optionally substituted acetylene group, and an optionally substituted N-hydroxysuccinimide ester group.

[0108] In some embodiments, PBG is associated with an antibody or a fragment thereof. In some embodiments, PBG is covalently bound to an antibody or a fragment thereof. In some embodiments, PBG is associated with albumin. In other embodiments, PBG is covalently bound to endogenous or exogenous albumin. In other embodiments, PBG is covalently bound to cysteine-34 of endogenous or exogenous albumin.

[0109] In certain embodiments, the present invention provides a compound having a structure represented by formula (II): [ka] or a pharma- ceutically acceptable salt, hydrate, solvate or isomer thereof. [wherein the drug, PBG, Y, R1, Z1, Z2, Z3 and Z4 are as defined for compounds of formula (I)].

[0110] In certain embodiments, the present invention provides a compound having a structure represented by formula (III): [ka] or a pharma- ceutically acceptable salt, hydrate, solvate or isomer thereof. wherein the drug, the spacer, PBG, Y, R1, Z2, Z3 and Z4 are as defined for compounds of formula (I); Z1 is an electron-withdrawing group.

[0111] In certain embodiments, the present invention provides a compound having a structure represented by formula (IV): [ka] or a pharma- ceutically acceptable salt, hydrate, solvate or isomer thereof. wherein Drug, PBG, Y, R1, Z2, Z3 and Z4 are as defined for compounds of formula (I); Z1 is an electron-withdrawing group.

[0112] In certain embodiments, the present invention provides a compound having a structure represented by formula (V): [ka] or a pharma- ceutically acceptable salt, hydrate, solvate or isomer thereof. [Wherein, drug, PBG, n, Y, R1, R 2、 Z1, Z2, Z3 and Z4 are as defined for compounds of formula (I).

[0113] In certain embodiments, the present invention provides a compound having a structure represented by formula (VI): [ka] or a pharma- ceutically acceptable salt, hydrate, solvate or isomer thereof. [In the formula, M is a pyrimidine or purine group containing at least one primary or secondary amino group and optionally containing one or more substituents selected from halogen; X1 and X2 are each independently selected from the group consisting of -H, -OH, C1-C6 alkyl, halogen, and -N3; X3 and X4 are each independently selected from the group consisting of absent, -H, -OH, C1-C6 alkyl, halogen, and -N3, wherever valence is possible; R' is -R3 or -CH2R3; R3, at each occurrence, is independently selected from the group consisting of -OH, -CH3, -OP(O)(OH)2, -P(O)(OH)OP(O)(OH)2, -OP(O)(OH)OP(O)(OH)OP(O)(OH)2, -OP(O)(OH)(NH2), an amino acid, an acyl group, and pharma- ceutically acceptable salts thereof, the salts of which contain an alkali metal ion, an alkaline metal ion, ammonium, or an alkyl substituted ammonium ion; X, n, Z1, Z2, Z3, Z4, Y, R1, R2 and PBG are as defined for compounds of formula (V).

[0114] In certain embodiments, the present invention provides a compound having a structure represented by formula (VI): [ka] or a pharma- ceutically acceptable salt, hydrate, solvate or isomer thereof, wherein M is a pyrimidine or purine group containing at least one primary or secondary amino group; X1 and X2 are each independently selected from the group consisting of -H, -OH, C1-C6 alkyl, halogen, and -N3; X3 and X4 are each independently selected from the group consisting of absent, -H, -OH, C1-C6 alkyl, halogen, and -N3, wherever valence is possible; R3 is selected from the group consisting of -OH, -OP(O)(OH), -P(O)(OH)OP(O)(OH), -OP(O)(OH)OP(O)(OH)OP(O)(OH), -OP(O)(OH)(NH), an amino acid, an acyl group, and pharma- ceutically acceptable salts thereof, the salts of which contain an alkali metal ion, an alkaline metal ion, ammonium, or an alkyl-substituted ammonium ion; X, n, Z1, Z2, Z3, Z4, Y, R1, R2 and PBG are as defined for compounds of formula (V).

[0115] In certain embodiments, the present invention provides a compound having a structure represented by formula (VII): [ka] or a pharma- ceutically acceptable salt, hydrate, solvate or isomer thereof. [wherein R' is -R3 or -CH2R3, and X, X1, X2, X3, X4, n, Y, R1, R2, R3, Z1, Z2, Z3, Z4 and PBG are as defined for compounds of formula (VI)].

[0116] In certain embodiments, the present invention provides a compound having a structure represented by formula (VII): [ka] or a pharma- ceutically acceptable salt, hydrate, solvate or isomer thereof. [wherein X, X1, X2, X3, X4, n, Y, R1, R2, R3, Z1, Z2, Z3, Z4 and PBG are as defined for compounds of formula (V)].

[0117] In certain embodiments, the present invention provides a compound having a structure represented by formula (VIII): [ka] or a pharma- ceutically acceptable salt, hydrate, solvate or isomer thereof, wherein Z1 is an electron withdrawing group and the drug, X, n, R2, PBG, Y, R1, Z2, Z3 and Z4 are as defined for compounds of formula (V).

[0118] In certain embodiments, the present invention provides a compound having a structure represented by formula (IX): [ka] or a pharma- ceutically acceptable salt, hydrate, solvate or isomer thereof. [In the formula, M is a pyrimidine or purine group containing at least one primary or secondary amino group and optionally containing one or more substituents selected from halogen; X1 and X2 are each independently selected from the group consisting of -H, -OH, C1-C6 alkyl, halogen, and -N3; X3 and X4 are each independently selected from the group consisting of absent, -H, -OH, C1-C6 alkyl, halogen, and -N3, wherever valence is possible; R' is -R3 or -CH2R3; R3, at each occurrence, is independently selected from the group consisting of -OH, -CH3, -OP(O)(OH)2, -P(O)(OH)OP(O)(OH)2, -OP(O)(OH)OP(O)(OH)OP(O)(OH)2, -OP(O)(OH)(NH2), an amino acid, an acyl group, and pharma- ceutically acceptable salts thereof, the salts of which contain an alkali metal ion, an alkaline metal ion, ammonium, or an alkyl substituted ammonium ion; X, n, Y, Z1, Z2, Z3, Z4, R1, R2 and PBG are as defined for compounds of formula (VIII).

[0119] In certain embodiments, the present invention provides a compound having a structure represented by formula (IX): [ka] or a pharma- ceutically acceptable salt, hydrate, solvate or isomer thereof, wherein M is a pyrimidine or purine group containing at least one primary or secondary amino group; X1 and X2 are each independently selected from the group consisting of -H, -OH, C1-C6 alkyl, halogen, and -N3; X3 and X4 are each independently selected from the group consisting of absent, -H, -OH, C1-C6 alkyl, halogen, and -N3, wherever valence is possible; R3 is selected from -OH, -OP(O)(OH), -P(O)(OH)OP(O)(OH), -OP(O)(OH)OP(O)(OH)OP(O)(OH), -OP(O)(OH)(NH), amino acids, acyl groups, and pharma- ceutically acceptable salts thereof, the salts of which contain an alkali metal ion, an alkaline metal ion, ammonium, or an alkyl-substituted ammonium ion; X, n, Y, Z1, Z2, Z3, Z4, R1, R2 and PBG are as defined for compounds of formula (VIII).

[0120] In certain embodiments, X1, X2, X3, and X4 are each independently selected from the group consisting of -H, -OH, -CH3, -F, -Cl, -Br, -I, and -N3.

[0121] In certain embodiments, the present invention provides a compound having a structure represented by formula (X): [ka] or a pharma- ceutically acceptable salt, hydrate, solvate or isomer thereof. [wherein R' is -R3 or -CH2R3, and X1, X2, X3, X4, R3, X, n, Y, Z1, Z2, Z3, Z4, R1 and R2 are as defined for compounds of formula (IX)].

[0122] In certain embodiments, the present invention provides a compound having a structure represented by formula (X): [ka] or a pharma- ceutically acceptable salt, hydrate, solvate or isomer thereof, wherein X1, X2, X3, X4, R3, X, n, Y, Z1, Z2, Z3, Z4, R1 and R2 are as defined for compounds of formula (IX).

[0123] In some embodiments, the agent is an N-nitrosourea; doxorubicin, 2-pyrrolepyrrolinoanthracycline, morpholinoanthracycline, diacetoxyalkylanthracycline, daunorubicin, epirubicin, idarubicin, nemorubicin, PNU-159682, mitoxantrone; amethantrone; chlorambucil, bendamustine, melphalan, oxazaphosphorine; 5-fluorouracil, 5'-deoxy-5- Fluorocitidine, 2'-deoxy-5-fluoroidine, cytarabine, cladribine, fludarabine, pentostatin, gemcitabine, 4-amino-1-(((2S,3R,4S,5R)-3,4-dihydroxy-5-methyltetrahydrofuran-2-yl)methyl)-5-fluoropyrimidin-2(1H)-one, thioguanine; methotrexate, raltitrexed, pemetrexed, previtrexed; paclitaxel, docetaxel ;Topotecan, Irinotecan, SN-38, 10-hydroxycamptothecin, GG211, Lurtotecan, 9-aminocamptothecin, Camptothecin, 7-formylcamptothecin, 7-acetylcamptothecin, 9-formylcamptothecin, 9-acetylcamptothecin, 9-formyl-10-hydroxycamptothecin, 10-formylcamptothecin, 10-acetylcamptothecin, 7-butyl-10-aminocamptothecin , 7-butyl-9-amino-10,11-methylenedioxocamptothecin; vinblastine, vincristine, vindesine, vinorelbine; calicheamicin; maytansine, maytansinol; auristatins (including, but not limited to, auristatin D, auristatin E, auristatin F, monomethylauristatin D, monomethylauristatin E, monomethylauristatin F, monomethylauristatin F methyl ester, auristatin PYE auristatin PHE, the related natural product dolastatin 10, and derivatives thereof); amatoxins (including, but not limited to, α-amanitin, β-amanitin, γ-amanitin, ε-amanitin, amanine, amaninamide, amanulin, and amanuric acid and derivatives thereof);Duocarmycin A, Duocarmycin B1, Duocarmycin B2, Duocarmycin C, Duocarmycin SA, CC1065, Adozelesin, Bizelesin, Carzelesin; Eribulin; Trabectedin; Pyrrolobenzodiazepines, Anthramycin, Tomeimycin, Sibiromycin, DC-81, DSB-120; Epothilones; Bleomycin; Dactinomycin; Plicamaycin; cyn, mitomycin C, and cis-configured platinum(II) complexes; or derivatives of any of the foregoing.

[0124] In some embodiments, the agent is an N-nitrosourea; doxorubicin, 2-pyrrolinoanthracycline, morpholinoanthracycline, diacetoxyalkylanthracycline, daunorubicin, epirubicin, idarubicin, nemorubicin, mitoxantrone; amethantrone; chlorambucil, bendamustine, melphalan, oxazaphosphorine; 5-fluorouracil, 2'-deoxy-5-fluoridine, cytarabine, cladribine, fludarabine, pentostatin, gemcitabine, thioguanine; methotrexate, raltitrate, or the like. are selected from the group consisting of: rexed, pemetrexed, previtrexed; paclitaxel, docetaxel; topotecan, irinotecan, SN-38, 10-hydroxycamptothecin, GG211, lurtotecan, 9-aminocamptothecin, camptothecin; vinblastine, vincristine, vindesine, vinorelbine; calicheamicin; maytansinoids; auristatins; epothilones; bleomycin, dactinomycin, plicamycin, mitomycin C and cis-configured platinum(II) complexes; or derivatives of any of the foregoing.

[0125] In some embodiments, Z1, Z2, Z3, and Z4 are each independently selected from the group consisting of -H, halogen, -C(O)OH, -C(O)O-C1-C6 alkyl, -NO2, haloalkyl, -S(O)2-C1-C6 alkyl, and -CN. In some embodiments, Z1, Z2, Z3, and Z4 are each independently selected from the group consisting of -H, -Cl, -Br, -I, -F, -C(O)OH, -NO2, -CF3, and -CN. In some embodiments, Z1, Z2, Z3, and Z4 are each independently selected from the group consisting of -H, -Cl, -F, -NO2, and -CF3. In some embodiments, Z1, Z2, Z3, and Z4 are each independently selected from the group consisting of -OP(O)(OH), -P(O)(OH)OP(O)(OH), -OP(O)(OH)OP(O)(OH)OP(O)(OH), -OP(O)(OH)(NH), -P(O)(OH), -SO3H, and pharma- ceutically acceptable salts thereof. In some embodiments, at least one of Z1, Z2, Z3, and Z4 is not -H.

[0126] In some embodiments, Z1, Z2, Z3, and Z4 are each independently selected from the group consisting of -H, halogen, -C(O)OH, -C(O)O-C1-C6 alkyl, -NO2, haloalkyl, -S(O)2-C1-C6 alkyl, and -CN. In some embodiments, Z1, Z2, Z3, and Z4 are each independently selected from the group consisting of -H, -Cl, -Br, -I, -F, -C(O)OH, -NO2, -CF3, and -CN. In some embodiments, Z1, Z2, Z3, and Z4 are each independently selected from the group consisting of -H, -Cl, -F, -NO2, and -CF3. In some embodiments, at least one of Z1, Z2, Z3, and Z4 is not -H.

[0127] In some embodiments, Z1 is selected from halogen, -C(O)OH, -C(O)O-C1-C6 alkyl, -NO2, haloalkyl, -S(O)2-C1-C6 alkyl, and -CN, and Z2, Z3, and Z4 are each independently selected from the group consisting of -H, halogen, -C(O)OH, -C(O)O-C1-C6 alkyl, -NO2, haloalkyl, -S(O)2-C1-C6 alkyl, and -CN. In some embodiments, Z1 is selected from the group consisting of -Cl, -Br, -I, -F, -C(O)OH, -NO2, -CF3, and -CN, and Z2, Z3, and Z4 are each independently selected from the group consisting of -H, -Cl, -Br, -I, -F, -C(O)OH, -NO2, -CF3, and -CN. In some embodiments, Z1 is selected from the group consisting of -Cl, -F, and -NO2, and Z2, Z3, and Z4 are each independently selected from the group consisting of -H, -Cl, -F, -NO2, and -CF3.

[0128] In some embodiments, R2 is methyl.

[0129] In some embodiments, X1 is -H, X2 is -F, X3 is -F, and X4 is -OH. Hydrazone moiety

[0130] The drug delivery system contains an acid-labile, cleavable hydrazone moiety. The cleavage of the hydrazone moiety and the half-life of drug release vary according to the electron-withdrawing substituents and their position on the phenyl ring to which the hydrazone is attached. The phenyl ring can be substituted as follows: [ka] [In the formula, PBG, R1, Y, Z1, Z2, Z3 and Z4 are as defined herein].

[0131] In some embodiments, the phenyl ring comprises at least one electron-withdrawing group. In some preferred embodiments, the phenyl ring comprises one electron-withdrawing group attached to the 1 position. In some embodiments, the phenyl ring comprises one electron-withdrawing group attached to the 2 position. In some embodiments, the phenyl ring comprises one electron-withdrawing group attached to the 3 position. In some preferred embodiments, the phenyl ring comprises two electron-withdrawing groups attached to the 1 and 2 positions. In some embodiments, the phenyl ring comprises two electron-withdrawing groups attached to the 1 and 3 positions. In some embodiments, the phenyl ring comprises two electron-withdrawing groups attached to the 1 and 4 positions. In some embodiments, the phenyl ring comprises two electron-withdrawing groups attached to the 1 and 5 positions. In some embodiments, the phenyl ring comprises two electron-withdrawing groups attached to the 2 and 3 positions. In some embodiments, the phenyl ring comprises two electron-withdrawing groups attached to the 2 and 4 positions. In some embodiments, the phenyl ring comprises two electron-withdrawing groups attached to the 2 and 5 positions. In some embodiments, the phenyl ring contains two electron-withdrawing groups attached to positions 3 and 4. In some embodiments, the phenyl ring contains two electron-withdrawing groups attached to positions 3 and 5. In some embodiments, the phenyl ring contains three electron-withdrawing groups attached to positions 1, 3, and 5.

[0132] In some embodiments, Z1, Z2, Z3, and Z4 are each independently selected from the group consisting of -H, halogen, -C(O)OH, -C(O)O-C1-C6 alkyl, -NO2, haloalkyl, -S(O)2-C1-C6 alkyl, and -CN. In some embodiments, Z1, Z2, Z3, and Z4 are each independently selected from the group consisting of -H, -Cl, -Br, -I, -F, -C(O)OH, -NO2, -CF3, and -CN. In some embodiments, Z1, Z2, Z3, and Z4 are each independently selected from the group consisting of -H, -Cl, -F, -NO2, and -CF3. In some embodiments, Z1, Z2, Z3, and Z4 are each independently selected from the group consisting of -OP(O)(OH), -P(O)(OH)OP(O)(OH), -OP(O)(OH)OP(O)(OH)OP(O)(OH), -OP(O)(OH)(NH), -P(O)(OH), -SO3H, and pharma- ceutically acceptable salts thereof. In some embodiments, at least one of Z1, Z2, Z3, and Z4 is not -H.

[0133] In some embodiments, Z1, Z2, Z3, and Z4 are each independently selected from the group consisting of -H, -Cl, -Br, -I, -F, -C(O)OH, -NO2, -CF3, and -CN. and at least one of Z1, Z2, Z3 and Z4 is not -H. In some embodiments, Z1, Z2, Z3 and Z4 are each independently selected from the group consisting of -H, -Cl, -F, -NO2 and -CF3, and at least one of Z1, Z2, Z3 and Z4 is not -H. In some embodiments, Z1, Z2, Z3 and Z4 are each independently selected from the group consisting of -H, -F, -NO2 and -CF3, and at least one of Z1, Z2, Z3 and Z4 is not -H.

[0134] In some embodiments, the half-life of drug release is about 1.5 hours, about 2.0 hours, about 2.5 hours, about 3.0 hours, about 3.5 hours, about 4.0 hours, about 4.5 hours, about 5.0 hours, about 5.5 hours, about 6.0 hours, about 6.5 hours, about 7.0 hours, about 7.5 hours, about 8.0 hours, about 8.5 hours, about 9.0 hours, about 9.5 hours, about 10.0 hours, about 10.5 hours, about 11.0 hours, about 11.5 hours, about 12.0 hours, about 12.5 hours, about 13.0 hours, about 13.5 hours, about 14.0 hours, about 14.5 hours, about 15.0 hours, about 15.5 hours, about 16.0 hours, about 16.5 hours, about 17.0 hours, about 17.5 hours, about 18.0 hours, about 18.5 hours, about 19.0 hours, about 19.5 hours, or about 20.0 hours.

[0135] Without wishing to be bound by theory, a phenyl ring containing one electron-withdrawing group attached at the 1-position stabilizes the hydrazone moiety, resulting in slow and sustained release of the drug under acidic conditions. In some embodiments, the position of the electron-withdrawing group on the phenyl ring relative to the position of the hydrazone moiety on the phenyl ring provides a way to control drug release.

[0136] In some embodiments, the present invention provides compounds as described herein for formula I, II, III, IV, V, VI, VII, VIII, IX, and X. [ka] or [ka] Methods for producing compounds for controlling drug release by modifying the drug to add moieties are provided.

[0137] Some embodiments of the invention include conjugates having the substitution pattern shown in Table A (HSA stands for human serum albumin) and the corresponding half-life of drug release. The structure of nemorubicin is: [ka] The nemorubicin conjugates presented in Table A have the following structures: [Table A-1] [Table A-2] [Table A-3]

[0138] In some embodiments, the compounds of the invention are [ka] [ka] or a pharma- ceutically acceptable salt, hydrate, solvate or isomer thereof. [In the formula, SG= [ka] and [ka] does not exist or [ka] is selected from the group consisting of R is [ka] (M1=Mg 2+ , 2Na + , 2K + , 2H + , 2NH4 + , Na + , K + , NH4 + and / or H + ),or [ka] (M2=Na + , K + , H + , and / or NH4 + ) [is].

[0139] In some embodiments, the compound is [ka] [ka] [ka] [ka] [ka] [ka] [ka] or a pharma- ceutically acceptable salt, hydrate, solvate or isomer thereof.

[0140] In some embodiments, the compounds of the invention are [ka] or a pharma- ceutically acceptable salt, hydrate, solvate or isomer thereof.

[0141] In some embodiments, the compounds of the invention are [ka] or a pharma- ceutically acceptable salt, hydrate, solvate or isomer thereof.

[0142] In some embodiments, the compound has the structure [ka] Compound 15 has the formula:

[0143] In some embodiments, compound 15 prevents inactivation of gemcitabine, providing sustained exposure to the tumor. Drugs

[0144] In some embodiments, the agent is selected from the group consisting of a cytostatic agent, a cytotoxic agent, a cytokine, an immunosuppressant, an antirheumatic agent, an anti-inflammatory agent, an antibiotic, an analgesic, an anti-inflammatory agent, a virostatic agent, an antifungal agent, a transcription factor inhibitor, a cell cycle modulator, an MDR modulator, a proteasome or protease inhibitor, an apoptosis modulator, an enzyme inhibitor, an angiogenesis inhibitor, a hormone or hormone derivative, an antibody or fragment thereof, a therapeutically or diagnostically active peptide, a radioactive material, a luminescent material, a light absorbing material, a derivative of any of the foregoing, a pharma- ceutically acceptable salt, hydrate, solvate or isomer of any of the foregoing.

[0145] In some embodiments, the agent is an N-nitrosourea; doxorubicin, 2-pyrrolepyrrolinoanthracycline, morpholinoanthracycline, diacetoxyalkylanthracycline, daunorubicin, epirubicin, idarubicin, nemorubicin, PNU-159682, mitoxantrone; amethantrone; chlorambucil, bendamustine, melphalan, oxazaphosphorine; 5-fluorouracil, 5'-deoxy-5- Fluorocitidine, 2'-deoxy-5-fluoroidine, cytarabine, cladribine, fludarabine, pentostatin, gemcitabine, 4-amino-1-(((2S,3R,4S,5R)-3,4-dihydroxy-5-methyltetrahydrofuran-2-yl)methyl)-5-fluoropyrimidin-2(1H)-one, thioguanine; methotrexate, raltitrexed, pemetrexed, previtrexed; paclitaxel, docetaxel ;Topotecan, Irinotecan, SN-38, 10-hydroxycamptothecin, GG211, Lurtotecan, 9-aminocamptothecin, Camptothecin, 7-formylcamptothecin, 7-acetylcamptothecin, 9-formylcamptothecin, 9-acetylcamptothecin, 9-formyl-10-hydroxycamptothecin, 10-formylcamptothecin, 10-acetylcamptothecin, 7-butyl-10-aminocamptothecin , 7-butyl-9-amino-10,11-methylenedioxocamptothecin; vinblastine, vincristine, vindesine, vinorelbine; calicheamicin; maytansine, maytansinol; auristatins (including, but not limited to, auristatin D, auristatin E, auristatin F, monomethylauristatin D, monomethylauristatin E, monomethylauristatin F, monomethylauristatin F methyl ester, auristatin PYE, auristatin PHE, the related natural product dolastatin 10, and derivatives thereof); amatoxins (including, but not limited to, α-amanitin, β-amanitin, γ-amanitin, ε-amanitin, amanine, amaninamide, amanulin, and amanuric acid and derivatives thereof);Duocarmycin A, Duocarmycin B1, Duocarmycin B2, Duocarmycin C, Duocarmycin SA, CC1065, adozelesin, bizelesin, carzelesin; eribulin; trabectedin; pyrrolobenzodiazepines, anthramycin, tomaymycin, sibiromycin, DC-81, DSB-120; epothilones; bleomycin; dactinomycin; plicamycin, mitomycin C, and cis-configured platinum(II) complexes; or a derivative of any of the foregoing.

[0146] In some embodiments, the agent is an N-nitrosourea; doxorubicin, 2-pyrrolepyrrolinoanthracycline, morpholinoanthracycline, diacetoxyalkylanthracycline, daunorubicin, epirubicin, idarubicin, nemorubicin, PNU-159682, mitoxantrone; amethantrone; chlorambucil, bendamustine, melphalan, oxazaphosphorine; 5-fluorouracil, 2'-deoxy-5-fluorouracil, Orijen, cytarabine, cladribine, fludarabine, pentostatin, gemcitabine, 4-amino-1-(((2S,3R,4S,5R)-3,4-dihydroxy-5-methyltetrahydrofuran-2-yl)methyl)-5-fluoropyrimidin-2(1H)-one, thioguanine; methotrexate, raltitrexed, pemetrexed, previtrexed; paclitaxel, docetaxel; topotecan, irinotecan, SN-38, 10- hydroxycamptothecin, GG211, lurtotecan, 9-aminocamptothecin, camptothecin, 7-formylcamptothecin, 9-formylcamptothecin, 9-formyl-10-hydroxycamptothecin, 7-butyl-10-aminocamptothecin, 7-butyl-9-amino-10,11,-methylenedioxocamptothecin; vinblastine, vincristine, vindesine, vinorelbine; calicheamicin; maytansinoids; auristatins; epothilones; bleomycin, dactinomycin, plicamycin, mitomycin C, and cis-configured platinum(II) complexes; or derivatives of any of the foregoing.

[0147] In some embodiments, the agent is an N-nitrosourea.

[0148] In some embodiments, the agent is an anthracycline, such as, but not limited to, doxorubicin, 2-pyrrolepyrrolinoanthracycline, morpholinoanthracycline, diacetoxyalkylanthracycline, daunorubicin, epirubicin, idarubicin, nemorubicin, PNU-159682, mitoxantrone, or amethantrone.

[0149] In some embodiments, the agent is an alkylating agent, such as, but not limited to, chlorambucil, bendamustine, melphalan, or oxazaphosphorine.

[0150] In some embodiments, the agent is an antimetabolite, such as, but not limited to, 5-fluorouracil, 2'-deoxy-5-fluoridine, cytarabine, cladribine, fludarabine, pentostatin, gemcitabine, 4-amino-1-(((2S,3R,4S,5R)-3,4-dihydroxy-5-methyltetrahydrofuran-2-yl)methyl)-5-fluoropyrimidin-2(1H)-one, or thioguanine. In some embodiments, the antimetabolite is a pyrimidine, or purine analog containing at least one primary or secondary amino group.

[0151] In some embodiments, the agent is a folate antagonist, such as, but not limited to, methotrexate, raltitrexed, pemetrexed, or previtrexed.

[0152] In some embodiments, the agent is a taxane, such as, but not limited to, paclitaxel or docetaxel.

[0153] In some embodiments, the agent is a camptothecin, such as, but not limited to, topotecan, irinotecan, SN-38, 10-hydroxycamptothecin, GG211, lurtotecan, 9-aminocamptothecin, camptothecin, -formylcamptothecin, 9-formylcamptothecin, 9-formyl-10-hydroxycamptothecin, 7-butyl-10-aminocamptothecin, or 7-butyl-9-amino-10,11,-methylenedioxocamptothecin.

[0154] In some embodiments, the agent is a vinca alkaloid, such as, but not limited to, vinblastine, vincristine, vindesine, vinorelbine, or calicheamicin.

[0155] In some embodiments, the agent is a maytansinoid, an auristatin, an epothilone, a bleomycin, a dactinomycin, a plicamycin, a mitomycin C, a cis-configured platinum(II) complex, or a derivative of any of the foregoing. Spacer Amide bond

[0156] In some embodiments, the spacer is [ka] where n, X and R2 are as defined herein.

[0157] In some embodiments, the spacer is [ka] where n, X and R2 are as defined herein.

[0158] In some embodiments, n is 0 or 1.

[0159] In some embodiments, X is an optionally substituted C1-C 18 Alkyl (C1-C 18up to 6 carbon atoms of the alkyl are each independently replaced with -OCHCH-; optionally substituted C1-C 18 Alkyl-NH-C(O)-R-(the above C1 to C 18 up to 6 carbon atoms of the alkyl are each independently replaced with -OCHCH-; optionally substituted C1-C 18 Alkyl-C(O)-NH-R5-(C1 to C 18 optionally substituted aryl; optionally substituted heteroaryl; and optionally substituted cycloalkyl; optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted cycloalkyl.

[0160] In some embodiments, X is an optionally substituted C1-C 18 In some embodiments, X is an optionally substituted C1-C 18 alkyl, 18 In some embodiments, X1 is an optionally substituted C1-C 18 alkyl, 18 In some embodiments, X is an optionally substituted C1-C 18 alkyl, 18 In some embodiments, X is an optionally substituted C1-C 18 alkyl, 18 In some embodiments, X is an optionally substituted C1-C 18 alkyl, 18 In some embodiments, 5 carbon atoms of the alkyl are replaced with -OCHCH-. In some embodiments, X is an optionally substituted C-C 18 alkyl,18 The 6 carbon atoms of the alkyl are replaced with -OCH2CH2-.

[0161] In some embodiments, X is an optionally substituted C1-C 18 In some embodiments, X is an optionally substituted C1-C 18 alkyl-NH-C(O)R-, 18 In some embodiments, X is optionally substituted with -OCH2CH2-. C1~C being replaced 18 alkyl-NH-C(O)R-, 18 In some embodiments, X is an optionally substituted C1-C 18 alkyl-NH-C(O)R-, 18 In some embodiments, X is an optionally substituted C1-C 18 alkyl-NH-C(O)R-, 18 In some embodiments, X is an optionally substituted C1-C 18 alkyl-NH-C(O)R-, 18 In some embodiments, 5 carbon atoms of the alkyl are replaced with -OCHCH-. In some embodiments, X is an optionally substituted C-C 18 alkyl-NH-C(O)R-, 18 The 6 carbon atoms of the alkyl are replaced with -OCH2CH2-.

[0162] In some embodiments, X is an optionally substituted C1-C 18 In some embodiments, X is an optionally substituted C1-C 18 alkyl-C(O)-NH-R5-,18 In some embodiments, X is an optionally substituted C1-C 18 alkyl-C(O)-NH-R5-, 18 In some embodiments, X is an optionally substituted C1-C 18 alkyl-C(O)-NH-R5-, 18 In some embodiments, X is an optionally substituted C1-C 18 alkyl-C(O)-NH-R5-, 18 In some embodiments, X is an optionally substituted C1-C 18 alkyl-C(O)-NH-R5-, 18 In some embodiments, 5 carbon atoms of the alkyl are replaced with -OCHCH-. In some embodiments, X is an optionally substituted C-C 18 alkyl-C(O)-NH-R5-, 18 The 6 carbon atoms of the alkyl are replaced with -OCH2CH2-.

[0163] In some embodiments, X is optionally substituted aryl. In some embodiments, X is [ka] wherein Z5, Z6, Z7, and Z8 are each independently selected from the group consisting of -H, halogen, -OH, -NO2, -CN, -OC1-C6 alkyl, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 haloalkyl, and optionally substituted C1-C6 haloalkoxy. In some embodiments, X is [ka] wherein Z5, Z6, Z7 and Z8 are each independently -H, halogen, -OH, -NO2, -CN, optionally substituted -OC1-C6 alkyl, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 haloalkyl. and optionally substituted C1-C6 haloalkoxy. In some embodiments, Z5, Z6, Z7 and Z8 are each -H.

[0164] In some embodiments, X is an optionally substituted heteroaryl.

[0165] In some embodiments, X is an optionally substituted cycloalkyl.

[0166] In some embodiments, R5 is selected from the group consisting of optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted cycloalkyl. In some embodiments, R5 is optionally substituted aryl.

[0167] In some embodiments, R2 is -H, optionally substituted C1-C 12 It is selected from the group consisting of alkyl, optionally substituted aryl, and optionally substituted heteroaryl.

[0168] In some embodiments, the spacer is absent.

[0169] In some embodiments, the spacer comprises an enzymatically cleavable moiety or bond. In some embodiments, the cleaved bond is a peptide bond, an imide bond, or an amide bond. In some embodiments, the amide bond may be designed to be specifically cleavable by esterases and / or amidases. In some embodiments, the spacer comprises an amide bond that is selectively cleaved by carboxylesterases. In a preferred embodiment, the spacer comprises an amide bond that is selectively cleaved by carboxylesterase 2 ..., attached to an aryl ring, as follows: [ka] In some embodiments, the spacer comprises an amide bond attached to the aryl ring, as follows: [ka] wherein Z5, Z6, Z7, and Z8 are each independently selected from the group consisting of -H, halogen, -OH, -NO2, -CN, -OC1-C6 alkyl, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 haloalkyl, and optionally substituted C1-C6 haloalkoxy. In some embodiments, the spacer is an amide bond attached to the aryl ring as follows: [ka] wherein Z5, Z6, Z7, and Z8 are each independently selected from the group consisting of -H, halogen, -OH, -NO2, -CN, -OC1-C6 alkyl, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 haloalkyl, and optionally substituted C1-C6 haloalkoxy. In some embodiments, Z5, Z6, Z7, and Z8 are each -H.

[0170] In some embodiments, the spacer is [ka] where R2 is -H, optionally substituted C1-C 12 alkyl, optionally substituted aryl, and optionally substituted heteroaryl, and W1, W2, W3, and W4 are each independently selected from the group consisting of -H, halogen, -C(O)OH, -C(O)O-C1-C6 alkyl, -NO2, haloalkyl, -S(O)2-C1-C6 alkyl, and -CN. In some embodiments, W1, W2, W3, and W4 are each independently selected from the group consisting of -H, -Cl, -Br, -I, -F, -C(O)OH, -NO2, -CF3, and -CN. In some embodiments, W1, W2, W3, and W4 are each independently selected from the group consisting of -H, -Cl, -F, -NO2, and -CF3. In some embodiments, W1, W2, W3, and W4 are each independently selected from the group consisting of a phenoxy group, a primary, secondary, or tertiary amine group, an ether group, a phenol group, an amide group, an ester group, an alkyl group, a substituted alkyl group, a phenyl group, and a vinyl group. In some embodiments, W1, W2, W3, and W4 are each independently selected from the group consisting of -OP(O)(OH), -P(O)(OH)OP(O)(OH), -OP(O)(OH)OP(O)(OH), -OP(O)(OH)(NH), -P(O)(OH), -SOH, and pharma- ceutically acceptable salts thereof. In some embodiments, at least one of W1, W2, W3, and W4 is not -H.

[0171] In some of the above embodiments, W1 is selected from the group consisting of halogen, -C(O)OH, -C(O)O-C1-C6 alkyl, -NO2, haloalkyl, -S(O)2-C1-C6 alkyl, and -CN, and W2, W3, and W4 are each independently selected from the group consisting of -H, halogen, -C(O)OH, -C(O)O-C1-C6 alkyl, -NO2, haloalkyl, -S(O)2-C1-C6 alkyl, and -CN. In some embodiments, W1 is selected from the group consisting of -Cl, -Br, -I, -F, -C(O)OH, -NO2, -CF3, and -CN, and W2, W3, and W4 are each independently selected from the group consisting of -H, -Cl, -Br, -I, -F, -C(O)OH, -NO2, -CF3, and -CN. In some embodiments, W1 is selected from the group consisting of -Cl, -F, and -NO2, and Z2, Z3, and Z4 are each independently selected from the group consisting of -H, -Cl, -F, -NO2, and -CF3.

[0172] In some embodiments, the spacer is [ka] wherein R2 is as defined herein. In some embodiments, the spacer is [ka] It is.

[0173] In some embodiments, the spacer is [ka] and m is 1, 2, 3, 4, 5, or 6.

[0174] In some embodiments, the spacer is [ka] It is.

[0175] In some embodiments, R2 is -H, optionally substituted C1-C 12 It is selected from the group consisting of alkyl, optionally substituted aryl, and optionally substituted heteroaryl.

[0176] In one aspect, the spacer acts as a protecting group to prevent metabolic degradation of the drug, thus allowing the targeting of the use of higher doses of the drug, hi some embodiments, the drug is gemcitabine. Linker

[0177] In some embodiments, the linker comprises Y and R1. In some embodiments, Y is absent. In some embodiments, R1 is absent. In some embodiments, both Y and R1 are absent.

[0178] In some embodiments, Y is selected from the group consisting of methyl, ethyl, -NH-C(O)-, -C(O)-NH-, -C(O)-O-, and -OC(O)-.

[0179] In some embodiments, R1 is an optionally substituted C1-C 18 In some embodiments, R is an optionally substituted C-C alkyl. 18 alkyl, 18 In some embodiments, R1 is an optionally substituted C1-C 18 alkyl, 18 In some embodiments, R1 is an optionally substituted C1-C 18 alkyl, 18 In some embodiments, R1 is an optionally substituted C1-C 18 alkyl, 18In some embodiments, R1 is an optionally substituted C1-C 18 alkyl, 18 In some embodiments, R1 is an optionally substituted C1-C 18 alkyl, 18 The 6 carbon atoms of the alkyl are replaced with -OCH2CH2-.

[0180] In some embodiments, R1 is an optionally substituted C1-C 18 In some embodiments, R is an optionally substituted C-C alkyl. 18 alkyl-NH-C(O)R-, 18 In some embodiments, R1 is an optionally substituted C1-C 18 alkyl-NH-C(O)R-, 18 In some embodiments, R1 is an optionally substituted C1-C 18 alkyl-NH-C(O)R-, 18 In some embodiments, R1 is an optionally substituted C1-C 18 alkyl-NH-C(O)R-, 18 In some embodiments, R1 is an optionally substituted C1-C 18 alkyl-NH-C(O)R-, 18 In some embodiments, R1 is an optionally substituted C1-C 18 alkyl-NH-C(O)R-, 18The 6 carbon atoms of the alkyl are replaced with -OCH2CH2-.

[0181] In some embodiments, R1 is an optionally substituted C1-C 18 In some embodiments, R is an optionally substituted C(O)-C alkyl. 18 alkyl-C(O)-NH-R5-, 18 In some embodiments, R1 is an optionally substituted C1-C 18 alkyl-C(O)-NH-R5-, 18 In some embodiments, R1 is an optionally substituted C1-C 18 alkyl-C(O)-NH-R5-, 18 In some embodiments, R1 is an optionally substituted C1-C 18 alkyl-C(O)-NH-R5-, 18 In some embodiments, R1 is an optionally substituted C1-C 18 alkyl-C(O)-NH-R5-, 18 In some embodiments, R1 is an optionally substituted C1-C 18 alkyl-C(O)-NH-R5-, 18 The 6 carbon atoms of the alkyl are replaced with -OCH2CH2-.

[0182] In some embodiments, R5 is selected from the group consisting of optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted cycloalkyl. are selected.

[0183] In some embodiments, the compounds of the present invention [ka] The part is [ka] [ka] [ka] is selected from the group consisting of: Protein Binding Group

[0184] Protein binding groups ("PBG") include, but are not limited to, a substituted or unsubstituted maleimide group, a substituted or unsubstituted haloacetamide group, a substituted or unsubstituted haloacetate group, a substituted or unsubstituted pyridylthio group, a substituted or unsubstituted isothiocyanate group, a substituted or unsubstituted vinylcarbonyl group, a substituted or unsubstituted aziridine group, a substituted or unsubstituted disulfide group, a substituted or unsubstituted acetylene group, a substituted or unsubstituted N-hydroxysuccinimide ester group, an antibody or a fragment thereof. In some embodiments, the protein binding group ("PBG") includes, but is not limited to, a substituted or unsubstituted maleimide group, a substituted or unsubstituted haloacetamide group, a substituted or unsubstituted haloacetate group, a substituted or unsubstituted pyridylthio group, a substituted or unsubstituted isothiocyanate group, a substituted or unsubstituted vinylcarbonyl group, a substituted or unsubstituted aziridine group, a substituted or unsubstituted disulfide group, a substituted or unsubstituted acetylene group, or a substituted or unsubstituted N-hydroxysuccinimide ester group. In some embodiments, the protein binding group is a substituted or unsubstituted maleimide group. In some embodiments, the protein binding group is [ka] In some embodiments, the PBG is substituted with C1-C6 alkyl or halogen. In some embodiments, the PBG is substituted with methyl, -Cl or -Br. In some embodiments, the PBG comprises an antibody or a fragment thereof. In some embodiments, the PBG comprises a ligand having specificity for a receptor, such as a low or high molecular weight compound, such as folic acid, a vitamin, a peptide, a sugar, a natural or modified protein.

[0185] Disulfide groups can be exchanged with thionitrobenzoic acid (e.g., 5'-thio-2- The maleimide, pyridyldithio or N-hydroxysuccinimide ester groups may be activated by nitrobenzoic acid). The maleimide, pyridyldithio or N-hydroxysuccinimide ester groups may be substituted, where appropriate, by alkyl groups or by water-soluble groups as mentioned above. In general, the protein-binding groups are endowed with the property of binding to proteins, i.e., in a physiological environment, they bind to specific amino acids on the surface of proteins, either covalently ("covalent protein-binding groups") or non-covalently ("non-covalent protein-binding groups"). Maleimide, haloacetamide, haloacetate, pyridyldithio, disulfide, vinylcarbonyl, aziridine and / or acetylene groups preferably react with the thiol (-SH) groups of cysteine, whereas N-hydroxysuccinimide ester and / or isothiocyanate groups preferably react with the amino groups (-NH) of lysines on the surface of proteins. For example, a protein-binding group (such as a maleimide group) can be bound to cysteine-34 of albumin. In some embodiments, the albumin is unmodified (e.g., unmodified to be positively or negatively charged). In some embodiments, the PBG described herein can bind to an antibody or fragment thereof, such as those described herein.

[0186] The compound used in the present invention comprises any and all combinations of one or more drugs, spacers, linkers, protein binding groups, cleavable moieties, i.e. hydrazones, amide bonds.The compound may comprise an anthracycline and an acid-cleavable moiety that can be cleaved in a manner that controls the release of the anthracycline.In certain embodiments, the therapeutically active substance comprises an anthracycline, a hydrazone as an acid-cleavable moiety (the half-life of its cleavage and drug release varies according to the electron-withdrawing substituent and their position on the phenyl ring to which the hydrazone is attached), and a maleimide group as a covalent protein binding group.In some other embodiments, the compound may comprise gemcitabine and an acid-cleavable moiety that can be cleaved in a manner that controls the release of gemcitabine.In some other embodiments, the compound may comprise a vinca alkaloid and an acid-cleavable moiety that can be cleaved in a manner that controls the release of the vinca alkaloid. Antibodies as carriers

[0187] Cancer cells have specific markers, known as antigens, that play a role in tumor growth and progression. Antigens are proteins that are often located on the tumor surface. An important feature of antibodies is their ability to bind target antigens with high specificity. However, despite specific binding to antigens, antibodies often lack therapeutic activity (Panowski et al., mAbs, vol. 6, pp. 34-45 (2014); Chari et al., Angewandte Chem. Int. Ed., 53, pp. 3796-3827 (2014). Antibodies have high specificity for antigens and can be used as carriers for drug delivery. Antibodies can be conjugated to therapeutically effective substances to form antibody-drug conjugates (ADCs) to deliver the therapeutically effective substances to target sites, such as tumors. When the ADC binds to an antigen, the antigen-ADC complex is internalized via endocytosis. Once inside the tumor, the ADC releases the therapeutically effective substance. For the success of an ADC, the selection of the therapeutically effective substance, linker, and antibody is important. The internalization efficiency of the antigen-antibody complex affects the amount of therapeutically effective substance delivered, so the selection of the antigen, and consequently the corresponding antibody, is important. Furthermore, for an ADC to be effective, the number of molecules of drug required to kill a cell must be less than the amount of drug that can be delivered. Thus, potent drugs with potency in the picomolar range are preferred. Finally, once the ADC is internalized, the linker should be cleaved to release the therapeutically effective substance. Preferred linkers provide efficient controlled release of the therapeutically active agent in the acidic environment of the tumor while simultaneously preventing release of the therapeutically active agent into the plasma, which may result in off-target toxicity and a narrower therapeutic window for the use of the therapeutically active agent. The linkers disclosed herein are capable of binding to any of the cytotoxic molecules expressed on malignant cells. The antibody can be conjugated to an antibody directed against an antigen or receptor. The antibody can be a chimeric, humanized, human, or genetically engineered or chemically modified antibody, such as a thio antibody (THIOMAB), and a linker can be attached to the antibody without significantly reducing the antibody's ability to bind to the target.

[0188] In some embodiments, the protein binding group (PBG) of the compounds described herein associates with an antibody or fragment thereof described herein, thereby forming an ADC. In some embodiments, the PBG is covalently bound to the antibody or fragment thereof. In other embodiments, the PBG is non-covalently bound to the antibody or fragment thereof.

[0189] In certain aspects, the PBG of the present application can be bound to a carrier. In some embodiments, the carrier is a polypeptide binding agent. The present disclosure includes, in part, polypeptide binding agents, such as antibodies, antigen-binding portions of antibodies, and non-immunoglobulin antigen-binding scaffolds that can effectively target antigens.

[0190] Monoclonal antibodies that bind to antigens present on the tumor surface can be used in the disclosed methods and compositions.

[0191] In some embodiments, the antibody may be a modified antibody, or an antigen-binding fragment thereof that binds to the extracellular domain of the antigen.

[0192] In some embodiments, a deimmunized antibody or antigen-binding fragment thereof that binds to the extracellular domain of an antigen comprises a heavy chain variable region and a light chain variable region, each of which has between 2 and 20 amino acid substitutions in a framework region compared to a nonhuman or parent antibody that binds to the extracellular domain of an antigen.

[0193] In some embodiments, the deimmunized antibody or antigen-binding fragment thereof has one or more complementarity determining regions (CDRs) from a non-human or parent antibody that binds to the extracellular domain of an antigen. In one embodiment, between 1 and 5 substitutions are present in the complementarity determining regions (CDRs).

[0194] In some embodiments, single chain antibodies, and chimeric, humanized or primatized (CDR-grafted) antibodies, as well as chimeric or CDR-grafted single chain antibodies, including portions derived from different species, can be used as the antigen-binding portion of the antibody. The various portions of these antibodies can be joined together chemically by conventional techniques or prepared as a contiguous protein using genetic engineering techniques. For example, nucleic acids encoding the chimeric or humanized chains can be expressed to produce a contiguous protein. See, e.g., Cabilly et al., U.S. Patent No. 4,816,567; Cabilly et al., European Patent No. 0,125,023B1; Boss et al., U.S. Patent No. 4,816,397; Boss et al., European Patent No. 0,120,694B1; Neuberger, MS et al., WO 86 / 01533; Neuberger, MS et al., European Patent No. 0,194,276B1; Winter, U.S. Patent No. 5,225,539; and Winter, European Patent No. 0,239,400B1. See also, Newman, R. et al., BioTechnology 10:1455-1460 (1992) regarding primatized antibodies. See, e.g., Ladner et al., U.S. Pat. No. 4,946,778; and Bird, RE et al., Science 242:423-426 (1988) regarding single chain antibodies.

[0195] Additionally, functional fragments of antibodies, including fragments of chimeric, humanized, primatized, or single chain antibodies, can also be used. Functional fragments of a subject antibody retain at least one binding function and / or modulation function of the full-length antibody from which they are derived. In certain embodiments, functional fragments retain the antigen-binding function (e.g., specificity for tumors) of the corresponding full-length antibody. Hold.

[0196] For example, antibody fragments capable of binding to an antigen receptor or portions thereof, including but not limited to Fv, Fab, Fab' and F(ab')2 fragments, are encompassed by the present invention. Such fragments can be produced by enzymatic cleavage or recombinant techniques. For example, papain or pepsin cleavage can generate Fab or F(ab')2 fragments, respectively. Antibodies produced in various truncated forms using antibody genes in which one or more stop codons have been introduced upstream of the natural stop site are encompassed by the present invention. For example, a chimeric gene encoding a F(ab')2 heavy chain portion can be designed to include DNA sequences encoding the CH1 domain and hinge region of the heavy chain.

[0197] The term "humanized immunoglobulin" as used herein refers to an immunoglobulin that comprises portions of immunoglobulins of different origins, at least one portion of which is of human origin. Thus, the present invention encompasses humanized immunoglobulins having binding specificity for an antigen (e.g., a human antigen), said immunoglobulins comprising an antigen-binding region of non-human origin (e.g., rodent) and at least a portion of an immunoglobulin of human origin (e.g., a human framework region, a human constant region or a portion thereof). For example, a humanized antibody can comprise a portion derived from an immunoglobulin of non-human origin, such as mouse, having the requisite specificity, and a portion derived from an immunoglobulin sequence of human origin (e.g., a chimeric immunoglobulin), joined together chemically by conventional techniques (e.g., synthesis) or prepared as a contiguous polypeptide using genetic engineering techniques (e.g., DNA encoding the protein portions of a chimeric antibody can be expressed to produce a contiguous polypeptide chain).

[0198] Another example of a humanized immunoglobulin is an immunoglobulin that contains one or more immunoglobulin chains that include CDRs of non-human origin (e.g., one or more CDRs derived from an antibody of non-human origin) and framework regions derived from light and / or heavy chains of human origin (e.g., a CDR-grafted antibody with or without framework alterations).

[0199] In some embodiments, the antibody is an antagonist antibody.As described herein, the term "antagonist antibody" refers to an antibody that can inhibit one or more functions of target, such as binding activity (e.g., ligand binding) and signal transduction activity (e.g., amino acid transport).For example, antagonist antibody can inhibit (reduce or prevent) the transport of glutamine by antigen.

[0200] In some embodiments, anti-idiotypic antibodies are also useful. Anti-idiotypic antibodies recognize antigenic determinants associated with the antigen-binding site of another antibody. Anti-idiotypic antibodies can be prepared against a second antibody by immunizing an animal of the same species, and may be of the same strain as the animal used to generate the second antibody. See, for example, U.S. Pat. No. 4,699,880. In one embodiment, antibodies are raised against a receptor or a portion thereof, and these antibodies are then used to generate anti-idiotypic antibodies. Such anti-idiotypic antibodies may also be inhibitors of antigen transport function, although they do not bind to the antigen itself. Such anti-idiotypic antibodies may also be called antagonist antibodies.

[0201] In some embodiments, suitable antibodies can be fragmented using conventional techniques and the fragments screened for utility in the same manner as described above for whole antibodies For example, F(ab)2 fragments can be generated by treating an antibody with pepsin. The resulting F(ab)2 fragment can be treated to reduce disulfide bridges to generate Fab fragments.

[0202] In some embodiments, suitable antibodies are further intended to include bispecific single chains, as well as chimeric and humanized molecules, that have affinity for an antigen polypeptide conferred by at least one CDR region of the antibody. Also, techniques for producing single chain antibodies (U.S. Pat. No. 4,946,778) can be adapted to produce single chain antibodies. Also, transgenic mice or other organisms, including other mammals, can be used to express humanized antibodies. Methods for producing these antibodies are known in the art. See, for example, Cabilly et al., U.S. Pat. No. 4,816,567; Cabilly et al., European Patent No. 0,125,023 B1; Queen et al., European Patent No. 0,451,216 B1; Boss et al., U.S. Pat. No. 4,816,567; 16,397; Boss et al., European Patent No. 0,120,694E1; Neuberger, MS et al., WO 86 / 01533; Neuberger, MS et al., European Patent No. 0,194,276B1; Winter, U.S. Patent No. 5,225,539; Winter, European Patent No. 0,239,400B1; Padlan, EA et al., European Patent Application No. 0,519,596A1. See also, Ladner et al., U.S. Pat. No. 4,946,778; Huston, U.S. Pat. No. 5,476,786; and Bird, RE et al., Science 242:423-426 (1988).

[0203] Such humanized immunoglobulins can be produced using synthetic and / or recombinant nucleic acids to prepare genes (e.g., cDNAs) encoding the desired humanized chains. For example, nucleic acid (e.g., DNA) sequences encoding humanized variable regions can be constructed using PCR mutagenesis methods to alter the DNA sequences encoding the human or humanized chains, e.g., DNA templates derived from variable regions that have already been humanized (see, e.g., Kamman, M. et al., Nucl. Acids Res., 17:5404 (1989); Sato, K. et al., Cancer Research, 53:851-856 (1993); Daugherty, BL et al., Nucleic Acids Res., 19(9):2471-2476 (1991); and Lewis, AP and JS Crowe, Gene, 101:297-302 (1991)). Also, variants can be readily generated using these or other suitable methods. In one embodiment, cloned variable regions can be mutagenized and sequences encoding variants with the desired specificity can be selected (e.g., from a phage library; see, e.g., Krebber et al., U.S. Pat. No. 5,514,548; Hoogenboom et al., WO 93 / 06213, published April 1, 1993).

[0204] In some embodiments, the antibody is a monoclonal antibody. For example, a method for producing a monoclonal antibody that specifically binds to an antigen polypeptide may include administering to a mouse an amount of an immunogenic composition that includes an antigen polypeptide effective to stimulate a detectable immune response, obtaining antibody-producing cells (e.g., cells from the spleen) from the mouse, fusing the antibody-producing cells with myeloma cells to obtain hybridomas that produce antibodies, and testing the antibody-producing hybridomas to identify hybridomas that produce monoclonal antibodies that specifically bind to the antigen polypeptide. Once a hybridoma is obtained, the hybridoma can be grown in cell culture, optionally under culture conditions in which cells derived from the hybridoma produce monoclonal antibodies that specifically bind to the antigen polypeptide. The monoclonal antibody can be purified from the cell culture.

[0205] Furthermore, the techniques used to screen antibodies to identify desirable antibodies can affect the properties of the resulting antibody. For example, antibodies used for certain therapeutic purposes may specifically target a cell type. Thus, to obtain this type of antibody, it may be desirable to screen for antibodies that bind to cells expressing the antigen of interest (e.g., by fluorescence-activated cell sorting). Similarly, antibodies When an antibody is used to bind an antigen in solution, it may be desirable to test solution binding. A variety of different techniques are available to test antibody:antigen interactions to identify particularly desirable antibodies. Such techniques include ELISA, surface plasmon resonance binding assays (e.g., Biacore binding assays, Biacore AB, Uppsala, Sweden), sandwich assays (e.g., paramagnetic bead systems from IGEN International, Inc., Gaithersburg, Md.), Western blots, immunoprecipitation assays, and immunohistochemistry. Pharmaceutical Compositions

[0206] In some embodiments, the present invention provides pharmaceutical compositions comprising the compounds described herein.

[0207] The total amount of the compound in the composition administered to the patient is an amount appropriate for that patient. Those skilled in the art will understand that different individuals may require different total amounts of therapeutically effective substances. In some embodiments, the amount of the compound is a pharma- ceutically effective amount. Those skilled in the art can determine the amount of the compound in the composition required to treat the patient based on factors such as the age, weight, and physical condition of the patient. The concentration of the compound depends on its solubility in the intravenous solution and the volume of fluid that may be administered. For example, the concentration of the compound may be about 0.1 mg / ml to about 50 mg / ml in the injectable composition. In some embodiments, the concentration of the compound may be about 0.1 mg / ml to about 25 mg / ml, about 7 mg / ml to about 17 mg / ml, about 0.1 mg / ml to about 5 mg / ml, or about 0.25 mg / ml to about 4.5 mg / ml. In certain embodiments, the concentration of the compound is about 0.1 mg / ml, about 0.2 mg / ml, about 0.3 mg / ml, about 0.4 mg / ml, about 0.5 mg / ml, about 0.6 mg / ml, about 0.7 mg / ml, about 0.8 mg / ml, about 0.9 mg / ml, about 1.0 mg / ml, about 1.1 mg / ml, about 1.2 mg / ml, about 1.3 mg / ml, about 1.4 mg / ml, about 1.5 mg / ml, about 1.6 mg / ml, about 1.7 mg / ml, about 1.8 mg / ml, about 1.9 mg / ml, about 2.0 mg / ml, about 2.1 mg / ml, about 2.2 mg / ml, about 2.3 mg / ml, about 2.4 mg / ml, about 2.5 mg / ml, about 2.6 mg / ml, about 2.7 mg / ml, about 2.8 mg / ml, about 2.9 mg / ml, about 3.0 mg / ml, about 3.5 mg / ml, about 3.6 mg / ml, about 3.7 mg / ml, about 3.8 mg / ml, about 3.9 mg / ml, about 4.0 mg / ml, about 4.1 mg / ml, about 4.2 mg / ml, about 4.3 mg / ml, about 4.4 mg / ml, about 4.5 mg / ml, about 4.6 mg / ml, about 4.7 mg / ml, about 4.8 mg / ml, about 4.9 mg / ml, about 5.0 mg / ml, about 5.1 mg / ml, about 5.2 mg / ml, about 5.3 mg / ml, about 5.4 mg / ml, about 5.5 mg / ml, about 5.6 mg / ml, about 5.7 mg / ml, about 5.8 mg / ml, about 5.9 mg / ml, about 6.0 mg g / ml, about 3.1 mg / ml, about 3.2 mg / ml, about 3.3 mg / ml, about 3.4 mg / ml, about 3.5 mg / ml, about 3.6 mg / ml, about 3.7 mg / ml, about 3. 8mg / ml, approx. 3.9mg / ml, approx. 4.0mg / ml, approx. 4.1mg / ml, approx. 4.2mg / ml, approx. 4.3mg / ml, approx. 4.4mg / ml, approx. 4.5mg / ml, approx. It can be about 4.6 mg / ml, about 4.7 mg / ml, about 4.8 mg / ml, about 4.9 mg / ml, about 5.0 mg / ml, about 5.1 mg / ml, about 5.2 mg / ml, about 5.3 mg / ml, about 5.4 mg / ml, about 5.5 mg / ml, about 5.6 mg / ml, about 5.7 mg / ml, about 5.8 mg / ml, about 5.9 mg / ml, or about 6.0 mg / ml.In some embodiments, the concentration of the compound may be about 7 mg / ml, about 8 mg / ml, about 9 mg / ml, about 10 mg / ml, about 11 mg / ml, about 12 mg / ml, about 13 mg / ml, about 14 mg / ml, about 15 mg / ml, about 16 mg / ml, about 17 mg / ml, about 18 mg / ml, about 19 mg / ml, about 20 mg / ml, about 21 mg / ml, about 22 mg / ml, about 23 mg / ml, about 24 mg / ml, about 25 mg / ml, about 26 mg / ml, about 27 mg / ml, about 28 mg / ml, about 29 mg / ml, or about 30 mg / ml.

[0208] The pharmaceutical compositions and kits of the present invention may also contain excipients, fillers, salts, buffers, stabilizers, solubilizers, and other materials known in the art. The term "pharmaceutical acceptable" refers to a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredient(s). The characteristics of the carrier depend on the route of administration.

[0209] The compositions can be administered in a variety of conventional ways. Exemplary routes of administration that can be used include These include oral, parenteral, intravenous, intraarterial, cutaneous, subcutaneous, intramuscular, topical, intracranial, intraorbital, ophthalmic, intravitreal, intraventricular, intraarticular, intraspinal, intracisternal, intraperitoneal, intranasal, aerosol, central nervous system (CNS) administration, or administration by suppository. In some embodiments, the compositions are suitable for parenteral administration. These compositions can be administered, for example, intraperitoneally, intravenously, or intrathecally. In some embodiments, the compositions are injected intravenously. In some embodiments, the reconstituted formulation can be prepared by reconstituting a composition of a lyophilized anthracycline compound with a reconstitution liquid comprising ethanol and water. Such reconstitution can include adding the reconstitution liquid and mixing, for example, by swirling or vortexing the mixture. The reconstituted formulation can then be made suitable for injection, for example, by mixing lactated Ringer's solution with the formulation to create an injectable composition. Those skilled in the art will understand that the method of administering a therapeutically effective agent formulation or composition will depend on factors such as the age, weight and physical condition of the patient being treated, as well as the disease or condition being treated. Thus, those skilled in the art will be able to select the most suitable administration method for a patient on a case-by-case basis.

[0210] In some embodiments, the present invention provides compounds and compositions for use as pharmaceuticals. In some embodiments, the present invention provides compounds and compositions for use in the treatment of cancer, viral diseases, autoimmune diseases, acute or chronic inflammatory diseases, and diseases caused by bacteria, fungi or other microorganisms.

[0211] In some embodiments, the compounds disclosed herein can be used in the manufacture or preparation of a medicament for treating a disease or condition selected from the group consisting of cancer, viral diseases, autoimmune diseases, acute or chronic inflammatory diseases, and diseases caused by bacteria, fungi and other microorganisms.

[0212] In some embodiments, the cancer is a hematological cancer or a solid tumor cancer, hi some embodiments, the cancer is selected from a carcinoma, a sarcoma, a leukemia, a lymphoma, multiple myeloma, or a melanoma.

[0213] In some embodiments, the cancer is adenocarcinoma, uveal melanoma, acute leukemia, acoustic neuroma, ampullary carcinoma, anal carcinoma, astrocytoma, basal cell carcinoma, pancreatic cancer, connective tissue tumors, bladder cancer, bronchial carcinoma, non-small cell bronchial carcinoma, breast cancer, Burkitt's lymphoma, uterine cancer, CUP syndrome, colon cancer, cancer of the small intestine, ovarian cancer, endometrial cancer, gallbladder cancer, uterine cancer, cervical cancer, cervical, nose and ear tumors, hematological neoplasia, hairy cell leukemia, urethral cancer, skin cancer, glioma, testicular cancer, Kaposi's sarcoma, laryngeal cancer, bone cancer, colorectal cancer, head / neck tumors, colon cancer, craniopharyngeoma, liver cancer, eukaemia, lung cancer, non-small cell lung cancer, alveolar lung cancer, Hodgkin's lymphoma, non-Hodgkin's lymphoma, gastric cancer, colon cancer, medulloblastoma, melanoma, meningioma, kidney cancer, renal cell carcinoma, oligodendroglioma, esophageal cancer, osteolytic and osteogenic carcinoma, osteosarcoma, ovarian cancer, pancreatic cancer, penile cancer, prostate cancer, tongue cancer, ovarian cancer or lymphatic cancer.

[0214] In some embodiments, the present invention provides kits comprising a compound described herein and a pharma- ceutically acceptable excipient, carrier and / or diluent.

[0215] In some embodiments, one or more additives may be included in the composition. Those skilled in the art will understand that the selection of any one additive may affect the selection of any other additive. For example, the selection of a particular additive may avoid the use of one or more additional additives because the combination of additives may produce undesirable effects. Those skilled in the art can empirically determine which additives, if any, to include in the composition. Additives include co-solvents, solubilizers, buffers, pH adjusters, bulking agents, surfactants, encapsulants, soaking agents, and the like. These may include, but are not limited to, osmolarity adjusting agents, stabilizers, protectants, and viscosity adjusting agents. In some embodiments, it may be beneficial to include a pharma- ceutically acceptable carrier in the composition.

[0216] In some embodiments, solubilizers may be included in the composition.Solubilizers may be useful for increasing the solubility of any of the components of the composition, including compounds or additives.The solubilizers described herein are not intended to constitute an exhaustive list, but are merely presented as exemplary solubilizers that may be used in the composition.In certain embodiments, the solubilizers include, but are not limited to, ethyl alcohol, tert-butyl alcohol, polyethylene glycol, glycerol, methylparaben, propylparaben, polyethylene glycol, polyvinylpyrrolidone, and any pharma-ceutically acceptable salts and / or combinations thereof.

[0217] The pH of the composition can be any pH that provides desirable properties for the formulation or composition. Desirable properties can include, for example, compound stability, increased compound retention compared to compositions at other pHs, and improved filtration efficiency. In some embodiments, the pH of the composition can be about 3.0 to about 9.0, such as about 5.0 to about 7.0. In certain embodiments, the pH of the composition can be 5.5±0.1, 5.6±0.1, 5.7±0.1, 5.8±0.1, 5.9±0.1, 6.0±0.1, 6.1±0.1, 6.2±0.1, 6.3±0.1, 6.4±0.1, or 6.5±0.1.

[0218] In some embodiments, it may be beneficial to buffer pH by including one or more buffering agents in the composition.In certain embodiments, the buffering agent may have a pKa of, for example, about 5.5, about 6.0, or about 6.5.Those skilled in the art will understand that a suitable buffering agent may be selected to be included in the composition based on its pKa and other properties.Buffering agents are well known in the art.Therefore, the buffering agents described herein are not intended to constitute an exhaustive list, but are merely presented as exemplary buffering agents that may be used in the formulation or composition of the present invention. In certain embodiments, buffering agents include, but are not limited to, Tris, Tris HCl, potassium phosphate, sodium phosphate, sodium citrate, sodium ascorbate, a combination of sodium and potassium phosphate, Tris / Tris HCl, sodium bicarbonate, arginine phosphate, arginine hydrochloride, histidine hydrochloride, cacodylate, succinate, 2-(N-morpholino)ethanesulfonic acid (MES), maleate, bis-tris, phosphate, carbonate, and any pharma- ceutically acceptable salts and / or combinations thereof.

[0219] In some embodiments, pH adjusting agents may be included in the composition. Adjustment of the pH of the composition may have beneficial effects, for example, on the stability or solubility of the compound, or may be useful for making the composition suitable for parenteral administration. pH adjusting agents are well known in the art. Thus, the pH adjusting agents described herein do not constitute an exhaustive list, but are merely presented as exemplary pH adjusting agents that may be used in the composition. pH adjusting agents may include, for example, acids and bases. In some embodiments, pH adjusting agents may include, but are not limited to, acetic acid, hydrochloric acid, phosphoric acid, sodium hydroxide, sodium carbonate, and combinations thereof.

[0220] In some embodiments, a bulking agent may be included in the composition. Bulking agents are commonly used in lyophilized compositions to add volume to the composition and aid in the visualization of the composition, especially when it would be difficult to see the lyophilized pellet without the bulking agent. Bulking agents can also help prevent the active component(s) of the pharmaceutical composition from blowing away and / or aid in the cryoprotection of the composition. Bulking agents are well known in the art. Thus, the bulking agents described herein do not constitute an exhaustive list, and They are merely presented as exemplary bulking agents that may be used in the compositions.

[0221] Exemplary bulking agents may include sugars, monosaccharides, disaccharides, polysaccharides, sugar alcohols, amino acids, and sugar acids, and combinations thereof. Sugar bulking agents include monosaccharides, disaccharides or polysaccharides, starches, aldoses, ketoses, amino sugars, glyceraldehyde, arabinose, lyxose, pentoses, ribose, xylose, galactose, glucose, hexoses, idose, mannose, talose, heptose, glucose, fructose, methyl a-D-glucopyranoside, maltose, lactones, sorbose, erythrose, threose, arabinose, allose, altrose, gulose, idose, talose, erythrulose, ribulose, xylulose, psicose, tagatose, glyceraldehyde ... Examples of bulking agents include, but are not limited to, glycerol, glucosamine, galactosamine, arabinan, fructan, fucan, galactan, galacturonan, glucan, mannan, xylan, inulin, levan, fucoidan, carrageenan, galactocarolose, pectin, amylose, pullulan, glycogen, amylopectin, cellulose, pustulan, chitin, agarose, keratin, chondroitin, dermatan, hyaluronic acid, xanthin gum, sucrose, trehalose, dextran, and lactose. Sugar alcohol bulking agents include, but are not limited to, alditol, inositol, sorbitol, and mannitol. Amino acid bulking agents include, but are not limited to, glycine, histidine, and proline. Sugar acid bulking agents include, but are not limited to, aldonic acid, uronic acid, aldaric acid, gluconic acid, isoascorbic acid, ascorbic acid, glucaric acid, gluconic acid, glucaric acid, galacturonic acid, mannuronic acid, neuraminic acid, pectinic acid, and alginic acid.

[0222] In some embodiments, surfactants may be included in the composition. Surfactants generally reduce the surface tension of liquid compositions. Surfactants may provide beneficial properties such as improved ease of filtering. Surfactants may also act as emulsifiers and / or solubilizers. Surfactants are well known in the art. Thus, the surfactants described herein do not constitute an exhaustive list, but are merely presented as exemplary surfactants that may be used in the formulations or compositions of the present invention. Surfactants that may be included include, but are not limited to, sorbitan esters, such as polysorbates (e.g., polysorbate 20 and polysorbate 80), lipopolysaccharides, polyethylene glycols (e.g., PEG400 and PEG3000), poloxamers (i.e., Pluronic), ethylene oxides and polyethylene oxides (e.g., Triton X-100), saponins, phospholipids (e.g., lecithin), and combinations thereof.

[0223] In some embodiments, an encapsulating agent may be included in the composition. The encapsulating agent can sequester molecules and help stabilize or solubilize them. Encapsulating agents are well known in the art. Therefore, the encapsulating agents described herein do not constitute an exhaustive list, but are merely presented as exemplary encapsulating agents that may be used in the composition. Encapsulating agents that may be included in the composition include, but are not limited to, dimethyl-β-cyclodextrin, hydroxyethyl-β-cyclodextrin, hydroxypropyl-β-cyclodextrin, and trimethyl-β-cyclodextrin, and combinations thereof.

[0224] In some embodiments, an osmolality adjusting agent may be included in the composition. The osmolality of a liquid composition is an important consideration when administering the composition to a patient, for example, by parenteral administration. Thus, an osmolality adjusting agent may be used to help make the composition suitable for administration. Osmolality adjusting agents are well known in the art. Thus, the osmolality adjusting agents described herein do not constitute an exhaustive list, but are exemplary agents that may be used in the composition. The osmotic modifier is merely presented as a suitable osmotic modifier. The osmotic modifier may be ionic or non-ionic, and includes, but is not limited to, inorganic salts, amino acids, sugars, sugars, sugar alcohols, and sugars. Exemplary inorganic salts may include sodium chloride, potassium chloride, sodium sulfate, and potassium sulfate. An exemplary amino acid is glycine. Exemplary sugars may include sugar alcohols, such as glycerol, propylene glycol, glucose, sucrose, lactose, and mannitol.

[0225] In some embodiments, a stabilizer may be included in the composition. The stabilizer helps to increase the stability of the compound in the composition. The increased stability may occur, for example, by reducing the degradation of the compound or preventing its aggregation. Without being bound by theory, the mechanism of enhancing stability may include sequestering the compound from the solvent or inhibiting free radical oxidation of the therapeutically effective substance. Stabilizing agents are well known in the art. Thus, the stabilizers described herein do not constitute an exhaustive list, but are merely presented as exemplary stabilizers that may be used in the composition. Stabilizing agents may include, but are not limited to, emulsifiers and surfactants.

[0226] In some embodiments, a protective agent may be included in the composition. A protective agent is an agent that protects a pharma- ceutical active ingredient (e.g., a therapeutically effective substance or compound) from undesirable conditions (e.g., instability caused by freezing or lyophilization, or oxidation). Protective agents may include, for example, cryoprotectants, lyoprotectants, and antioxidants. Cryoprotectants are useful for preventing loss of potency of active pharmaceutical ingredients (e.g., anthracycline compounds) when the composition is exposed to temperatures below its freezing point. For example, a cryoprotectant may be included in a reconstituted lyophilized formulation so that the formulation can be frozen and then diluted for intravenous (IV) administration. Cryoprotectants are well known in the art. Thus, the cryoprotectants described herein do not constitute an exhaustive list, but are merely presented as exemplary cryoprotectants that may be used in the composition. Cryoprotectants include, but are not limited to, solvents, surfactants, encapsulants, stabilizers, viscosity modifiers, and combinations thereof. Cryoprotectants can include, for example, disaccharides (eg, sucrose, lactose, maltose, and trehalose), polyols (eg, glycerol, mannitol, sorbitol, and dulcitol), glycols (eg, ethylene glycol, polyethylene glycol, and propylene glycol).

[0227] Lyoprotectants are useful for stabilizing the components of the composition. For example, therapeutically effective substances can be reconstituted after lyophilization with lyoprotectants. Lyoprotectants are well known in the art. Thus, the lyoprotectants described herein do not constitute an exhaustive list, but are merely presented as exemplary lyoprotectants that may be used in the composition. Lyoprotectants include, but are not limited to, solvents, surfactants, encapsulants, stabilizers, viscosity modifiers, and combinations thereof. Exemplary lyoprotectants may be, for example, sugars and polyols. Trehalose, sucrose, dextran, and hydroxypropyl-beta-cyclodextrin are non-limiting examples of lyoprotectants.

[0228] Antioxidants are useful for preventing oxidation of the components of the composition. Oxidation may cause drug product to aggregate or have other adverse effects on the purity or potency of the drug product. Antioxidants are well known in the art. Thus, the antioxidants described herein do not constitute an exhaustive list, but are merely presented as exemplary antioxidants that may be used in the composition. Antioxidants may be, for example, sodium ascorbate, citrate, thiol, metabisulfite, and combinations thereof.

[0229] In some embodiments, a viscosity modifier may be included in the composition. The viscosity of the composition is changed. Viscosity modifiers can be beneficial because viscosity plays an important role in the ease of filtering of liquid compositions. The composition can be filtered before lyophilization and reconstitution or after reconstitution. Viscosity modifiers are well known in the art. Thus, the viscosity modifiers described herein do not constitute an exhaustive list, but are merely presented as exemplary viscosity modifiers that can be used in the composition. Viscosity modifiers include solvents, solubilizers, surfactants, and encapsulating agents. Exemplary viscosity modifiers that can be included in the composition include, but are not limited to, N-acetyl-DL-tryptophan and N-acetyl-cysteine. Treatment

[0230] The compounds and compositions described herein are useful in a variety of clinical applications.

[0231] The compounds and compositions of the present invention can induce prolonged or long-term inhibition of tumor growth. In certain embodiments, the prolonged or long-term inhibition of tumor growth is not accompanied by any weight loss or bone marrow toxicity.

[0232] The disclosure also provides a method of treating a condition or disease in a patient selected from cancer, a viral disease, an autoimmune disease, an acute or chronic inflammatory disease, and a disease caused by a bacteria, fungus or other microorganism, comprising administering to the patient a compound or pharmaceutical composition described herein.

[0233] In some embodiments, the cancer is a hematological cancer or a solid tumor cancer, hi some embodiments, the cancer is selected from a carcinoma, a sarcoma, a leukemia, a lymphoma, multiple myeloma, or a melanoma.

[0234] In some embodiments, the cancer is adenocarcinoma, uveal melanoma, acute leukemia, acoustic neuroma, ampullary carcinoma, anal carcinoma, astrocytoma, basal cell carcinoma, pancreatic cancer, connective tissue tumors, bladder cancer, bronchial carcinoma, non-small cell bronchial carcinoma, breast cancer, Burkitt's lymphoma, uterine cancer, CUP syndrome, colon cancer, cancer of the small intestine, ovarian cancer, endometrial cancer, gallbladder cancer, gallbladder cancer, uterine cancer, cervical cancer, cervical, nasal and ear tumors, hematological neoplasia, hairy cell leukemia, urethral cancer. , skin cancer, glioma, testicular cancer, Kaposi's sarcoma, laryngeal cancer, bone cancer, colorectal cancer, head / neck tumors, colon cancer, craniopharyngioma, liver cancer, leukemia, lung cancer, non-small cell lung cancer, Hodgkin's lymphoma, non-Hodgkin's lymphoma, gastric cancer, colon cancer, medulloblastoma, melanoma, meningioma, kidney cancer, renal cell carcinoma, oligodendroglioma, esophageal cancer, osteolytic and osteogenic carcinoma, osteosarcoma, ovarian cancer, pancreatic cancer, penile cancer, prostate cancer, tongue cancer, ovarian cancer or lymph node cancer. Changes and modifications

[0235] Variations, modifications, and other implementations of what is described herein may occur to those skilled in the art without departing from the spirit and scope of the present invention. Therefore, the present invention should not be limited to the above description or the following examples. Example

[0236] Having now broadly described aspects of the present invention, the same will be more readily understood by reference to the following examples, which are included merely for the purpose of illustrating, and not limiting, certain features and embodiments of the invention. Equivalent

[0237] Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, numerous equivalents to the compounds, compositions, and methods of use described herein which equivalents are considered to be within the scope of this invention. EXAMPLES

[0238] Example 1 Evaluation of gemcitabine and albumin-bound gemcitabine phosphate compound 15 in the human xenograft non-small cell lung cancer model LXFE397. Female NMRI nude mice were anesthetized with isoflurane and received unilateral tumor implants containing human LXFE397 (squamous cell carcinoma, poorly differentiated) subcutaneously in the left flank until the tumors were palpable and had a volume of 50–150 mm. 3 The animals were kept in cages with a temperature of 25 ± 1 °C, a relative humidity of 45-65%, and 60 air changes per hour in the cage. The animals were fed autoclaved Teklad Global 19% protein extruded diet (T.2019S.12) from Harlan Laboratories and had access to sterile filtered acidified (pH 2.5) tap water, which was changed twice weekly. Food and water were available ad libitum. The animals were randomized (8 mice per group) prior to treatment, taking into account comparable median and mean tumor volumes of the groups. The animals were routinely monitored twice daily during the week and once daily on Saturday and Sunday. Starting on day 0, the animals were weighed twice weekly. The relative body weight (RBW) of individual animals was calculated by dividing the individual absolute body weight (BWx) on day X by the individual body weight on the day of randomization. Tumor volumes are determined by bidimensional measurement with calipers on the day of randomization (day 0) and then twice weekly. Tumor volume is calculated according to the following equation: Tumor volume [mm 3 ]=a[mm]×b 2 [mm 2] × 0.5, where "a" is the maximum diameter of the idealized ellipsoid and "b" is the perpendicular diameter. The relative volume of an individual tumor on day X (RTVx) is calculated by multiplying the absolute volume [mm 3 The schedule is applied to the extent permitted by the animal welfare policy. Individual mice were randomized to receive a tumor volume >2000 mm. 3 Stock solutions of Compound 15 were prepared for the two treatment groups as follows. 1) 8 mice, average weight 40 g: 24 mg / kg gemcitabine equivalent ≡ 78.48 mg / kg ≡ 3.14 mg / mouse. Sample preparation: Weighed 154 mg into a 20 mL vial and dissolved in 14.7 mL 20 mM sodium phosphate buffer, pH 7. Four aliquots of 3.6 mL each were placed into 10 mL vials. Frozen in liquid nitrogen, lyophilized (>48 hours), and stoppered. 2) 8 mice, average weight 40 g: gemcitabine equivalent of 36 mg / kg ≡ 117.7 mg / kg ≡ 4.71 mg / mouse. Sample preparation: Weighed 231 mg into a 20 mL vial and dissolved in 14.7 mL 20 mM sodium phosphate buffer, pH 7. Four aliquots of 3.6 mL each were placed into 10 mL vials. Frozen in liquid nitrogen, lyophilized (>48 hours), and stoppered. On the day of treatment, the lyophilized samples were dissolved in 20 mM sodium phosphate buffer, pH 7, containing 5% glucose, and injected intravenously. Intravenous administration of vehicle (20 mM sodium phosphate buffer, 5% D-glucose-pH 7.0), gemcitabine (dissolved in 5% D-glucose; dose 240 mg / kg) and compound 15 (dissolved in 20 mM sodium phosphate buffer, 5% D-glucose-pH 7.0; gemcitabine equivalent of 24 mg / kg) was performed on days 1, 8, 15 and 22. On day 23, 3 mice in the control group and 2 mice in the gemcitabine-treated group had tumor volumes of 2000 mm 3Compound 15 (day 27) -0.5%. Tumor growth in the NSLC xenograft model LXFE397 was significantly increased with gemcitabine at 1 / 10th the dose, with equitoxic toxicity as indicated by comparable and less body weight loss. The superior antitumor efficacy of compound 15 over tabine is shown (p<0.05). See FIG.

[0239] FIG. 1 shows the effect of compound 15 and gemcitabine on tumor growth in the NSLC xenograft model LXFE397. Example 2

[0240] Evaluation of gemcitabine and albumin-bound gemcitabine phosphate compound 15 in the human non-small cell carcinoma xenograft model LXFE937. Female NMRI nude mice were implanted with unilateral tumor implants containing human LXFE937 tumor pieces subcutaneously in the left flank area under isoflurane anesthesia until the tumors became palpable and reached a volume of approximately 100 mm. 3 The animals were housed in cages maintained at a temperature of 25 ± 1 °C, a relative humidity of 45-65%, and an air change rate of 60 times per hour. The animals were kept in autoclaved Teklad fertilizers (Harlan Laboratories). The animals were fed a Global 19% protein extruded diet (T.2019S.12) and provided with sterile filtered acidified (pH 2.5) tap water, which was changed twice weekly. Food and water were available ad libitum. The animals were randomized (8 mice per group) prior to treatment, taking into account comparable median and mean tumor volumes of the groups. The animals were routinely monitored twice daily on weekdays and once daily on Saturdays and Sundays. Starting on day 0, the animals were weighed twice weekly. The relative body weight (RBW) of individual animals is calculated by dividing the individual absolute body weight (BWx) on day X by the individual body weight on the day of randomization. Tumor volumes are determined by bidimensional measurements with calipers on the day of randomization (day 0) and then twice weekly. Tumor volumes are calculated according to the following equation: Tumor volume [mm 3 ]=a[mm]×b 2 [mm 2 ] × 0.5, where "a" is the maximum diameter of the idealized ellipsoid and "b" is the perpendicular diameter. The relative volume of an individual tumor on day X (RTVx) is calculated by multiplying the absolute volume [mm 3 The schedule is applied to the extent permitted by the animal welfare policy. Individual mice were randomized to receive a tumor volume >2000 mm. 3 Stock solutions of Compound 15 were prepared for the two treatment groups as follows. 1) 8 mice, average weight 40 g: 2 x 18 mg / kg gemcitabine equivalents (given twice weekly; on days 0, 3, 7, 10, etc. for 4 weeks) ≡ 58.4 mg / kg ≡ 2.35 mg / mouse. Sample preparation: Weighed 115.5 mg into a 10 mL vial and dissolved in 7.35 mL 20 mM sodium phosphate buffer, pH 7. Four aliquots of 1.86 mL each were placed into 10 mL vials. Frozen in liquid nitrogen, lyophilized (>48 hours), and stoppered. On the day of treatment, the lyophilized samples were dissolved in 20 mM sodium phosphate buffer, pH 7, containing 5% glucose, and injected intravenously. Vehicle (20 mM sodium phosphate buffer, 5% D-glucose-pH 7.0), gemcitabine (dissolved in 5% D-glucose; dose 240 mg / kg) were administered intravenously on days 1, 8, 15, and 22, and compound 15 (dissolved in 20 mM sodium phosphate buffer, 5% D-glucose-pH 7.0; gemcitabine equivalent of 18 mg / kg) was administered intravenously on days 0, 3, 7, 10, 14, 17, 21, and 24. Body weight change (BWC) versus controls was comparable, approximately +10% in the gemcitabine-treated group and approximately +2% in the group treated with compound 15. Tumors in the gemcitabine-treated group began to regrow after about 20 days of treatment, with a mean tumor volume of approximately 700 mm after about 50 days of treatment. 3 Two mice in the gemcitabine-treated group had tumors with volumes of 2,000 mm 3 The mice had to be sacrificed between days 78 and 85 due to the tumor growth rate exceeding 100%. In contrast, complete tumor remission was observed approximately 60 days after the end of treatment in the 15-treated group. Thus, tumor growth development in the human non-small cell carcinoma xenograft model LXFE937 indicates superior antitumor efficacy of compound 15 versus gemcitabine at approximately one-seventh the gemcitabine dose with equitoxicity as indicated by comparable body weight gain (p<0.05). See Figures 2 and 3.

[0241] FIG. 2 shows tumor growth curves for the control group, the gemcitabine-treated group, and the compound 15-treated group in the human non-small cell carcinoma xenograft model LXFE937.

[0242] FIG. 3 shows the body weight change curves of the control group, the gemcitabine-treated group, and the compound 15-treated group in the human non-small cell carcinoma xenograft model LXFE937. Example 3

[0243] Evaluation of gemcitabine and albumin-bound gemcitabine phosphate compound 15 in the human ovarian cancer xenograft model OVXF899. Female NMRI nude mice were implanted with unilateral tumor implants containing human OVXF899 tumor pieces subcutaneously in the left flank area under isoflurane anesthesia until the tumors became palpable and reached a volume of approximately 200 mm. 3 The animals were housed in cages maintained at a temperature of 25 ± 1 °C, a relative humidity of 45-65%, and an air change rate of 60 times per hour. The animals were kept in autoclaved Teklad fertilizers (Harlan Laboratories). The animals were fed a Global 19% protein extruded diet (T.2019S.12) and provided with sterile filtered acidified (pH 2.5) tap water, which was changed twice weekly. Food and water were available ad libitum. The animals were randomized (8 mice per group) prior to treatment, taking into account comparable median and mean tumor volumes of the groups. The animals were routinely monitored twice daily on weekdays and once daily on Saturdays and Sundays. Starting on day 0, the animals are weighed twice weekly. The relative body weight (RBW) of individual animals is calculated by dividing the individual absolute body weight (BWx) on day X by the individual body weight on the day of randomization. Tumor volumes are determined by bidimensional measurements with calipers on the day of randomization (day 0) and then twice weekly. Tumor volumes are calculated according to the following equation: Tumor volume [mm 3 ]=a[mm]×b 2 [mm 2 ] × 0.5, where "a" is the maximum diameter of the idealized ellipsoid and "b" is the perpendicular diameter. The relative volume of an individual tumor on day X (RTVx) is calculated by multiplying the absolute volume [mm 3 The schedule is applied to the extent permitted by the animal welfare policy. Individual mice were randomized to receive a tumor volume >2000 mm. 3 Stock solutions of Compound 15 were prepared for the two treatment groups as follows. 8 mice, average weight 40 g: 2 x 18 mg / kg gemcitabine equivalents (given twice weekly; days 1, 4, 8, etc. for 4 weeks) ≡ 58.4 mg / kg ≡ 2.35 mg / mouse. Sample preparation: Weighed 115.5 mg into a 10 mL vial and dissolved in 7.35 mL 20 mM sodium phosphate buffer, pH 7. Four aliquots of 1.86 mL each into 10 mL vials. Frozen in liquid nitrogen, lyophilized (>48 hours), and stoppered. On the day of treatment, the lyophilized samples were dissolved in 20 mM sodium phosphate buffer, pH 7, containing 5% glucose, and injected intravenously. Vehicle (20 mM sodium phosphate buffer, 5% D-glucose-pH 7.0), gemcitabine (dissolved in 5% D-glucose; dose 240 mg / kg) were administered intravenously on days 1, 8, 15, and 22, and compound 15 (dissolved in 20 mM sodium phosphate buffer, 5% D-glucose-pH 7.0; equivalent to 18 mg / kg gemcitabine) was administered intravenously on days 1, 4, 8, 11, 15, 18, 22, and 25. Body weight change (BWC) versus controls was comparable, approximately +5% in the gemcitabine-treated group and approximately +10% in the group treated with compound 15. Tumors in the gemcitabine-treated group began to regrow approximately 10 days after treatment, with a mean tumor volume of approximately 2000 mm after 50 days of treatment. 3 In the gemcitabine-treated group, three mice had tumors with volumes of 2,000 mm 3 The mice had to be sacrificed on day 74 due to the tumor growth rate exceeding 100%. In contrast, a complete tumor remission was observed 50 days after the end of treatment in the group treated with 15. Thus, Tumor growth development in the OVXF899 model indicates superior antitumor efficacy of compound 15 versus gemcitabine at approximately 1 / 7 the dose of gemcitabine with equitoxicity as indicated by comparable body weight gain (p<0.05). See Figures 4, 5 and 6.

[0244] FIG. 4 shows tumor growth curves for the control group, the gemcitabine-treated group, and the compound 15-treated group in a human ovarian OVXF cancer xenograft model.

[0245] FIG. 5 shows the body weight change curves of the control group, the gemcitabine-treated group, and the compound 15-treated group in a human ovarian OVXF cancer xenograft model.

[0246] FIG. 6 shows a scatter plot of individual tumor volumes following treatment with compound 15 or gemcitabine in an ovarian cancer OVXF899 xenograft model. Example 4

[0247] Evaluation of gemcitabine and albumin-bound gemcitabine phosphate compound 15 in the human pancreatic cancer xenograft model Panc11159 Female NMRI nude mice (nu / nu) were implanted with unilateral Panc11159 tumor pieces subcutaneously until the tumors became palpable and reached a volume of approximately 200 mm. 3 The mice were kept in cages (Macrolon type-II wire-mesh) with a temperature of 22 ± 1 °C and a relative humidity of 50 ± 10%. Light / dark period: artificial; 12 h dark / 12 h light rhythm (lights 06.00-18.00 h). The health of the mice was checked at the beginning and twice daily during the experiment. Identification: ear tags and cage labels. The animals were fed Ssniff NM, Soest, Germany, and had access to autoclaved acidic (pH 4.0) beverages. Food and water were available ad libitum. The animals were randomized (10 mice per group) before treatment, taking into account comparable median and mean tumor volumes of the groups. Measurement of body weight change was performed twice or three times a week. Tumor diameter (median and mean) was measured twice or three times a week using calipers. Tumor volume was calculated according to V=(length×(width)2) / 2. For calculation of relative tumor volume (RTV), the tumor volume of each measurement day was related to the first treatment day. Stock solutions of compound 15 were prepared for the two treatment groups as follows: 10 mice, average weight 30-40 g: 2 × 18 mg / kg gemcitabine equivalent (twice weekly for 4 weeks) ≡ 58.4 mg / kg ≡ 2.35 mg / mouse. Sample preparation: 115.5 mg was weighed into a 10 mL vial and dissolved in 7.35 mL 20 mM sodium phosphate buffer, pH 7. Four aliquots of 1.86 mL each were placed into 10 mL vials. Frozen in liquid nitrogen, lyophilized (>48 h), and stoppered. On the day of treatment, the lyophilized samples were dissolved in 20 mM sodium phosphate buffer, pH 7, containing 5% glucose, and injected intravenously. Vehicle (20 mM sodium phosphate buffer, 5% D-glucose-pH 7.0), gemcitabine (dissolved in 5% D-glucose; dose 240 mg / kg) were administered intravenously on days 36, 43, 50, and 57, and compound 15 (dissolved in 20 mM sodium phosphate buffer, 5% D-glucose-pH 7.0; gemcitabine equivalent of 18 mg / kg) was administered intravenously on days 36, 40, 43, 47, 50, 54, 57, and 60. Body weight change (BWC) versus controls was comparable, approximately +3% in both gemcitabine and compound 15 treated groups. The tumor volume in the gemcitabine-treated group doubled by day 85, whereas the tumor volume in the group treated with 15 demonstrated only minor regression or stable disease. Thus, tumor growth development in the human pancreatic cancer xenograft model Panc11159 demonstrated superior antitumor activity of compound 15 versus gemcitabine at approximately one-seventh the gemcitabine dose with equitoxicity as indicated by comparable body weight gain. Tumor efficacy was demonstrated (p<0.05). See Figures 7 and 8.

[0248] FIG. 7 shows tumor growth curves of the control group, the gemcitabine-treated group, and the compound 15-treated group in the pancreatic cancer Panc11159 xenograft model.

[0249] FIG. 8 shows the body weight change curves of the control group, the gemcitabine-treated group, and the compound 15-treated group in the pancreatic cancer Panc11159 xenograft model. Example 5

[0250] A general procedure for the synthesis of substituted maleimidobenzoylhydrazone derivatives of nemorubicin. Typically, anhydrous methanol was added to a mixture of nemorubicin (1 eq.) and substituted maleimidobenzoic acid hydrazide trifluoroacetate (2 eq.) at room temperature (RT), and the reaction mixture was stirred at RT. After the reaction was complete as shown by TLC, the substituted maleimidobenzoyl hydrazone derivative of nemorubicin was isolated as a red solid by precipitation or crystallization with a mixture of isopropanol and diisopropyl ether, and the resulting product was dried under high vacuum.

[0251] A general procedure for release studies of albumin-bound substituted maleimidobenzoylhydrazone derivatives of nemorubicin. Typically, the substituted maleimidobenzoylhydrazone derivative of nemorubicin was dissolved in 20:80 EtOH / 5%-glucose and added to human serum albumin (HSA) in which cysteine ​​34 position was fully reduced in 4 mM phosphate buffer, pH 7.4, and incubated at 37°C for 2 hours. The albumin drug conjugate was isolated using Sephadex G-25 and eluted with 4 mM phosphate buffer, pH 7.4, containing 150 mM NaCl. The purity of the nemorubicin albumin conjugate was measured and analyzed by RP-HPLC, and the content of anthracycline in the sample was determined by spectrophotometry. In the drug release study at pH 5.0, a 200 μM solution of each nemorubicin human serum albumin (HSA) conjugate adjusted to pH 5.0 with 50 mM sodium acetate buffer was monitored by using RP-HPLC, and the release of nemorubicin was determined at 495 nm. The results are presented in Table A. Example 6

[0252] Method A: Preparation of Compound 15 Compound 15 can be prepared as shown in Scheme 1, as follows. [ka]

[0253] Synthesis of 4-acetyl-N-(1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)benzamide (B) [ka] To a stirred solution of 4-acetylbenzoic acid (8.25 g, 50.30 mmol) in CH2Cl2 (165 mL) was added oxalyl chloride (8.31 mL, 95.57 mmol) and DMF (catalytic amount) at 0 °C. The resulting mixture was stirred at room temperature for 2 h. The reaction mixture was concentrated to dryness under high vacuum to give 4-acetylbenzoyl chloride as a pale yellow solid. The crude material was used directly in the next step without any further purification. Yield: 9.15 g, 99.67%. To a stirred solution of gemcitabine hydrochloride (15 g, 50 mmol) in pyridine (150 mL) was added dropwise over 30 min at 0° C. [about 1.0 mL / min]. The resulting mixture was stirred at room temperature for 2 h. 4-Acetylbenzoyl chloride (9.12 g, 50 mmol) was added portionwise to the reaction mixture over 15 min (three portions, about 3.04 g / 5.0 min). The resulting mixture was stirred at 45° C. for 16 h. Ethanol (150 mL) was then added to the previous reaction mixture and stirred for 30 min. Demineralized water (75 mL) was then added and stirred for another 5 h. The reaction mixture was then concentrated to dryness and the residue was quenched with ice water (300 mL). The resulting solid was filtered through Whatman filter paper (11 μm) and dried under high vacuum for 5 h. The crude product was purified by silica gel flash chromatography. The crude mass was dissolved in CHCl, adsorbed onto silica gel (60-120 mesh, 60 g) and purified on a 60×12.5 cm flash column using 60-120 mesh silica gel and about 20 L of 60% ethyl acetate in petroleum ether as eluent. The resulting solid was washed with methanol (100 mL), filtered and dried under high vacuum for 5 h to give 4-acetyl-N-(1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)benzamide (B) as a white solid. Yield: 5.2 g, 12.71 mmol, 25.42%.

[0254] Synthesis of intermediate (C) [ka] In a 50 mL flask, 1.816 mL (19.54 mmol) of phosphoryl chloride was added to 12.2 mL of trimethyl phosphate. The clear, colorless solution was cooled in an ice bath, after which 2 g (4.89 mmol) of (B) was added. The suspension became clear after about 15 min, and the resulting pale yellow solution was stirred in an ice bath. After 2 h, 5 μL of the reaction mixture was carefully added to 1 mL of a 1:1 mixture of diethyl ether and saturated aqueous sodium bicarbonate. The milk suspension in the organic phase dissipated upon thorough mixing. 50 μL of the aqueous phase was removed and diluted with 150 μL of Millipore water and analyzed by LC-MS. After about 2.5 h, the reaction mixture was added dropwise with intermittent shaking to a mixture of 140 mL of Millipore water, 140 mL of saturated NaHCO3, and 600 mL of diethyl ether in a 1000 mL Erlenmeyer flask cooled in an ice bath. The mixture was transferred to a 1000 mL separatory funnel and shaken thoroughly. The aqueous phase was washed with an additional 400 mL of diethyl ether. The aqueous phase (pH 7-8) was isolated, filtered through a fritted funnel (pore size 3), placed in a 500 mL flask and acidified to pH 4 with concentrated HCl. The mixture was transferred to eight 50 mL Falcon tubes (approximately 40 mL each) and then stored overnight at 4° C. in a refrigerator. The suspension was centrifuged (3220 rpm / 30 min), the supernatant was removed by pipette and the residue was freeze-dried. Yield: (4.195 g / 175%, theoretical: 2.393 g). The solid was dissolved in 275 mL of methanol, then 75 mL of tetrahydrofuran was added and the mixture was stored at 5° C. for 3 days. The solvent was removed in vacuo to about 150 mL, then 60 mL of tetrahydrofuran was added to form a white precipitate which was filtered and washed with 20 mL of tetrahydrofuran / methanol (1:1). (C) was isolated from the filtrate as a white solid. Yield: 3 g.

[0255] Synthesis of Linker (A) [ka] 4-Amino-2-nitrobenzoic acid (4.62 g, 25.36 mmol) was stirred with tert-butyl carbazate (5.04 g, 38.14 mmol), HOBt hydrate (5.297 g, 34.6 mmol) and EDC (4.84 g, 25.25 mmol) in 120 mL of a 1:2 dimethylformamide / dichloromethane mixture in an ice bath for 15 minutes, then stirred at room temperature overnight. TLC (CHCl3 / methanol, 9:1) showed the reaction was complete after 26 hours. The crude product was purified by column chromatography on silica to give the pure compound as a yellow foam (6.2 g, 82%). In a 250 mL flask, 4-amino-2-nitrocarbazate (2.827 g, 9.54 mmol) was dissolved in 80 mL of tetrahydrofuran. To the stirred solution was added 6-maleimidocaproic acid chloride (2.41 g, 10.5 mmol) dissolved in 30 mL of tetrahydrofuran. Triethylamine (1.455 mL, 10.5 mmol) mixed with 40 mL of THF was added dropwise to the mixture over 1 h using a dropping funnel. The resulting light brown suspension was stirred at room temperature for 15 h. TLC (CHCl3 / methanol, 9:1) showed the reaction was complete. The crude product was purified by silica gel flash chromatography (CHCl3 / methanol, 9:1) to give the pure product as a yellow solid (3 g, 64%). The product (3 g, 6.13 mmol) was suspended in 10 mL of dichloromethane and cooled in an ice bath. 10 mL of trifluoroacetic acid was added dropwise to the cooled stirred mixture over 30 min using a dropping funnel. After 3 hours, TLC (CHCl3 / methanol, 9:1) of the yellow solution indicates complete cleavage of the BOC group. All solvents were removed under reduced pressure and the residue was dried under high vacuum overnight. The residue was dissolved in a minimum amount of tetrahydrofuran, precipitated in a 1:1 mixture of diisopropyl ether and n-hexane, then stored at 5°C overnight. The cream-colored precipitate was isolated by centrifugation, washed with diethyl ether, and dried under high vacuum to give 2.5 g (81%) of Linker A as a beige solid.

[0256] Synthesis of compound 15 [ka] (C) was dissolved (2 x 375 mg (1.226 mmol) in 30 mL of anhydrous methanol in two 50 mL Falcon tubes each), centrifuged (3220 rpm, 10 min), and the supernatant was added to linker (A) (1.235 g, 2.452 mmol) and suspended in 20 mL of anhydrous methanol in a 250 mL flask. An additional 40 mL of methanol and 2 mL of acetonitrile were added and the pale yellow cloudy solution was stirred at room temperature. After 15 h, TLC of the reaction mixture (RP-18, acetonitrile / NaH2PO4, 30:70) shows complete consumption of (C). The mixture was evaporated to approximately 30 mL, transferred to a 50 mL Falcon tube, and stored at 5 °C (1 h). The precipitate was collected by centrifugation (3220 rpm, 10 min) and the supernatant (3 × 10 mL) was diluted with chilled 3:1 mixture of diisopropyl ether / isopropanol (3 × 30 mL) in three 50 mL Falcon tubes. and stored at 5 °C overnight. The precipitate was collected by centrifugation (3220 rpm, 15 min), washed with 5 mL of diethyl ether, and air-dried under high vacuum to give 903 mg (85.6% of theoretical 1.055 g) of compound 15 as a yellow solid. The crude products were combined in one 50 mL Falcon tube, washed with tetrahydrofuran (6 × 10-15 mL), and centrifuged after each washing step (3220 rpm, 10 min). Finally, the product was washed three times with 5-10 mL of diethyl ether and air-dried under high vacuum to give 694.4 mg (66%) of compound 15 as a yellowish solid.

[0257] pH-dependent stability of HSA compound 15 at pH 7.0 and 5.0 Stability at pH 7.0 (4 mM phosphate buffer, 150 mM NaCl): Compound 15 was added to a solution of fully reduced HSA (human serum albumin) and complete conjugation to cysteine-34 was confirmed by HPLC. The resulting 200 μM solution of the HSA conjugate of compound 15 was incubated at 37° C. and analyzed by HPLC every hour. Approximately 0.18% of (C) was released per hour. Stability at pH 5.0 (4 mM phosphate buffer, 150 mM NaCl adjusted with 1 M HCl): The HSA conjugate of compound 15 was prepared at pH 7.0 (see above) and adjusted to pH 5.0 by adding 1 M HCl. The resulting 200 μM solution of the HSA conjugate of compound 15 was incubated at 37° C. and analyzed by HPLC every hour. The half-life (t 1 / 2 ) is approximately 13 hours.

[0258] Method B: Preparation of Compound 15. Compound 15 can be prepared by the following alternative method.

[0259] Synthesis of 4-acetyl-N-(1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)benzamide (B) Synthesis of 2,5-dioxopyrrolidin-1-yl 4-acetylbenzoate: Under nitrogen atmosphere, a 4-L three-necked round bottom flask was charged with 4-acetylbenzoic acid (1.0 equiv., 487.8 mmol, 80.00 g), N-hydroxysuccinimide (NHS) (1.1 equiv., 536.6 mmol, 61.75 g), and anhydrous THF (1.80 L). The contents of the reaction solution were stirred at a constant speed using an IKA Eurostar digital overhead stirrer (power controlled at 190 rpm). The solution was cooled using an ice bath (60 min). Next, a solution of N,N'-dicyclohexylcarbodiimide (DCC) (1.1 equiv., 536.6 mmol, 110.71 g) in anhydrous THF (720 mL) was added dropwise (over 90 min) with stirring under nitrogen (the addition funnel was washed with 2 x 5 mL anhydrous THF). Approximately 30 min after the addition of DCC, the reaction mixture became cloudy due to the formation of N,N'-dicyclohexylurea (DCU) as a white precipitate. Ice was added continuously to the ice bath while the reaction mixture was stirred at 0°C for an additional 2 h. The reaction mixture was then allowed to warm slowly to room temperature without removing the ice bath and react until HPLC analysis showed complete consumption of the carboxylic acid after 25 h 30 min. The solid material was removed by suction filtration. The solid was washed with dry THF (4 x 100 mL) and the combined fractions were evaporated to dryness in vacuo at 40°C. The residue was dissolved in dry dichloromethane (400 mL) and the solution was stored at 4° C. for 15 h then filtered again. The solid was rinsed with pre-cooled dry dichloromethane (2×20 mL). The solvent was removed in vacuo at 30° C., the residue was redissolved in dry DCM (750 mL) and the organic layer was washed with chilled 5% aqueous NaOH (2×400 mL). The organic layer was washed with distilled H2O (400 mL) then dried over sodium sulfate (ca. 20 g), suction filtered and concentrated in vacuo at 30° C. to give the title compound. The compound was dried under high vacuum for 24 h to give (100.2 g, 79%) as an off-white solid (HPLC: 250nm >95.9%).

[0260] Synthesis of (B): Gemcitabine (1.0 equiv., 76.02 mmol, 20.00 g) was added to THF (532 mL) and distilled water (45.6 mL) was added in one portion to form a fine suspension that became a clear solution after 5 min of reflux (67° C.). Then, a solution of 2,5-dioxopyrrolidin-1-yl 4-acetylbenzoate (1.05 equiv., 79.82 mmol, 20.84 g) in THF (229 mL) was added dropwise via cannula over 6 min. After the addition was complete, the reaction mixture was stirred at reflux (67° C.) for 16 h. After 16 h, HPLC (PDA 266 nm) and LC-MS analysis showed approximately 20% unreacted starting gemcitabine. By HPLC analysis (PDA 266 nm), the reaction solution contained 53.8% product, 33.6% total polar impurities, and 12.6% total non-polar impurities. Purification of this batch of product involved successive selective washing steps of the crude product to remove any undesirable polar and non-polar impurities. The process involved slurry washing steps with different solvents that selectively dissolve the polar and non-polar impurities, in which the product is ideally insoluble or only slightly soluble. Thus, after 16 hours, the pale yellow reaction solution was brought to room temperature and the solvent was evaporated under vacuum at 40° C. to give a sticky residue. A first purification step was applied to remove polar impurities by washing with water, followed by filtration and further washing with water. Thus, water (300 mL) was added to the above crude product and the contents of the flask were triturated at room temperature (30 min) until a white fine suspension was obtained. The resulting suspension was then stirred at 50° C. for 15 min, filtered through a filter funnel (Por.4) and washed with water (2×25 mL) to obtain an amorphous solid (Solid 1), which was dried under vacuum for 15 h to obtain 26.34 g. HPLC analysis (266 nm) of this solid (Solid 1) showed a purity of 91.9%, with a total of 3.7% polar impurities and 4.4% non-polar impurities. A second purification step was applied to remove non-polar and remaining polar impurities from solid 1 by washing the slurry with a mixture of water and chloroform (2:1, v / v). Thus, water (200 mL) was poured into the flask containing solid 1, and the resulting suspension was stirred at 50° C. for 5 min, cooled to room temperature (0.5 h), slurried with chloroform (100 mL) at room temperature and stirred for 10 min until homogenous. The mixture was then allowed to settle (approximately 5 min), and the heterogeneous mixture was filtered off through a filter funnel (Por.4) and washed with cold water (2×15 mL) to obtain an amorphous solid (solid 2), which was then dried under high vacuum for 24 h to give the title compound (23.60 g, 76%) as a white solid (HPLC (266 nm)>94.21%). HPLC analysis (266 nm) of the filtered solid 2 showed 94.2% purity with a total of 1.7% polar impurities and 4.1% non-polar impurities. Chemical formula:C 18 H 17 F2N3O6, calculated value [M+H] + 410.12, Measured value [M+H] + 410.15

[0261] Synthesis of intermediate (C) Phosphorus oxychloride (4.2 equiv., 102.6 mmol, 9.59 mL) was added to cooled (0° C., ice-water bath) trimethyl phosphate (60 mL) and the clear solution was kept at 0° C. for 20 min. Solid (B) (1.0 equiv., 24.42 mmol, 10.00 g) was then added in three portions (3 g, 3 g, and 4 g). After about 20 min, the reaction mixture became homogenous, turned pale yellow, and was kept at 0° C. for 3.5 h. After 3 h, HPLC and LC-MS analysis indicated approximately 99% conversion. Once phosphorylation was complete (3.5 h), the mixture was filtered through a fritted funnel and then cooled (0° C.), vigorously stirred, and added dropwise to a freshly prepared mixture of saturated aqueous sodium bicarbonate (NaHCO3) and diethyl ether (450 mL, 300 mL) for 30 min. Stirring was continued for 10 min at 0° C. and 60 min at room temperature until a clear aqueous phase was obtained (internal temperature 15° C.). The organic layer was removed and the aqueous layer was washed with diethyl ether (1×300 mL). The emulsion remained partially emulsified until further addition of saturated NaHCO3 reached a de-emulsified state. 30 mL of saturated NaHCO3 was added to help break up the emulsified droplets and the phases were separated. The combined aqueous extracts (780 mL) were stirred at room temperature, adjusted to pH 4.0 with concentrated HCl (approximately 19 mL), and the solution was divided evenly into 50 mL Falcon tubes (total of 16) and stored at 4° C. for 2.5 days. After this period, a white solid precipitate had formed and the following steps were taken prior to analysis: · Samples were centrifuged at 10°C and 4,000 rpm for 20 minutes. The supernatant (aqueous phase) was removed by decantation, combined and dried in vacuum at 50° C., and the resulting solid was dried under high vacuum for 17 hours. The amorphous precipitate was redissolved in methanol (400 ml). The solution was transferred to a 1 liter round bottom flask and the solvent was evaporated under vacuum at 40° C. to give a white solid (Solid 1, 10.96 g), which was further dried under high vacuum for 20 h. HPLC analysis of the solid 95.4% (220 nm). Chemical formula:C 18 H 18 F2N3O9P, calculated value [MH] + 488.07, measured value [MH] + 488.55

[0262] Synthesis of Linker (A) [ka] Synthesis of tert-butyl 2-(4-amino-2-nitrobenzoyl)hydrazine-1-carboxylate: 4-amino-2-nitrobenzoic acid (1.0 equiv., 164.7 mmol, 30.00 g) was dissolved in a mixture of acetonitrile and tetrahydrofuran (1:1; 720 mL) and cooled to 6° C. using a salt-ice bath, then tert-butyl carbazate (1.5 equiv., 247.1 mmol, 32.65 g), HOBt (1.1 equiv., 181.2 mmol, 27.93 g) and EDC-HCl (1.0 equiv., 164.7 mmol, 31.64 g) were added and the reaction mixture was stirred on ice for 90 min, after which the ice bath was removed and the solution was stirred at room temperature for 16 h. The solids initially remaining in the reaction mixture dissolved within the first 2 h upon stirring. After the reaction solution was stirred for 16 h, the solvent was removed under reduced pressure (water bath: 40° C.). The crude (dark brown viscous oil) was dissolved in 2% n-butanol in dichloromethane (600 mL) and washed with saturated NH4Cl (2×600 mL), saturated NaHCO3 (1×600 mL), and distilled water (1×600 mL). The organic layer was then dried over sodium sulfate, Na2SO4 (200 g). The solvent was removed under reduced pressure (water bath: 40° C.) to give the title compound as a brown foam (purity: 98.4% by HPLC (220 nm); yield: 30.42 g (62%). Chemical formula: C 12 H 16 N4O5, calculated value [M+Na] + : 319.10, measured value [M+Na] + :319.08. Synthesis of 6-maleimidocaproic acid chloride: Dry dichloromethane (250 mL) was mixed with 10 mL of 6-maleimidocaproic acid (1.0 equiv, 236.6 mmol, 49.97 g) The reaction mixture was stirred at room temperature and added in one portion to a 1-liter, single-necked, round-bottom flask to give a yellow solution. A small amount of insoluble impurities was removed by filtering through a filter paper (MN 617 1 / 4, Φ185 mm) followed by rinsing with dry DCM (25 mL). To the solution, oxalic acid chloride (1.1 equiv., 259.6 mmol, 22.50 mL) was added dropwise (over 2 h) via a dropping funnel while stirring the reaction solution at room temperature. Note: gas evolution was observed during the addition process. The reaction mixture was stirred at room temperature and allowed to react until HPLC analysis showed complete consumption of 6-maleimidocaproic acid after 7 h 30 min. During the reaction time, the color of the reaction solution changed to dark yellow. 5 h 30 min after the addition of oxalic acid chloride was completed, the solvent was removed in vacuum at 30° C. The resulting dark yellow oil was then dried under high vacuum for 20 h. The resulting light brownish solid was crushed with a spatula and dried under high vacuum for an additional 20 h to give (53.35 g, 98%) as a light brownish solid (HPLC (220 nm) >97.6% as the methyl ester). Synthesis of Boc-protected linker A: A solution of 6-maleimidocaproic acid chloride (1.1 eq., 216.6 mmol, 49.70 g) in dry THF (382 mL) was added in one portion to a solution of tert-butyl 2-(4-amino-2-nitrobenzoyl)hydrazine-1-carboxylate (1.0 eq., 196.9 mmol, 58.34 g) in dry THF (580 mL) at room temperature. The clear reaction mixture was stirred at room temperature for 10 min. Then, a solution of DIPEA (1.1 eq., 216.6 mmol, 37.7 mL) in dry THF (120 mL) was added dropwise (over 1 h) via a dropping funnel with gentle stirring at room temperature. After the reaction was complete as shown by HPLC, the reaction mixture was stored at 4° C. for 14 h. The solvent was then removed under reduced pressure to give a dark brown viscous oil, which was then dissolved in DCM (450 mL) while shaking at room temperature for 10 min using a KL2 shaker (approximately 150 rpm; Edmund Buehler GmbH, Hechingen, Germany). The solution was transferred to a 2 L separatory funnel and the round-bottom flask was rinsed with additional DCM (450 mL), which was then added to the separatory funnel. The organic phase was washed successively with 5% HCl (900 mL), saturated aqueous NaHCO3 (900 mL), and 1 M NaH2PO4 (900 mL). After aqueous workup, the organic phase was dried over Na2SO4. The solvent was removed under reduced pressure and the residue was dried under high vacuum for 16 h to give the title compound (79.25 g) as a light brown foam. The crude product was further purified by flash chromatography to give 31.21 g, HPLC purity 99.6% (220 nm). 22 H 27 N5O8, calculated value [M+Na] + : 512.18, measured value [M+Na] + :512.04. Synthesis of Linker A: The protected linker (1.0 equiv., 30.60 mmol, 15.06 g) was placed in a 250 mL single-neck round-bottom flask and pre-cooled in an ice bath for 10 min. Pre-cooled TFA (26 equiv., 784 mmol, 60 mL) was added in one portion with stirring (250 rpm) with a magnetic stir bar. The mixture was further stirred for 45 min under ice bath cooling until HPLC analysis showed complete consumption of the protected linker. Since removal of TFA at room temperature or above was found to result in dimerization of Linker A, TFA was removed under high vacuum at low temperature (ice bath). Toluene was chosen as the addition solvent to facilitate the removal of TFA. Toluene (30 mL) was added to the reaction solution at 0° C., and then the TFA-toluene mixture was removed under high vacuum at 0° C. (Note: 1) the high vacuum was carefully controlled, and 2) the solution was not stirred to avoid the solution moving into the trap too quickly). An empty two-neck round-bottom flask (500 mL) cooled with liquid nitrogen was used as an additional cold trap for the condensed TFA and toluene. During the removal of TFA, the mixture foamed occasionally, and some of the solution spilled onto the inside of the connecting tube. After 30 min, most of the TFA-toluene mixture was removed, yielding an oily residue. To further remove TFA, another 30 mL of toluene was added to the flask, and TFA was removed as before. After 80 min, this process was repeated after adding an additional 20 mL of toluene. After 110 min, the additional cold trap was removed, and the wax-like material was directly connected to the high vacuum system. After 3 h 30 min, the ice bath was removed, and the oily residue was dried at room temperature for another 30 min to yield a foamy material. The foam-like residue was dissolved in N,N-dimethylformamide, DMF (30 mL) and the product was precipitated by dropwise addition of the DMF solution to a diisopropyl ether / methanol mixture (45:5, 1.5 L) at room temperature under vigorous stirring. Another 2 mL of DMF was used to rinse the reaction flask. The precipitate was filtered by suction through a fritted filter (Por.4) and washed with diisopropyl ether (3 x 200 mL) without drying the product (filter cake). After a final washing step with 200 mL of n-pentane, the cake was sucked dry. The yellowish solid was collected in a flask and dried under high vacuum for 18 hours. The product was stored at -20°C. Yield: 10.94 g (91.8%). Purity (average of three determinations): 99.0% (220 nm), 98.7% (247 nm). Calculated [M+H] + 390.14, Measured value [M+H] + 390.12.

[0263] Synthesis of compound 15 Gemcitabine derivative (C) (1.0 equiv., 9.29 mmol, 4.55 g) was suspended in anhydrous methanol (68.9 mL), followed by anhydrous DMSO (45.9 mL) and the clear transparent solution was stirred at room temperature for 5 min. After this period, linker (A) (1.0 equiv., 9.29 mmol, 3.62 g) was added in three portions, followed by 1.0 equiv. of TFA. The reaction mixture turned pale yellow and was stirred at room temperature. Once the reaction was complete (4 h), as confirmed by HPLC (220 nm) and LC-MS analysis, the mixture was cooled (0° C.) and added dropwise to a freshly prepared 1:3 mixture of tert-butyl methyl ether and isopropanol (600 mL) with vigorous stirring over a period of 2-3 min. Stirring was continued at 0° C. for 10 min (internal temperature: 5° C.). The precipitate was filtered, washed four times with cold THF, transferred to a new fritted funnel, and slurried with cold tert-butyl methyl ether (1×100 mL, 4° C.). The final amorphous precipitate was transferred to a 250 mL round bottom flask and dried under high vacuum for 20 hours to give the title compound 15 as a pale solid (4.52 g). HPLC analysis 96.2% (220 nm), chemical formula: C35 H 35 F2N8O 14 P, calculated value [MH] + 859.19, measured value [MH] + 859.40. Example 7

[0264] Preparation of compound 16 [ka] 80 mg of doxorubicin·HCl (138 μmol) and 139 mg of linker A (276 μmol; 2 equiv.) were dissolved in 20 mL of anhydrous methanol at room temperature with vigorous stirring. The reaction was stirred for 4 h. Precipitation was performed with 105 mL of a 2:1 mixture of isopropanol and diisopropyl ether, and the reaction was stored overnight at −20 °C. The red precipitate was centrifuged (3200 × g, 10 min), discarded, and the supernatant was transferred to a new container. The supernatant was precipitated again with 150 mL of diisopropyl ether and stored overnight at −20 °C. The red precipitate was centrifuged and washed twice with 8 mL of acetonitrile and once with 40 mL of a 1:3 mixture of isopropanol / diisopropyl ether. The resulting product was then dried under high vacuum to give compound 16 as a red solid. Yield: 53.9 mg (40%).

[0265] Stability of the HSA conjugate of compound 16 at pH 7.0 and 5.0 Stability at pH 7 (4 mM phosphate buffer, 150 mM NaCl): Compound 16 was added to a solution of fully reduced HSA (human serum albumin) and complete conjugation to cysteine-34 was confirmed by HPLC. A 200 μM solution of the resulting HSA conjugate of compound 16 was incubated at 37° C. and analyzed by HPLC every hour. Only 0.36% of free doxorubicin was released per hour. Stability at pH 5 (phosphate buffer 4 mM, sodium chloride 150 mM and sodium acetate buffer 50 mM): The HSA conjugate of compound 16 was prepared at pH 7 (see above) and sodium acetate buffer (50 mM) was added to adjust the pH value to 5.0. A 200 μM solution of the resulting HSA conjugate of compound 16 at pH 5.0 was incubated at 37° C. and analyzed every hour using HPLC. The half-life of the release of doxorubicin was approximately 9 hours. Example 8

[0266] Synthesis of vinblastine prodrugs based on linker A [ka] 12'-formylvinblastine was prepared from vinblastine and hexamethylenetetramine according to the procedure published in WO2005 / 055939A2. 12'-formylvinblastine (320 mg, 336 μmol) and linker A (172.3 mg, 442.5 μmol; 1.31 equiv.) were dissolved in dry MeOH (32 mL) in a 50 mL reaction tube with vigorous stirring. After 2 h, the reaction was terminated by adding diisopropyl ether (34 mL) and the solution was stored at -20°C for 2 h. A small amount of impurity precipitated, which was separated by centrifugation and discarded. To the supernatant, n-hexane / diisopropyl ether mixture (20 mL, 50:50) was added and stored at -20°C for 16 h. The precipitate was centrifuged, dissolved in 1 mL of CHCl3 / MeOH (90:10), reprecipitated from 20 mL of n-hexane / diisopropyl ether (50:50), centrifuged, washed with 8 mL of AcN / diethyl ether (1:3), and centrifuged again. The product was dissolved in 5 mL of CHCl3 / MeOH (99:1), reprecipitated from 20 mL of n-hexane / diisopropyl ether (50:50), and centrifuged. This washing step was repeated twice. The product was then dried under high vacuum to give a white solid. Yield: 253 mg (57%), Purity HPLC: 90.1% (220 nm) 93.0% (310 nm) Chemical formula:C64 H 75 N9O 15 , calculated value [M+H] + : 1210.55, measured value [M+H] + :1210.42 Example 9

[0267] Synthesis of vinblastine prodrugs based on linker B [ka] 12'-Formylvinblastine was prepared from vinblastine and hexamethylenetetramine according to the procedure published in WO2005 / 055939A2. 12'-Formylvinblastine (300 mg, 315 μmol) and Linker B (153 mg, 321 μmol; 1.02 equiv.) were dissolved in dry MeOH (25 mL) and stirred at RT. After 1 h, the reaction was terminated by adding n-hexane / diisopropyl ether (23 mL, 50:50) and the solution was stored at -20 °C for 4 h. A small amount of impurity precipitated, which was separated by centrifugation and discarded. Diisopropyl ether (20 mL) was then added to the supernatant and stored at -20 °C for 2 h. The precipitate was centrifuged, dissolved in 1 mL of CHCl3 / MeOH (99:1), reprecipitated from 20 mL of n-hexane / diisopropyl ether (50:50), centrifuged, washed with 10 mL of AcN / diethyl ether (1:3), and centrifuged again. The product was dissolved in 5 mL of CHCl3 / MeOH (90:1), reprecipitated from 20 mL of diisopropyl ether, centrifuged, and dried under high vacuum to give a white powder. Yield: 251 mg (63%), Purity HPLC: 90.1% (220 nm) 94.0% (310 nm). Chemical formula:C 64 H 75 FN8O 12 , calculated value [M+H] + : 1183.55, measured value [M+H] + :1183.45

[0268] Preparation of Linker B [ka] To a solution of 4-amino-2-fluorobenzoic acid (8.1 g, 52.22 mmol), tert-butyl carbazate (8.28 g, 62.66 mmol) and N-methylmorpholine (14.35 ml, 130.54 mmol) in tetrahydrofuran (25 ml) and EtOAc7 (5 ml) was added 1.67 M T3P (50% in ethyl acetate, 40.65 ml) dropwise via a funnel. The mixture was stirred at RT for 16 h. Water was added and the organic layer was washed with saturated KHCO3 and water, dried over MgSO4, filtered and concentrated in vacuo. The crude product was triturated in MTBE, filtered and dried in vacuo to give 9.7 g (69%) of tert-butyl 2-(4-amino-2-fluorobenzoyl)hydrazinecarboxylate as a white solid. Chemical formula: C 12 H 16 FN3O3, calculated value [MH] + :268.11, measured value [MH] + :268.00 To a solution of tert-butyl 2-(4-amino-2-fluorobenzoyl)hydrazinecarboxylate (9.68 g, 35.94 mmol), 6-maleimidohexanoic acid (6.6 g, 31.25 mmol) and N-methylmorpholine (8.59 ml, 0.08 mol) in tetrahydrofuran (40 ml) and EtOAc (120 ml) was added 1.67 M T3P (50% in ethyl acetate, 24.32 ml) and the mixture was stirred at 60° C. for 48 h. Water and EtOAc were added and the organic layer was washed with saturated KHCO3, water and brine, dried over MgSO4, filtered and concentrated in vacuo. The crude was purified by chromatography column using n-hexane:EtOAc 1:1 to 1:2 as eluent. The resulting solid was triturated in MTBE to give 7.5 g (51.9%, purity >98%) of N-Boc-O-fluoro linker as a white solid. Chemical formula:C 22 H 27 FN4O6, calculated value [MH] + : 461.18, measured value [MH] +:461.00. To a suspension of N-Boc-O-fluoro linker (7 g, 15.14 mmol) in dichloromethane (40 ml) was added TFA (40.54 ml, 0.53 mol) at 0° C. The mixture was stirred at 0° C. for 15 min and at RT for 15 min. The solvent was removed in vacuum at 0° C. The crude product was triturated in MTBE / DCM 7:1. The solid was filtered and dried in vacuum to give 6.5 g (90.1%) of O-Fluor maleimide linker as a white solid. Purity HPLC 96.8% (220 nm). Chemical formula: C 17 H 18 FN4O4, calculated value [MH] + : 361.13, measured value [MH] + :361.10. Example 10

[0269] Preparation of Linker C The linkers of the present invention can be made by the methods illustrated in the reaction schemes shown below. [ka] Synthesis of fmoc-L-proline phosphate chloride: Fmoc-L-proline (250 mg, 0.74 mmol) was dissolved in CHCl (4 mL). Thionyl chloride (800 μL, 10.36 mmol) was added, quenched with methanol as diluent, and the solution was stirred at reflux for 3 h while being monitored by TLC for the formation of the methanol adduct (CHCl:MeOH; 9:1). The reaction was then dried in vacuum to give 250 mg of crude material, which was then used in subsequent reactions without any further purification. Synthesis of tert-butyl 2-(2-nitro-4-(pyrrolidine-2-carboxamido)benzoyl)hydrazine-1-carboxylate: To a solution of tert-butyl 2-(4-amino-2-nitrobenzoyl)hydrazine-1-carboxylate (104 mg, 0.35 mmol) in THF (2 mL) was added (9H-fluoren-9-yl)methyl (S)-2-(chlorocarbonyl)pyrrolidine-1-carboxylate (250 mg, 0.70 mmol) as a solution in THF (2 mL), followed by the dropwise addition of triethylamine (49 μL, 0.35 mmol) as a solution in THF (200 μL). Stir for 12 h. After 2 h, TLC (CHCl3 / acetone, 7:3) showed complete conversion of the starting material. The reaction mixture was filtered and dried in vacuum by rotoevaporation. The resulting oil was purified by Biotage FCC using a methanol and chloroform gradient to give 279 mg of a pale solid. To a solution of the above solid in anhydrous CH2Cl2 (2 mL) was added DBU (10%, 200 μL) and the mixture was stirred at RT for 30 min. The reaction was monitored by LC / MS until the starting material was consumed. The reaction mixture was dried in vacuum by rotary evaporation. The resulting oil was then purified by Biotage FCC using a methanol and chloroform gradient to give the title compound as a brown solid (63 mg, 46% yield, 2 steps). Chemical formula: C 17 H 23 N5O6, calculated value [M+H] + : 394.17, measured value [M+NH] + :394.14. Synthesis of (((9H-fluoren-9-yl)methoxy)carbonyl)(sulfo)-D-alanine: L-cysteic acid (500 mg, 2.95 mmol) was suspended in a mixture of 10% aqueous Na2CO3 (17.5 mL) and 1,4-dioxane (7.5 mL) and cooled in an ice bath. N-fluorenylmethoxycarbonylsuccinimide (1.19 g, 3.54 mmol) was dissolved in 1,4-dioxane (12.5 mL) by gentle heating and the solution was added via a dropping funnel over 30 min with efficient stirring. The reaction mixture was stirred overnight and the organic solvent was removed in vacuo. The suspension was diluted with HO (10 mL), washed with tert-butyl methyl ether (2 x 10 mL) and the aqueous phase was acidified to pH 3.0 with concentrated HCl. The solution was lyophilized to give 1.02 g of fmoc-cysteic acid as a hygroscopic white solid, which was used without further purification. Chemical formula: C 18 H 17 NO7S, calculated value [MH] + : 390.06, measured value [MH] + =390.07. Synthesis of (R)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-((S)-2-((4-(2-(tertbutoxycarbonyl)hydrazine-1-carbonyl)-3-nitrophenyl)carbamoyl)pyrrolidin-1-yl)-3-oxopropane-1-sulfonic acid: In a flame-dried flask, fmoc-L-cysteic acid (96 mg, 0.30 mmol) was dissolved in a mixture of anhydrous DMSO:CHCl:DMF (1:1:1, 3 mL). HATU (114 mg, 0.30 mmol) was added followed by HOAt (41 mg, 0.30 mmol). After 5 min, a solution of tert-butyl (S)-2-(2-nitro-4-(pyrrolidine-2-carboxamido)benzoyl)hydrazine-1-carboxylate (100 mg, 0.25 mmol) in anhydrous DMF (2 mL) was added, followed by dropwise addition of NMM (55 μL, 0.50 mmol) and the resulting solution was stirred at room temperature for 17 h. Normal phase flash chromatography (CHCl3:methanol gradient) afforded the title compound (152 mg, 78%). Chemical formula: C 35 H38 NO 12 S, calculated value [M-CO2 t Bu+H] + : 667.18, measured value [M-CO2 t Bu+H] + , 667.11. Synthesis of (R)-2-amino-3-((S)-2-((4-(2-(tert-butoxycarbonyl)hydrazine-1-carbonyl)-3-nitrophenyl)carbamoyl)pyrrolidin-1-yl)-3-oxopropane-1-sulfonic acid: To a solution of (S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-((S)-2-((4-(2-(tert-butoxycarbonyl)hydrazine-1-carbonyl)-3-nitrophenyl)carbamoyl)pyrrolidin-1-yl)-3-oxopropane-1-sulfonic acid (152 mg, 0.198 mmol) in anhydrous CHCl (2 mL) was added DBU (10%, 200 μL) at 0° C. and the mixture was stirred at rt for 30 min. LC-MS (sample in MeCN) chromatogram showed complete conversion of starting material. The organic solvent was evaporated under vacuum to give an oily residue. Purification of this residue by flash (CHCl3 / methanol gradient; 2-95%) afforded the title compound as a brown solid (80.4 mg, 75% yield). Chemical formula: C 20 H 28 NO 10 S, calculated value [M+Na] + 567.15, Measured value [M+Na] + 567.19. Synthesis of (R)-3-((S)-2-((4-(2-(tert-butoxycarbonyl)hydrazine-1-carbonyl)-3-nitrophenyl)carbamoyl)pyrrolidin-1-yl)-2-(6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamide)-3-oxopropane-1-sulfonic acid: (R)-2-amino-3-((S)-2-(( To a solution of 4-(2-(tert-butoxycarbonyl)hydrazine-1-carbonyl)-3-nitrophenyl)carbamoyl)pyrrolidin-1-yl)-3-oxopropane-1-sulfonic acid (80.4 mg, 0.14 mmol) in THF (2 mL) was added 6-maleimidocaproic acid chloride (41.0 mg, 0.14 mmol) as a solution in THF (1 mL) in one portion. After stirring at rt for 5 min, a solution of triethylamine (24 μL, 0.14 mmol) in THF (200 μL) was added dropwise over 10 min. The brown solution was stirred at rt for an additional 3 h. The reaction mixture was filtered and dried under vacuum to give a brown oily residue. Purification of this residue by flash chromatography (CHCl3 / MeOH gradient, 100:0 to 2:98) afforded the title compound (71 mg, 65%). Chemical formula:C 30 H 39 N7O 13 S, calculated value [M-CO2 t Bu+H] + : 638.18, measured value [M-CO2 t Bu+H] + :638,02. (R)-2-(6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamide)-3-((S)-2-((4-(hydrazinecarbonyl)-3-nitrophenyl)carbamoyl)pyrrolidin-1-yl)-3-oxopropane-1-sulfonic acid: (R)-3-((S)-2-((4-(2-(tert-butoxycarbonyl) To a solution of )hydrazine-1-carbonyl)-3-nitrophenyl)carbamoyl)pyrrolidin-1-yl)-2-(6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamide)-3-oxopropane-1-sulfonic acid (71 mg, 0.09 mmol) in CHCl (1 mL) was added TFA (293 μL, 3.83 mmol). The reaction mixture was stirred for 2 h until LC-MS showed consumption of starting material. The desired product was obtained from the reaction mixture by evaporation of the solvent and used without further purification. Brown solid (91 mg, traces of TFA). C 25 H 31 N7O 11 LRMS(ESI) of S, calculated value [M+H] + : 637.18, measured value [M+H] + :638.07(M+H). Purity: 96% (HPLC, 220nm). Example 11

[0270] Synthesis of gemcitabine hydrazine: (R)-3-((R)-2-((4-(2-((Z)-1-(4-((1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)carbamoyl)phenyl)ethylidene)hydrazine-1-carbonyl)-3-nitrophenyl)carbamoyl)pyrrolidin-1-yl)-2-(6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamide)-3-oxopropane-1-sulfonic acid. [ka] 4-Acetyl-N-(1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-oxo-1,2-dihydropyrimidin-4-yl)benzamide (3 mg, 0.071 mmol) and R)-2-(6-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanamide)-3-((S)-2-((4-(hydrazinecarbonyl)-3-nitro To a stirred suspension of (phenyl)carbamoyl)pyrrolidin-1-yl)-3-oxopropane-1-sulfonic acid (5 mg, 0.078 mmol) in methanol (250 μL) was added TFA (9 μL, 0.117 mmol). The reaction mixture was stirred for 3 days and monitored by LC-MS. After this time, the pale solution was concentrated in vacuo. Normal phase flash chromatography (CHCl3:methanol gradient) afforded the title compound (5.6 mg, 74%). Chemical formula: C 43 H 46 F2N 10 O 16 S, calculated value [M+H] + : 1028.27, measured value [M+H] + :1029.05. Example 12

[0271] Synthesis of nemorubicin hydrazone. [ka] Nemorubicin (3 mg, 4.7 μmol, 1 equiv.) was dissolved in dry MeOH (750 μL) and added to Linker C (10.5 mg, 14.0 μmol, 3 equiv.) in a 2 mL reaction tube. TFA (1.1 μL, 2 equiv.) was added and the reaction mixture was stirred overnight. Precipitation could be observed during the reaction. After 16 h, MeOH (800 μL) was added and the reaction mixture was centrifuged (20000×g, 2 min). The supernatant was divided into two new 2 mL reaction tubes and further precipitated with 1 mL of diisopropyl ether each. The second precipitate was separated by centrifugation, dried and analyzed. Purity: 89% (220nm) 80% (495nm) Chemical formula:C 57 H 66 N8O23 S , calculated value [MH] + :1261.39, measured value [MH] + :1261.60 (Example 13)

[0272] Synthesis of N-(4-acetylbenzoyl)-MMAE (compound 17) [ka] 54.9 mg of 4-acetylbenzoic acid (334 μmol, 2 equiv.), 127 mg of HATU (334 μmol, 2 equiv.) and 45.6 mg of HOAt (334 μmol, 2 equiv.) were dissolved in 5 mL of anhydrous DMF and 36.7 μL of NMM (2 equiv.) were added. The reaction mixture was stirred at room temperature for 15 min. Then, a solution of 120 mg of MMAE (167 μmol, 1 equiv.) and 36.7 μL of NMM (334 μmol, 2 equiv.) in 5 mL of anhydrous DMF was added and stirring was continued at room temperature for 72 h. The reaction mixture was diluted with 40 mL of chloroform and washed twice with 10 mL of 5% HCl solution and three times with 10 mL of saturated sodium bicarbonate solution. The organic layer was dried over sodium sulfate, filtered and the solvent was removed under vacuum. The residue was dissolved in 32 mL of CHCl and purified using flash chromatography (solvent A:C HCl3, Solvent B: MeOH, 36 mL / min, column volume (CV) = 19 mL, gradient: 2 CV (0% B), 4 CV (0-3% B), 2.4 CV (3% B), 2 CV (3-5% B), 3 CV (5% B), 1.5 CV (5-9% B), ZIP® Sphere 10 g, Biotage® Isolera™ One). After drying in vacuum, compound 17 (115 mg, 80%) was obtained as a colorless foam. HPLC purity: 97.5% (220 nm).

[0273] Synthesis of hydrazone of N-(4-acetylbenzoyl)-MMAE (compound 18) using maleimide linker A [ka] To a solution of 20.6 mg of compound 17 (23.3 μmol, 1 equiv.) in 3 mL of methanol in a 50 mL reaction tube, 23.5 mg of maleimide linker A (46.6 μmol, 2 equiv.) was added. Then, 3.7 μL of TFA (46.6 μmol, 2 equiv.) was added to the slightly cloudy reaction mixture, which immediately became clear. After stirring at room temperature for 4 h, 4 mL of n-hexane / diisopropyl ether (1:1) was added, followed by 16 mL of n-hexane. The precipitate formed was centrifuged (3,220 × g, 10 min), dissolved in 1 mL of chloroform / methanol (1:1) and purified using repeated flash chromatography (1. Chromatography: Solvent A: CHCl3, Solvent B: MeOH, 32 mL / min, column volume (CV) = 19 mL, gradient: 1 CV (1-5% B), 2 CV (5% B), 3 CV (5-8% B), 4 CV (8% B), 1 CV (8-9% B), 6 CV (9% B), ZIP® Sphere 10 g, Biotage® Isolera™ One, 2. Chromatography: Solvent A: water, Solvent B: acetonitrile, 12 mL / min, column volume (CV) = 21 mL, gradient: 1 CV (10% B), 4 CV (10-50% B), 3 CV (50% B), 6 CV (50-80% B) SNAP® Ultra C18 12 g, Biotage® Isolera™ One). After drying in vacuum, compound 18 (17.0 mg, 58%) was obtained as a colorless powder. HPLC purity: 99.1% (220 nm).

[0274] Synthesis of the conjugate of compound 18 with trastuzumab (compound 19) Commercially available trastuzumab (Herceptin®, Roche) was reconstituted with WFI and the pH was adjusted to pH 8 with 0.5 M Tris buffer, 25 mM EDTA (4% of batch volume). The mAb solution was diluted to 10 mg / ml with 10 mM PBS, pH 7.4. 2.25 equivalents of TCEP (tris-(2-carboxyethyl)phosphine) were then added and the mixture was incubated at 20° C. for 90 min. The NMA (N,N-dimethylacetamide) content of the mixture was then adjusted to 5% and 5.5 equivalents of compound 18 were added. The mixture was incubated at 20° C. for 60 min. The reaction was then quenched by adding 11 equivalents of NAC (N-acetylcysteine). Removal of unbound drug and conversion of the buffer to 10 mM PBS, pH 7.4 was achieved by tangential flow filtration (10 dia-volumes). The solution was concentrated and the protein concentration was determined. The solution was then diluted to 7.2 mg / mL with 10 mM PBS, pH 7.4. The resulting trastuzumab conjugate (compound 19) had a DAR of 4.0 as determined by HIC (TOSOH Biosciences). ce, Butyl-NPR 4.6 mm ID x 3.5 cm, 2.5 μm; Mobile phase A: 3 M ammonium sulfate in purified water, 25 mM sodium phosphate monobasic monohydrate, pH 6.95; Mobile phase B: 25% isopropanol and 75% 25 mM sodium phosphate monobasic monohydrate in purified water, pH 6.95; Flow rate: 0.8 mL min -1 , 18 min at 25° C. using a systematic gradient) had 0.41% unbound compound 18 as determined by HPLC (Waters Xterra MS, C18, 3.5 μM, 2.1×100 mm, gradient: mobile phase A: 20 mM ammonium acetate, pH 7.0±0.1, mobile phase B: acetonitrile, gradient: 0 min: 70% A, 20 min: 30% A, 25 min: 10% A, 25.1 min: 70% A, 35 min: 70% A).

[0275] Stability and release kinetics of compound 19 in buffer solutions at pH 4.0 and pH 7.4 To study the stability and release kinetics, the conjugated compound 19 was incubated in a buffer solution at 37°C. Thus, a 3mL aliquot of compound 19 in phosphate buffer (7.2mg / mL in 10mM PBS) was acidified to pH 4.0 using 0.5M acetic acid and placed in a heating block at 37°C together with a 3mL untreated aliquot (pH 7.4). After an appropriate interval, samples (50μL aliquots) at both pH were removed and stored at -20°C until analysis. Prior to analysis, the samples were removed from the freezer and 7μL of 5M NaCl and 93μL of chilled methanol were added. The samples were then stored at -20°C for 30 minutes and centrifuged at 4°C and 200rpm for 60 minutes. Afterwards, 75 μL of the supernatant was diluted with 75 μL of purified water, the mixture was vortexed and analyzed using HPLC (Waters Xterra MS, C18, 3.5 μM, 2.1 × 100 mm, gradient: mobile phase A: 20 mM ammonium acetate, pH 7.0 ± 0.1, mobile phase B: acetonitrile, gradient: 0 min: 70% A, 20 min: 30% A, 25 min: 10% A, 25.1 min: 70% A, 35 min: 70% A). A standard curve of compound 17 was prepared at 2.00 μM, 1.00 μM, 0.50 μM, 0.30 μM, 0.20 μM, 0.10 μM, 0.05 μM and 0.01 μM. For UV quantification at 214 nm, a range of 2.00 to 0.05 μM was used. Compound 17 was found to be the only release product. After 24 h, 2.7% of compound 17 was released from the ADC at pH 7.4, while 39.6% of free compound 17 was observed at pH 4.0.

[0276] According to a preferred embodiment of the present invention, for example, the following is provided: (Section 1) Compounds having the structure of formula (I) [ka] or a pharma- ceutically acceptable salt, hydrate, solvate or isomer thereof [In the formula, Drugs include cytostatics, cytotoxics, cytokines, immunosuppressants, antirheumatics, anti-inflammatory drugs, antibiotics, analgesics, virus stasis agents, anti-inflammatory drugs, antifungal drugs, transcription factor inhibitors, pericellular inhibitors, and is selected from the group consisting of a phase modulator, an MDR modulator, a proteasome or protease inhibitor, an apoptosis modulator, an enzyme inhibitor, a signal transduction inhibitor, a protease inhibitor, an angiogenesis inhibitor, a hormone or hormone derivative, an antibody or fragment thereof, a therapeutically or diagnostically active peptide, a radioactive substance, a luminescent substance, a light absorbing substance, and a derivative of any of the foregoing; The spacer is absent or [ka] and [ka] is selected from the group consisting of n is 0 or 1, X is an optionally substituted C1-C 18 Alkyl (C1-C 18 up to 6 carbon atoms of the alkyl are each independently replaced with -OCHCH-; optionally substituted C1-C 18 Alkyl-NH-C(O)-R-(the above C1 to C 18 up to 6 carbon atoms of the alkyl are each independently replaced with -OCHCH-; optionally substituted C1-C 18 Alkyl-C(O)-NH-R5-(C1 to C 18 optionally substituted aryl; optionally substituted heteroaryl; and optionally substituted cycloalkyl; R5 is selected from the group consisting of optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted cycloalkyl; Y is selected from the group consisting of absent or optionally substituted C1-C6 alkyl, -NH-C(O)-, -C(O)-NH-, -C(O)-O-, and -OC(O)-; R1 is absent or optionally substituted C1-C 18 Alkyl (C1-C 18 up to 6 carbon atoms of the alkyl are each independently replaced with -OCHCH-; optionally substituted C1-C 18 Alkyl-NH-C(O)R-(the above C1 to C 18 up to 6 carbon atoms of alkyl are each independently replaced with -OCHCH-; and optionally substituted C1-C 18 Alkyl-C(O)-NH-R5-(C1 to C 18 optionally up to 6 carbon atoms of alkyl are each independently replaced with -OCHCH-; or R1 is a naturally occurring or non-naturally occurring amino acid; Or R1 is of the following formula: [ka] It has [ka] does not exist or [ka] is selected from the group consisting of R is [ka] (M1=Mg 2+ , 2Na + , 2K + , 2H + , 2NH4 + ),or [ka] (M2=Na + , K + , H + , NH4 + ) and R2 is -H, optionally substituted C1-C 12 selected from the group consisting of alkyl, optionally substituted aryl, and optionally substituted heteroaryl; Z1, Z2, Z3 and Z4 are each independently -H, an electron withdrawing group, and / or a water soluble group; PBG is a protein binding group selected from the group consisting of an optionally substituted maleimide group, an optionally substituted haloacetamide group, an optionally substituted haloacetate group, an optionally substituted pyridylthio group, an optionally substituted isothiocyanate group, an optionally substituted vinylcarbonyl group, an optionally substituted aziridine group, an optionally substituted disulfide group, an optionally substituted acetylene group, an optionally substituted N-hydroxysuccinimide ester group, a derivatized antibody of an antibody or fragment thereof, and a derivatized fragment thereof; When the spacer is absent, the drug is linked to the nitrogen adjacent to the spacer by a double bond; At least one of Z1, Z2, Z3 and Z4 is an electron withdrawing group. (Section 2) Compounds having the structure of formula (I) [ka] or a pharma- ceutically acceptable salt, hydrate, solvate or isomer thereof [In the formula, the drug is selected from the group consisting of cytostatic agents, cytotoxic agents, cytokines, immunosuppressants, antirheumatic agents, anti-inflammatory agents, antibiotics, analgesics, virostatic agents, anti-inflammatory agents, antifungal agents, transcription factor inhibitors, cell cycle modulators, MDR modulators, proteasome or protease inhibitors, apoptosis modulators, enzyme inhibitors, signal transduction inhibitors, protease inhibitors, angiogenesis inhibitors, hormones or hormone derivatives, antibodies or fragments thereof, therapeutically or diagnostically active peptides, radioactive substances, luminescent substances, light absorbing substances, and derivatives of any of the foregoing; The spacer is absent or [ka] and n is 0 or 1, X is an optionally substituted C1-C 18 Alkyl (C1-C 18 up to 6 carbon atoms of the alkyl are each independently replaced with -OCHCH-; optionally substituted C1-C 18 Alkyl-NH-C(O)-R-(the above C1 to C 18 up to 6 carbon atoms of the alkyl are each independently replaced with -OCHCH-; optionally substituted C1-C 18 Alkyl-C(O)-NH-R5-(C1 to C 18 optionally substituted aryl; optionally substituted heteroaryl; and optionally substituted cycloalkyl; R5 is selected from the group consisting of optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted cycloalkyl; Y is selected from the group consisting of absent or optionally substituted C1-C6 alkyl, -NH-C(O)-, -C(O)-NH-, -C(O)-O-, and -OC(O)-; R1 is absent or optionally substituted C1-C 18 Alkyl (C1-C 18 up to 6 carbon atoms of the alkyl are each independently replaced with -OCHCH-; optionally substituted C1-C 18 Alkyl-NH-C(O)R-(the above C1 to C 18 up to 6 carbon atoms of the alkyl are each independently replaced with -OCH2CH2-; and optionally substituted C1 ~C 18 Alkyl-C(O)-NH-R5-(C1 to C 18 optionally up to 6 carbon atoms of alkyl are each independently replaced with -OCHCH-; R2 is -H, optionally substituted C1-C 12 selected from the group consisting of alkyl, optionally substituted aryl, and optionally substituted heteroaryl; Z1, Z2, Z3, and Z4 are each independently selected from the group consisting of -H and an electron withdrawing group; PBG is a protein binding group selected from the group consisting of an optionally substituted maleimide group, an optionally substituted haloacetamide group, an optionally substituted haloacetate group, an optionally substituted pyridylthio group, an optionally substituted isothiocyanate group, an optionally substituted vinylcarbonyl group, an optionally substituted aziridine group, an optionally substituted disulfide group, an optionally substituted acetylene group, an optionally substituted N-hydroxysuccinimide ester group; and an antibody or fragment thereof, When the spacer is absent, the drug is linked to the nitrogen adjacent to the spacer by a double bond; At least one of Z1, Z2, Z3 and Z4 is an electron withdrawing group. (Section 3) The compound according to item 1 or 2 above, having the structure of formula (II): [ka] or a pharma- ceutically acceptable salt, hydrate, solvate or isomer thereof [wherein the drug, PBG, Y, R1, Z1, Z2, Z3 and Z4 are as described in items 1 or 2 above]. (Section 4) The compound according to item 1 or 2 above, having the structure of formula (III): [ka] or a pharma- ceutically acceptable salt, hydrate, solvate or isomer thereof [In the formula, the drug, the spacer, Z2, Z3, Z4, Y, R1 and PBG are as described in the above item 1 or 2, Z1 is an electron-withdrawing group. (Section 5) The compound according to item 1 or 2 above, having the structure of formula (IV): [ka] or a pharma- ceutically acceptable salt, hydrate, solvate or isomer thereof [In the formula, the drug, PBG, Y, R1, Z2, Z3 and Z4 are as described in the above item 1 or 2, Z1 is an electron-withdrawing group. (Section 6) The compound according to item 1 or 2 above, having the structure of formula (V): [ka] or a pharma- ceutically acceptable salt, hydrate, solvate or isomer thereof [wherein the drug, n, X, R1, R2, Z1, Z2, Z3, Z4, Y, R1, and PBG are as described in items 1 or 2 above]. (Section 7) The compound according to item 6 above, having the structure of formula (VI): [ka] or a pharma- ceutically acceptable salt, hydrate, solvate or isomer thereof [In the formula, M is a pyrimidine or purine group containing at least one primary or secondary amino group and optionally containing one or more substituents selected from halogen; X1 and X2 are each independently selected from the group consisting of -H, -OH, C1-C6 alkyl, halogen, and -N3; X3 and X4 are each independently selected from the group consisting of absent, -H, -OH, C1-C6 alkyl, halogen, and -N3, wherever valence is possible; R' is -R3 or -CH2R3; R3, at each occurrence, is independently selected from the group consisting of -OH, -CH3, -OP(O)(OH)2, -P(O)(OH)OP(O)(OH)2, -OP(O)(OH)OP(O)(OH)OP(O)(OH)2, -OP(O)(OH)(NH2), an amino acid, an acyl group, and pharma- ceutically acceptable salts thereof, wherein said salts contain an alkali metal ion, an alkaline metal ion, ammonium, or an alkyl substituted ammonium ion; X, n, Z1, Z2, Z3, Z4, Y, R1, R2 and PBG are as described in section 6 above. (Section 8) The compound according to item 6 above, having the structure of formula (VI): [ka] or a pharma- ceutically acceptable salt, hydrate, solvate or isomer thereof [In the formula, M is a pyrimidine or purine group containing at least one primary or secondary amino group; X1 and X2 are each independently selected from the group consisting of -H, -OH, C1-C6 alkyl, halogen, and -N3; X3 and X4 are each independently selected from the group consisting of absent, -H, -OH, C1-C6 alkyl, halogen, and -N3, wherever valence is possible; R3 is selected from the group consisting of -H, -OH, -OP(O)(OH), -OP(O)(OH)OP(O)(OH), -OP(O)(OH)OP(O)(OH)OP(O)(OH), -OP(O)(OH)(NH), an amino acid, an acyl group, and pharma- ceutically acceptable salts thereof, said salts containing an alkali metal ion, an alkaline metal ion, ammonium, or an alkyl-substituted ammonium ion; X, n, Z1, Z2, Z3, Z4, Y, R1, R2 and PBG are as described in section 6 above. (Section 9) The compound according to item 7 or 8, having the structure of formula (VII): [ka] or a pharma- ceutically acceptable salt, hydrate, solvate or isomer thereof [wherein R' is -R3 or -CH2R3, and X, X1, X2, X3, X4, n, Y, R1, R2, R3, Z1, Z2, Z3, Z4 and PBG are as described in items 7 or 8 above]. (Section 10) The compound according to item 7 or 8, having the structure of formula (VII): [ka] or a pharma- ceutically acceptable salt, hydrate, solvate or isomer thereof [In the formula, X, X1, X2, X3, X4, n, Y, R1, R2, R3, Z1, Z2, Z3, Z4 and PBG are as described in items 7 or 8 above]. (Section 11) The compound according to item 6 above, having the structure of formula (VIII): [ka] or a pharma- ceutically acceptable salt, hydrate, solvate or isomer thereof [In the formula, the drug, X, n, R2, PBG, Y, R1, Z2, Z3 and Z4 are as described in item 6 above, Z1 is an electron-withdrawing group. (Section 12) The compound according to the above item 11, having the structure of formula (IX): [ka] or a pharma- ceutically acceptable salt, hydrate, solvate or isomer thereof [In the formula, M is a pyrimidine or purine group containing at least one primary or secondary amino group and optionally containing one or more substituents selected from halogen; X1 and X2 are each independently selected from the group consisting of -H, -OH, C1-C6 alkyl, halogen, and -N3; X3 and X4 are each independently selected from the group consisting of absent, -H, -OH, C1-C6 alkyl, halogen, and -N3, wherever valence is possible; R' is -R3 or -CH2R3; R3, at each occurrence, is independently selected from the group consisting of -OH, -CH3, -OP(O)(OH)2, -P(O)(OH)OP(O)(OH)2, -OP(O)(OH)OP(O)(OH)OP(O)(OH)2, -OP(O)(OH)(NH2), an amino acid, an acyl group, and pharma- ceutically acceptable salts thereof, wherein said salts contain an alkali metal ion, an alkaline metal ion, ammonium, or an alkyl substituted ammonium ion; X, n, Y, Z1, Z2, Z3, Z4, R1, R2 and PBG are as described in section 11 above. (Section 13) The compound according to the above item 11, having the structure of formula (IX): [ka] or a pharma- ceutically acceptable salt, hydrate, solvate or isomer thereof [In the formula, M is a pyrimidine or purine group containing at least one primary or secondary amino group; X1 and X2 are each independently selected from the group consisting of -H, -OH, C1-C6 alkyl, halogen, and -N3; X3 and X4 are each independently selected from the group consisting of absent, -H, -OH, C1-C6 alkyl, halogen, and -N3, wherever valence is possible; R3 is selected from the group consisting of -H, -OH, -OP(O)(OH), -OP(O)(OH)OP(O)(OH), -OP(O)(OH)OP(O)(OH)OP(O)(OH), -OP(O)(OH)(NH), an amino acid or an acyl group, and pharma- ceutically acceptable salts thereof, said salts containing an alkali metal ion, an alkaline metal ion, ammonium, or an alkyl-substituted ammonium ion; X, n, Y, Z1, Z2, Z3, Z4, R1, R2 and PBG are as described in section 11 above. (Section 14) The compound according to item 12 or 13 above, having the structure of formula (X): [ka] or a pharma- ceutically acceptable salt, hydrate, solvate or isomer thereof [In the formula, R' is -R3 or -CH2R3, and X1, X2, X3, X4, R3, X, n, Y, Z1, Z2, Z3, Z4, R1 and R2 are as described in items 12 or 13 above.] (Section 15) The compound according to item 12 or 13 above, having the structure of formula (X): [ka] or a pharma- ceutically acceptable salt, hydrate, solvate or isomer thereof [In the formula, X1, X2, X3, X4, R3, X, n, Y, Z1, Z2, Z3, Z4, R1 and R2 are as described in items 12 or 13 above]. (Section 16) Drugs include N-nitrosoureas; doxorubicin, 2-pyrrolepyrrolinoanthracyclines, morpholinoanthracyclines, diacetoxyalkylanthracyclines, daunorubicin, epirubicin, idarubicin, nemorubicin, PNU-159682, mitoxantrone; amethantrone; chlorambucil, bendamustine, melphalan, oxazaphosphorine; 5-fluorouracil, 5'-deoxy-5-fluorocytidine , 2'-deoxy-5-fluoropyrimidin, cytarabine, cladribine, fludarabine, pentostatin, gemcitabine, 4-amino-1-(((2S,3R,4S,5R)-3,4-dihydroxy-5-methyltetrahydrofuran-2-yl)methyl)-5-fluoropyrimidin-2(1H)-one, thioguanine; methotrexate, raltitrexed, pemetrexed, previtrexed; paclitaxel, docetaxel; topotec camptothecin, irinotecan, SN-38, 10-hydroxycamptothecin, GG211, lurtotecan, 9-aminocamptothecin, camptothecin, 7-formylcamptothecin, 7-acetylcamptothecin, 9-formylcamptothecin, 9-acetylcamptothecin, 9-formyl-10-hydroxycamptothecin, 10-formylcamptothecin, 10-acetylcamptothecin, 7-butyl-10-aminocamptothecin, 7 -butyl-9-amino-10,11,-methylenedioxocamptothecin; vinblastine, vincristine, vindesine, vinorelbine; calicheamicin; maytansine, maytansinol; auristatins (including, but not limited to, auristatin D, auristatin E, auristatin F, monomethylauristatin D, monomethylauristatin E, monomethylauristatin F, monomethylauristatin F methyl ester, auristatin PYE auristatin PHE, the related natural product dolastatin 10, and derivatives thereof); amatoxins (including, but not limited to, α-amanitin, β-amanitin, γ-amanitin, ε-amanitin, amanine, amaninamide, amanulin, and amanuric acid and derivatives thereof);Duocarmycin A, Duocarmycin B1, Duocarmycin B2, Duocarmycin C, Duocarmycin SA, CC1065, Adozelesin, Bizelesin, Carzelesin; Eribulin; Trabectedin; Pyrrolobenzodiazepine; 16. The compound according to any one of claims 1 to 15, selected from the group consisting of pin, anthramycin, tomaycin, sibiromycin, DC-81, DSB-120; epothilones; bleomycins; dactinomycins; plicamycin, mitomycin C and cis-configured platinum(II) complexes; or derivatives of any of the foregoing. (Section 17) The drug is N-nitrosourea; doxorubicin, 2-pyrrolepyrrolinoanthracycline, morpholinoanthracycline, diacetoxyalkylanthracycline, daunorubicin, epirubicin, idarubicin, nemorubicin, PNU-159682, mitoxantrone; amethanthrone; chlorambucil, bendamustine, melphalan, oxazaphosphorine; 5-fluorouracil, 2'-deoxy-5-fluoridine, cytarabine, cladribine, fludarabine, pentostatin, gemcitabine, 4-amino-1-(((2S,3R,4S,5R)-3,4-dihydroxy-5-methyltetrahydrofuran-2-yl)methyl)-5-fluoropyrimidin-2(1H)-one, thioguanine; methotrexate, raltitrexed, pemetrexed, previtrexed 16. The compound according to any one of claims 1 to 15, selected from the group consisting of paclitaxel, docetaxel, topotecan, irinotecan, SN-38, 10-hydroxycamptothecin, GG211, lurtotecan, 9-aminocamptothecin, camptothecin, 7-formylcamptothecin, 9-formylcamptothecin, 9-formyl-10-hydroxycamptothecin, 7-butyl-10-aminocamptothecin, 7-butyl-9-amino-10,11,-methylenedioxocamptothecin, vinblastine, vincristine, vindesine, vinorelbine, calicheamicin, maytansinoids, auristatins, epothilones, bleomycin, dactinomycin, plicamycin, mitomycin C and cis-configured platinum(II) complexes; or a derivative of any of the above. (Section 18) 18. The compound according to any one of the above items 1 to 17, wherein Z1, Z2, Z3 and Z4 are each independently selected from the group consisting of -H, halogen, -C(O)OH, -C(O)O-C1-C6 alkyl, -NO2, haloalkyl, -S(O)2-C1-C6 alkyl, and -CN, and at least one of Z1, Z2, Z3 and Z4 is not -H. (Section 19) 19. The compound according to item 18, wherein Z1, Z2, Z3 and Z4 are each independently selected from the group consisting of -H, -Cl, -Br, -I, -F, -C(O)OH, -NO2, -CF3 and -CN. (Section 20) 20. The compound according to item 19, wherein Z1, Z2, Z3 and Z4 are each independently selected from the group consisting of -H, -Cl, -F, -NO2 and -CF3. (Section 21) The compound according to any one of the preceding claims, wherein Z1, Z2, Z3 and Z4 are each independently selected from the group consisting of -OP(O)(OH)2, -P(O)(OH)OP(O)(OH)2, -OP(O)(OH)OP(O)(OH)OP(O)(OH)2, -OP(O)(OH)(NH2), -P(O)(OH)2, -SO3H, and pharma- ceutically acceptable salts thereof. (Section 22) Z1 is selected from the group consisting of halogen, -C(O)OH, -C(O)O-C1-C6 alkyl, -NO2, haloalkyl, -S(O)2-C1-C6 alkyl, and -CN; Z2, Z3 and Z4 are each independently selected from -H, halogen, -C(O)OH, -C(O)O-C1-C6 alkyl, -NO2, haloalkyl, -S(O)2-C1-C6 alkyl, or -CN; 19. The compound according to any one of items 1 to 18. (Section 23) Z1 is selected from the group consisting of -Cl, -Br, -I, -F, -C(O)OH, -NO2, -CF3, and -CN; Z2, Z3 and Z4 are each independently selected from the group consisting of -H, -Cl, -Br, -I, -F, -C(O)OH, -NO2, -CF3, and -CN; 23. The compound according to item 22 above. (Section 24) Z1 is selected from the group consisting of -Cl, -F, and -NO2; Z2, Z3 and Z4 are each independently selected from the group consisting of -H, -Cl, -F, -NO2, and -CF3; 24. The compound according to item 23 above. (Section 25) [ka] but, [ka] 19. The compound according to any one of claims 1 to 18, selected from the group consisting of: (Section 26) [ka] but, [ka] 19. The compound according to any one of claims 1 to 18, selected from the group consisting of: (Section 27) The compound according to any one of the above items 1 to 26, wherein Y is -C(O)-NH-. (Item 28) 27. The compound according to any one of the preceding claims, wherein Y is -C(O)-O-. (Section 29) 27. The compound according to any one of the preceding claims, wherein Y is absent. (Section 30) R1 is an optionally substituted C1-C 18 Alkyl (C1-C 18 up to 6 carbon atoms of the alkyl are each independently replaced with -OCHCH-; optionally substituted C1-C 18 Alkyl-NH-C(O)-R-(the above C1 to C 18 up to 6 carbon atoms of alkyl are each independently replaced with -OCHCH-; and optionally substituted C1-C 18 Alkyl-C(O)-NH-R5-(C1 to C 18Optionally up to 6 carbon atoms of alkyl are each independently replaced with -OCHCH-; 30. The compound according to any one of items 1 to 29. (Section 31) R1, [ka] or [ka] 31. The compound according to item 30, wherein (Section 32) 30. The compound according to any one of the preceding claims, wherein R1 is absent. (Section 33) 30. The compound according to any one of paragraphs 1 and 3 to 29, wherein R1 is a naturally occurring or non-naturally occurring amino acid. (Section 34) R1, [ka] and [ka] does not exist or [ka] is selected from the group consisting of R is [ka] (M1=Mg 2+ , 2Na + , 2K + , 2H + , 2NH4 + ),or [ka] (M2=Na + , K + , H + , NH4 + ), The compound according to any one of items 1 and 3 to 29. (Section 35) The PBG is an optionally substituted maleimide group, an optionally substituted haloacetamide group, an optionally substituted haloacetate group, an optionally substituted 35. The compound according to any one of claims 1 to 34, wherein the protein binding group is selected from the group consisting of an optionally substituted pyridylthio group, an optionally substituted isothiocyanate group, an optionally substituted vinylcarbonyl group, an optionally substituted aziridine group, an optionally substituted disulfide group, an optionally substituted acetylene group, and an optionally substituted N-hydroxysuccinimide ester group. (Section 36) 36. The compound according to claim 35, wherein the PBG is associated with an antibody or a fragment thereof. (Section 37) The compound according to the above item 35, wherein the PBG is covalently bound to an antibody or a fragment thereof. 36. The compound according to item 35, wherein the PBG is associated with albumin. (Section 39) 36. The compound according to claim 35, wherein the PBG is covalently bound to endogenous or exogenous albumin. (Section 40) 36. The compound according to claim 35, wherein the PGB is covalently bound to cysteine-34 of endogenous or exogenous albumin. (Section 41) The compound according to any one of the above items 1 to 35, 37, 39 and 40, wherein PBG is an optionally substituted maleimide group. (Section 42) PBG, [ka] 42. The compound according to any one of claims 1 to 35, 37, 39, 40, and 41, wherein (Section 43) [ka] but, [ka] [ka] [ka] 43. The compound according to any one of claims 1 to 42, selected from the group consisting of: (Section 44) The spacer is [ka] and n is 0 or 1; X is an optionally substituted C1-C 18 Alkyl (C1-C 18 optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted cycloalkyl; R2 is as described in item 1 or 2 above; The compound according to any one of items 1, 2, 4, or 16 to 43. (Section 45) The spacer is [ka] and R2 is -H, optionally substituted C1-C12 alkyl, optionally substituted aryl, and optionally substituted heteroaryl; and W1, W2, W3, and W4 are each independently selected from the group consisting of -H, halogen, -C(O)OH, -C(O)O-C1-C6 alkyl, -NO2, haloalkyl, -S(O)2-C1-C6 alkyl, and -CN; The compound according to any one of items 1, 2, 4, or 16 to 44. (Section 46) 46. ​​The compound according to claim 45, wherein W1, W2, W3 and W4 are each independently selected from the group consisting of -H, -Cl, -Br, -I, -F, -C(O)OH, -NO2, -CF3 and -CN. (Section 47) 47. The compound according to item 46, wherein W1, W2, W3 and W4 are each independently selected from the group consisting of -H, -Cl, -F, -NO2 and -CF3. (Section 48) The spacer is [ka] and R2 is -H, optionally substituted C1-C 12 alkyl, optionally substituted aryl, or optionally substituted heteroaryl; and W1, W2, W3, and W4 are each independently selected from a phenoxy group, a primary, secondary, or tertiary amine group, an ether group, a phenol group, an amide group, an ester group, an alkyl group, a substituted alkyl group, a phenyl group, and a vinyl group; The compound according to any one of items 1, 2, 4, or 16 to 44. (Section 49) The spacer is [ka] and R2 is -H, optionally substituted C1-C 12alkyl, optionally substituted aryl, or optionally substituted heteroaryl; and W1, W2, W3, and W4 are each independently selected from -OP(O)(OH), -P(O)(OH)OP(O)(OH), -OP(O)(OH)OP(O)(OH)OP(O)(OH), -OP(O)(OH)(NH), -P(O)(OH), -SO3H, and pharma- ceutically acceptable salts thereof; The compound according to any one of items 1, 2, 4, or 16 to 44. (Section 50) The spacer is [ka] and R2 is -H, optionally substituted C1-C 12 selected from the group consisting of alkyl, optionally substituted aryl, and optionally substituted heteroaryl; W1 is selected from the group consisting of halogen, -C(O)OH, -C(O)O-C1-C6 alkyl, -NO2, haloalkyl, -S(O)2-C1-C6 alkyl, and -CN; W2, W3 and W4 are each independently selected from the group consisting of -H, halogen, -C(O)OH, -C(O)O-C1-C6 alkyl, -NO2, haloalkyl, -S(O)2-C1-C6 alkyl, and -CN; The compound according to any one of items 1, 2, 4, or 16 to 44. (Section 51) 51. The compound according to claim 50, wherein W1 is selected from the group consisting of -Cl, -Br, -I, -F, -C(O)OH, -NO2, -CF3, and -CN, and W2, W3, and W4 are each independently selected from the group consisting of -H, -Cl, -Br, -I, -F, -C(O)OH, -NO2, -CF3, and -CN. (Section 52) 52. The compound according to claim 51, wherein W1 is selected from the group consisting of -Cl, -F, and -NO2, and Z2, Z3, and Z4 are each independently selected from the group consisting of -H, -Cl, -F, -NO2, and -CF3. (Section 53) The spacer is [ka] and R2 is -H, optionally substituted C1-C 12 Selected from the group consisting of alkyl, optionally substituted aryl, and optionally substituted heteroaryl. R, 45. The compound according to item 44 above. (Section 54) The spacer is [ka] 54. The compound according to item 53, wherein (Section 55) The spacer is [ka] 45. The compound according to claim 44, wherein m is 1, 2, 3, 4, 5, or 6. (Section 56) The spacer is [ka] 56. The compound according to item 55, wherein (Section 57) The compound according to any one of claims 7 to 10 and 12 to 56, wherein X1, X2, X3, and X4 are each independently selected from the group consisting of -H, -OH, -CH3, -F, -Cl, -Br, -I, and -N3. (Section 58) [ka] [ka] The compound according to the above item 1, or a pharma- ceutically acceptable salt, hydrate, solvate or isomer thereof, selected from [In the formula, SG= [ka] and [ka] does not exist or [ka] is selected from the group consisting of R is [ka] (M1=Mg 2+ , 2Na + , 2K + , 2H + , 2NH4 + , Na + , K + , NH4 + and / or H + ),or [ka] (M2=Na + , K + , H + , and / or NH4 + ) [is]. (Section 59) [ka] [ka] [ka] [ka] [ka] [ka] [ka] 3. The compound according to item 1 or 2 above, or a pharma- ceutically acceptable salt, hydrate, solvate or isomer thereof, selected from: (Section 60) [ka] Item 1, or a pharma- ceutically acceptable salt, hydrate, solvate or isomer thereof. (Section 61) [ka] Item 1, or a pharma- ceutically acceptable salt, hydrate, solvate or isomer thereof. (Section 62) 62. A pharmaceutical composition comprising a compound according to any one of paragraphs 1 to 61 above and a pharma- ceutically acceptable carrier. (Section 63) A method for treating a disease or condition selected from the group consisting of cancer, viral diseases, autoimmune diseases, acute or chronic inflammatory diseases, and diseases caused by bacteria, fungi or other microorganisms, comprising the step of administering to a patient in need thereof a therapeutically effective amount of a compound described in any of items 1 to 61 or a pharmaceutical composition described in item 62. (Section 64) 62. A compound according to any one of clauses 1 to 61 above for use as a medicament. (Section 65) 62. The compound according to any one of claims 1 to 61, for use in treating a disease or condition selected from the group consisting of cancer, viral diseases, autoimmune diseases, acute or chronic inflammatory diseases, and diseases caused by bacteria, fungi or other microorganisms. (Section 66) Cancer, viral diseases, autoimmune diseases, acute or chronic inflammatory diseases, and bacterial, fungal or 6. Use of a compound according to any one of claims 1 to 61 or a composition according to claim 62 in the preparation of a medicament for the treatment of a disease or condition selected from the group consisting of diseases caused by microbial organisms or other microorganisms.

Claims

1. A delivery system for providing controlled release of a therapeutic agent, wherein the delivery system comprises a compound represented by formula (I): 【Chemistry 1-1】 or a pharma- ceutically acceptable salt, hydrate, solvate, tautomer, E (entgegen) isomer, Z (zusammen) isomer, or stereoisomer thereof. [In the formula, the drug is selected from the group consisting of a cytostatic drug and a cytotoxic drug; The spacer is absent or 【Chemistry 1-2】 and 【Chemistry 1-3】 is selected from the group consisting of n is 0 or 1; X is optionally substituted -C 1 -C 18 alkylene, wherein optionally up to 6 carbon atoms of said -C 1 -C 18 alkylene are each independently replaced with -OCH 2 CH 2 -; optionally substituted -C 1 -C 18 alkylene-NH-C(O)-R 5 -, wherein optionally up to 6 carbon atoms of said -C 1 -C 18 alkylene- are each independently replaced with -OCH 2 CH 2 -; optionally substituted -C 1 -C 18 alkylene-C(O)-NH-R 5 -, wherein optionally up to 6 carbon atoms of said -C 1 -C 18 alkylene- are each independently replaced with -OCH 2 CH 2 -; -substituted; optionally substituted aryl; optionally substituted heteroaryl; and optionally substituted cycloalkyl; R 5 is selected from the group consisting of optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted cycloalkyl; Y is absent or selected from the group consisting of optionally substituted -Ci-C6 alkylene-, -NH-C(O)-, -C(O)-NH-, -C(O)-O-, and -O-C(O)-; R 1 is selected from the group consisting of absent or optionally substituted —C 1 -C 18 alkylene-, wherein optionally up to 6 carbon atoms of said —C 1 -C 18 alkylene- are each independently replaced with —OCH 2 CH 2 —; optionally substituted —C 1 -C 18 alkylene-NH—C(O)R 5 —, wherein optionally up to 6 carbon atoms of said —C 1 -C 18 alkylene- are each independently replaced with —OCH 2 CH 2 —; and optionally substituted —C 1 -C 18 alkylene-C(O)—NH—R 5 —, wherein optionally up to 6 carbon atoms of said —C 1 -C 18 alkylene- are each independently replaced with —OCH 2 CH 2 —; or R 1 is a naturally occurring or non-naturally occurring amino acid; Or R 1 is of the formula 【Chemistry 1-4】 It has 【Chemistry 1-4A】 does not exist or 【Chemistry 1-5】 is selected from the group consisting of R is 【Chemistry 1-6】 (wherein M1 = Mg2+, 2Na+, 2K+, 2H+, 2NH4+); or 【Chemistry 1-7】 (where M2 = Na+, K+, H+, NH4+), R 2 is selected from the group consisting of -H, optionally substituted C 1 -C 12 alkyl, optionally substituted aryl, and optionally substituted heteroaryl; Z 1 , Z 2 , Z 3 and Z 4 are each independently selected from the group consisting of -H, halogen, -C(O)OH, -C(O)O-C ​​1 -C 6 alkyl, -NO 2 , haloalkyl, -S(O) 2 -C 1 -C 6 alkyl, and -CN, -OP(O)(OH) 2 , -P(O)(OH)OP(O)(OH) 2 , -OP(O)(OH)OP(O)(OH)OP(O)(OH) 2 , -OP(O)(OH)(NH 2 ), -P(O)(OH) 2 , -SO 3 H, and pharma- ceutically acceptable salts thereof; PBG is an optionally substituted maleimide group; where if the spacer is absent, the drug is linked to the nitrogen adjacent to the spacer by a double bond, and wherein at least one of Z 1 , Z 2 , Z 3 and Z 4 is selected from the group consisting of halogen, -C(O)OH, -C(O)O-C ​​1 -C 6 alkyl, -NO 2 , haloalkyl, -S(O) 2 -C 1 -C 6 alkyl, and -CN, -OP(O)(OH) 2 , -P(O)(OH)OP(O)(OH) 2 , -OP(O)(OH)OP(O)(OH)OP(O)(OH) 2 , -OP(O)(OH)(NH 2 ), -P(O)(OH) 2 , -SO 3 H.

2. The delivery system of claim 1, wherein R 1 is absent or selected from the group consisting of optionally substituted -C 1 -C 18 alkylene- (wherein optionally up to 6 carbon atoms of said -C 1 -C 18 alkylene- are each independently replaced with -OCH 2 CH 2 -); optionally substituted -C 1 -C 18 alkylene-NH-C(O)R 5 - (wherein optionally up to 6 carbon atoms of said -C 1 -C 18 alkylene- are each independently replaced with -OCH 2 CH 2 -); and optionally substituted -C 1 -C 18 alkylene-C(O)-NH-R 5 - (wherein optionally up to 6 carbon atoms of said -C 1 -C 18 alkylene- are each independently replaced with -OCH 2 CH 2 -).

3. The compound of claim 2, wherein the compound has formula (II): 【Chemistry 3】 or a pharma- ceutically acceptable salt, hydrate, solvate, tautomer, E (entgegen) isomer, Z (zusammen) isomer, or stereoisomer thereof. wherein the drug, PBG, Y, R 1 , Z 1 , Z 2 , Z 3 and Z 4 are as defined in claim 1 or 2.

4. The compound of claim 1, wherein the compound has formula (III): 【Chemistry 4】 or a pharma- ceutically acceptable salt, hydrate, solvate, tautomer, E (entgegen) isomer, Z (zusammen) isomer, or stereoisomer thereof. wherein the drug, the spacer, Z 2 , Z 3 , Z 4 , Y, R 1 and PBG are as defined in claim 1 or 2; and wherein Z 1 is selected from the group consisting of halogen, -C(O)OH, -C(O)O-C ​​1 -C 6 alkyl, -NO 2 , haloalkyl, -S(O) 2 -C 1 -C 6 alkyl, -CN, -OP(O)(OH) 2 , -P(O)(OH)OP(O)(OH) 2 , -OP(O)(OH)OP(O)(OH)OP(O)(OH) 2 , -OP(O)(OH)(NH 2 ), -P(O)(OH) 2 and -SO 3 H.

5. The compound of claim 1, wherein the compound has formula (IV): 【Chemistry 5】 or a pharma- ceutically acceptable salt, hydrate, solvate, tautomer, E (entgegen) isomer, Z (zusammen) isomer, or stereoisomer thereof. wherein the drug, PBG, Y, R 1 , Z 2 , Z 3 and Z 4 are as defined in claim 1 or 2; and wherein Z 1 is selected from the group consisting of halogen, -C(O)OH, -C(O)O-C ​​1 -C 6 alkyl, -NO 2 , haloalkyl, -S(O) 2 -C 1 -C 6 alkyl, -CN, -OP(O)(OH) 2 , -P(O)(OH)OP(O)(OH) 2 , -OP(O)(OH)OP(O)(OH)OP(O)(OH) 2 , -OP(O)(OH)(NH 2 ), -P(O)(OH) 2 and -SO 3 H.

6. The compound of claim 1, wherein the compound has formula (V): 【Chemistry 6】 or a pharma- ceutically acceptable salt, hydrate, solvate, tautomer, E (entgegen) isomer, Z (zusammen) isomer, or stereoisomer thereof. wherein the drug, n, X, R1, R2, Z1, Z2, Z3, Z4, Y, R1, and PBG are as defined in claim 1 or 2.

7. The compound of claim 1, wherein the compound has formula (VI): 【Chemistry 7】 or a pharma- ceutically acceptable salt, hydrate, solvate, tautomer, E (entgegen) isomer, Z (zusammen) isomer, or stereoisomer thereof. [In the formula, M is a pyrimidine or purine group containing at least one primary or secondary amino group and optionally containing one or more substituents selected from halogens; X 1 and X 2 are each independently selected from the group consisting of -H, -OH, C 1 -C 6 alkyl, halogen, and -N 3 ; X 3 and X 4 are each independently, where valence is possible, absent or selected from the group consisting of -H, -OH, C 1 -C 6 alkyl, halogen, and -N 3 ; R' is -R 3 or -CH 2 R 3 ; wherein R 3 at each occurrence is independently selected from the group consisting of -OH, -CH 3 , -OP(O)(OH) 2 , -P(O)(OH)OP(O)(OH) 2 , -OP(O)(OH)OP(O)(OH)OP(O)(OH) 2 , -OP(O)(OH)(NH 2 ), amino acids, acyl groups, and pharma- ceutically acceptable salts thereof, wherein said salts contain an alkali metal ion, alkaline metal ion, ammonium, or an alkyl substituted ammonium ion; and wherein X, n, Z1, Z2, Z3, Z4, Y, R1, R2 and PBG are as defined in claim 6.

8. The compound of claim 7, wherein the compound has formula (VI): 【Chemistry 8】 or a pharma- ceutically acceptable salt, hydrate, solvate, tautomer, E (entgegen) isomer, Z (zusammen) isomer, or stereoisomer thereof. [In the formula, M is a pyrimidine or purine group containing at least one primary or secondary amino group; X 1 and X 2 are each independently selected from the group consisting of -H, -OH, C 1 -C 6 alkyl, halogen, and -N 3 ; X 3 and X 4 are each independently, where valence is possible, absent or selected from the group consisting of -H, -OH, C 1 -C 6 alkyl, halogen, and -N 3 ; R 3 is selected from the group consisting of -H, -OH, -OP(O)(OH) 2 , -OP(O)(OH)OP(O)(OH) 2 , -OP(O)(OH)OP(O)(OH)OP(O)(OH) 2 , -OP(O)(OH)(NH 2 ), an amino acid, an acyl group, and pharma- ceutically acceptable salts thereof, wherein said salts contain an alkali metal ion, an alkaline metal ion, ammonium, or an alkyl substituted ammonium ion; and wherein X, n, Z1, Z2, Z3, Z4, Y, R1, R2 and PBG are as defined in claim 6.

9. The compound of claim 8, wherein the compound has formula (VII): 【Chemistry 9】 or a pharma- ceutically acceptable salt, hydrate, solvate, tautomer, E (entgegen) isomer, Z (zusammen) isomer, or stereoisomer thereof. [wherein R' is -R3 or -CH2R3, and X, X1, X2, X3, X4, n, Y, R1, R2, R3, Z1, Z2, Z3, Z4 and PBG are as defined in claim 7 or 8].

10. The compound of claim 1, wherein the compound has formula (VII): 【Chemistry 10】 or a pharma- ceutically acceptable salt, hydrate, solvate, tautomer, E (entgegen) isomer, Z (zusammen) isomer, or stereoisomer thereof. wherein X, X1, X2, X3, X4, n, Y, R1, R2, R3, Z1, Z2, Z3, Z4 and PBG are as defined in claim 7 or 8.

11. The compound of claim 1, wherein the compound has formula (VIII): 【Chemistry 11】 or a pharma- ceutically acceptable salt, hydrate, solvate, tautomer, E (entgegen) isomer, Z (zusammen) isomer, or stereoisomer thereof. wherein the drug, X, n, R2, PBG, Y, R1, Z2, Z3 and Z4 are as defined in claim 6; and wherein Z 1 is selected from the group consisting of halogen, -C(O)OH, -C(O)O-C ​​1 -C 6 alkyl, -NO 2 , haloalkyl, -S(O) 2 -C 1 -C 6 alkyl, -CN, -OP(O)(OH) 2 , -P(O)(OH)OP(O)(OH) 2 , -OP(O)(OH)OP(O)(OH)OP(O)(OH) 2 , -OP(O)(OH)(NH 2 ), -P(O)(OH) 2 and -SO 3 H.

12. The compound of claim 1, wherein the compound has formula (IX): 【Chemistry 12】 or a pharma- ceutically acceptable salt, hydrate, solvate, tautomer, E (entgegen) isomer, Z (zusammen) isomer, or stereoisomer thereof. [In the formula, M is a pyrimidine or purine group containing at least one primary or secondary amino group and optionally containing one or more substituents selected from halogens; X 1 and X 2 are each independently selected from the group consisting of -H, -OH, C 1 -C 6 alkyl, halogen, and -N 3 ; X 3 and X 4 are each independently, where valence is possible, absent or selected from the group consisting of -H, -OH, C 1 -C 6 alkyl, halogen, and -N 3 ; R' is -R 3 or -CH 2 R 3 ; wherein R 3 at each occurrence is independently selected from the group consisting of -OH, -CH 3 , -OP(O)(OH) 2 , -P(O)(OH)OP(O)(OH) 2 , -OP(O)(OH)OP(O)(OH)OP(O)(OH) 2 , -OP(O)(OH)(NH 2 ), amino acids, acyl groups, and pharma- ceutically acceptable salts thereof, wherein said salts contain an alkali metal ion, alkaline metal ion, ammonium, or an alkyl substituted ammonium ion; and wherein X, n, Y, Z1, Z2, Z3, Z4, R1, R2 and PBG are as defined in claim 11.

13. The compound of claim 12, wherein the compound has formula (IX): 【Chemistry 13】 or a pharma- ceutically acceptable salt, hydrate, solvate, tautomer, E (entgegen) isomer, Z (zusammen) isomer, or stereoisomer thereof. [In the formula, M is a pyrimidine or purine group containing at least one primary or secondary amino group; X 1 and X 2 are each independently selected from the group consisting of -H, -OH, C 1 -C 6 alkyl, halogen, and -N 3 ; X 3 and X 4 are each independently, where valence is possible, absent or selected from the group consisting of -H, -OH, C 1 -C 6 alkyl, halogen, and -N 3 ; R 3 is selected from the group consisting of -H, -OH, -OP(O)(OH) 2 , -OP(O)(OH)OP(O)(OH) 2 , -OP(O)(OH)OP(O)(OH)OP(O)(OH) 2 , -OP(O)(OH)(NH 2 ), an amino acid or an acyl group, and pharma- ceutically acceptable salts thereof, wherein said salts contain an alkali metal ion, an alkaline metal ion, ammonium, or an alkyl substituted ammonium ion; and wherein X, n, Y, Z1, Z2, Z3, Z4, R1, R2 and PBG are as defined in claim 11.

14. The compound of claim 1, wherein the compound has the formula (X): 【Chemistry 14】 or a pharma- ceutically acceptable salt, hydrate, solvate, tautomer, E (entgegen) isomer, Z (zusammen) isomer, or stereoisomer thereof. [wherein R' is -R3 or -CH2R3, and X1, X2, X3, X4, R3, X, n, Y, Z1, Z2, Z3, Z4, R1 and R2 are as defined in claim 12 or 13].

15. The compound of claim 1, wherein the compound has the formula (X): 【Chemistry 15】 or a pharma- ceutically acceptable salt, hydrate, solvate, tautomer, E (entgegen) isomer, Z (zusammen) isomer, or stereoisomer thereof. wherein X1, X2, X3, X4, R3, X, n, Y, Z1, Z2, Z3, Z4, R1 and R2 are as defined in claim 12 or 13.

16. The drug is an N-nitrosourea; doxorubicin, 2-pyrrolepyrrolinoanthracycline, morpholinoanthracycline, diacetoxyalkylanthracycline, daunorubicin, epirubicin, idarubicin, nemorubicin, PNU-159682, mitoxantrone; amethantrone; chlorambucil, bendamustine, melphalan, oxazaphosphorine; 5-fluorouracil, 5'-deoxy-5-fluorocytidine, dine, 2'-deoxy-5-fluroidine, cytarabine, cladribine, fludarabine, pentostatin, gemcitabine, 4-amino-1-(((2S,3R,4S,5R)-3,4-dihydroxy-5-methyltetrahydrofuran-2-yl)methyl)-5-fluoropyrimidin-2(1H)-one, thioguanine; methotrexate, raltitrexed, pemetrexed, previtrexed; paclitaxel, docetaxel; Topotecan, irinotecan, SN-38, 10-hydroxycamptothecin, GG211, lurtotecan, 9-aminocamptothecin, camptothecin, 7-formylcamptothecin, 7-acetylcamptothecin, 9-formylcamptothecin, 9-acetylcamptothecin, 9-formyl-10-hydroxycamptothecin, 10-formylcamptothecin, 10-acetylcamptothecin, 7-butyl-10-aminocamptothecin Tothecin, 7-butyl-9-amino-10,11-methylenedioxocamptothecin; Vinblastine, Vincristine, Vindesine, Vinorelbine; Calicheamicin; Maytansine, Maytansinol; Auristatin D, Auristatin E, Auristatin F, Monomethylauristatin D, Monomethylauristatin E, Monomethylauristatin F, Monomethylauristatin F methyl ester, Auristatin PYE an auristatin selected from the group consisting of auristatin PHE, and dolastatin 10; an amatoxin selected from the group consisting of α-amanitin, β-amanitin, γ-amanitin, ε-amanitin, amanine, amaninamide, amanulin, and amanuric acid; duocarmycin A, duocarmycin B1, duocarmycin B2, duocarmycin C, duocarmycin SA, CC1065, adozelesin, bizeresin, carzelesin; eribulin;16. The delivery system of any one of claims 1 to 15, selected from the group consisting of trabectedin, pyrrolobenzodiazepines, anthramycin, tomaycin, sibiromycin, DC-81, DSB-120, epothilones, bleomycin, dactinomycin, plicamycin, mitomycin C and cis-configured platinum(II) complexes.

17. The drug is N-nitrosourea; doxorubicin, 2-pyrrolepyrrolinoanthracycline, morpholinoanthracycline, diacetoxyalkylanthracycline, daunorubicin, epirubicin, idarubicin, nemorubicin, PNU-159682, mitoxantrone; amethanthrone; chlorambucil, bendamustine, melphalan, oxazaphosphorine; 5-fluorouracil, 2'-deoxy-5-fluoridine, cytarabine, cladribine, fludarabine, pentostatin, gemcitabine, 4-amino-1-(((2S,3R,4S,5R)-3,4-dihydroxy-5-methyltetrahydrofuran-2-yl)methyl)-5-fluoropyrimidin-2(1H)-one, thioguanine; methotrexate, raltitrexed, pemetrexed, protease, 16. The delivery system of any one of claims 1 to 15, wherein the drug is selected from the group consisting of levitrexed; paclitaxel, docetaxel; topotecan, irinotecan, SN-38, 10-hydroxycamptothecin, GG211, lurtotecan, 9-aminocamptothecin, camptothecin, 7-formylcamptothecin, 9-formylcamptothecin, 9-formyl-10-hydroxycamptothecin, 7-butyl-10-aminocamptothecin, 7-butyl-9-amino-10,11,-methylenedioxocamptothecin; vinblastine, vincristine, vindesine, vinorelbine; calicheamicin; maytansinoids; auristatins; epothilones; bleomycin, dactinomycin, plicamycin, mitomycin C, and cis-configured platinum(II) complexes.

18. The delivery system of any one of claims 1 to 17, wherein Z1, Z2, Z3 and Z4 are each independently selected from the group consisting of -H, halogen, -C(O)OH, -C(O)O-C1-C6 alkyl, -NO2, haloalkyl, -S(O)2-C1-C6 alkyl, and -CN, wherein at least one of Z1, Z2, Z3 and Z4 is not -H.

19. The delivery system of claim 18, wherein Z 1 , Z 2 , Z 3 and Z 4 are each independently selected from the group consisting of -H, -Cl, -Br, -I, -F, -C(O)OH, -NO 2 , -CF 3 and -CN.

20. The delivery system of claim 19, wherein Z 1 , Z 2 , Z 3 and Z 4 are each independently selected from the group consisting of -H, -Cl, -F, -NO 2 and -CF 3 .

21. A delivery system according to any one of claims 1 to 17, wherein Z1, Z2, Z3 and Z4 are each independently selected from the group consisting of -OP(O)(OH)2, -P(O)(OH)OP(O)(OH)2, -OP(O)(OH)OP(O)(OH)OP(O)(OH)2, -OP(O)(OH)(NH2), -P(O)(OH)2, -SO3H, and pharma-ceutically acceptable salts thereof.

22. The compound according to claim 21, wherein Z 1 is selected from the group consisting of halogen, -C(O)OH, -C(O)O-C ​​1 -C 6 alkyl, -NO 2 , haloalkyl, -S(O) 2 -C 1 -C 6 alkyl, and -CN; and Z 2 , Z 3 and Z 4 are each independently selected from the group consisting of -H, halogen, -C(O)OH, -C(O)O-C ​​1 -C 6 alkyl, -NO 2 , haloalkyl, -S(O) 2 -C 1 -C 6 alkyl, and -CN; 19. A delivery system according to any one of claims 1 to 18.

23. The compound according to claim 22, wherein Z 1 is selected from the group consisting of -Cl, -Br, -I, -F, -C(O)OH, -NO 2 , -CF 3 , and -CN; and Z 2 , Z 3 and Z 4 are each independently selected from the group consisting of -H, -Cl, -Br, -I, -F, -C(O)OH, -NO 2 , -CF 3 , and -CN; 23. The delivery system of claim 22.

24. The compound according to claim 24, wherein Z 1 is selected from the group consisting of -Cl, -F, and -NO 2 , and Z 2 , Z 3 and Z 4 are each independently selected from the group consisting of -H, -Cl, -F, -NO 2 and -CF 3 ; 24. The delivery system of claim 23. 【Request 25】 【Chemical 25-1】 but, 【Chemistry 25-2】 19. The delivery system of any one of claims 1 to 18, selected from the group consisting of: 【Request 26】 【Chemical 26-1】 but, 【Chemistry 26-2】 19. The delivery system of any one of claims 1 to 18, selected from the group consisting of:

27. The delivery system of any one of claims 1 to 26, wherein Y is -C(O)-NH-.

28. The delivery system of any one of claims 1 to 26, wherein Y is -C(O)-O-.

29. A delivery system according to any one of claims 1 to 26, wherein Y is absent.

30. R 1 is optionally substituted -C 1 -C 18 alkylene- (wherein optionally up to 6 carbon atoms of said -C 1 -C 18 alkylene- are each independently replaced with -OCH 2 CH 2 -); optionally substituted -C 1 -C 18 alkylene-NH-C(O)-R 5 - (wherein optionally up to 6 carbon atoms of said -C 1 -C 18 alkylene- are each independently replaced with -OCH 2 CH 2 -); and optionally substituted -C 1 -C 18 alkylene-C(O)-NH-R 5 - (wherein optionally up to 6 carbon atoms of said -C 1 -C 18 alkylene- are each independently replaced with -OCH 2 CH 2 -).

30. The delivery system of any one of claims 1 to 29, wherein said compound is selected from the group consisting of:

31. R 1 is 【Chemistry 31】 31. The delivery system of claim 30, wherein 32. The delivery system of any one of claims 1 to 29, wherein R 1 is absent.

33. The delivery system of any one of claims 1 and 3 to 29, wherein R 1 is a naturally occurring or non-naturally occurring amino acid.

34. R 1 is 【Chemistry 34-1】 and 【Chemistry 34-2】 does not exist or 【Chemistry 34-3】 is selected from the group consisting of R is 【Chemistry 34-4】 (M 1 = Mg 2+ , 2Na + , 2K + , 2H + , 2NH 4 + ), or 【Chemistry 34-5】 (M2 = Na+, K+, H+, NH4+), 30. A delivery system according to any one of claims 1 and 3 to 29.

35. A delivery system according to any one of claims 1 to 34, wherein the PBG is associated with an antibody or a fragment thereof.

36. A delivery system according to any one of claims 1 to 34, wherein the PBG is covalently linked to an antibody or fragment thereof.

37. A delivery system according to any one of claims 1 to 34, wherein the PBG is associated with albumin.

38. A delivery system according to any one of claims 1 to 34, wherein the PBG is covalently bound to endogenous or exogenous albumin.

39. A delivery system described in any one of claims 1 to 34, wherein the PGB is covalently bound to cysteine-34 of endogenous or exogenous albumin.

40. PBG, 【Chemistry 40】 35. The delivery system of any one of claims 1 to 34, wherein 41. A delivery system for providing controlled release of a therapeutic agent, wherein the delivery system comprises: Formula (I): 【Chemistry 41-1】 or a pharma- ceutically acceptable salt, hydrate, solvate, tautomer, E (entgegen) isomer, Z (zusammen) isomer, or stereoisomer thereof. [In the formula, the drug is selected from the group consisting of a cytostatic drug and a cytotoxic drug; The spacer is absent or 【Chemistry 41-2】 and 【Chemistry 41-3】 is selected from the group consisting of n is 0 or 1; X is optionally substituted -C 1 -C 18 alkylene, wherein optionally up to 6 carbon atoms of said -C 1 -C 18 alkylene are each independently replaced with -OCH 2 CH 2 -; optionally substituted -C 1 -C 18 alkylene-NH-C(O)-R 5 -, wherein optionally up to 6 carbon atoms of said -C 1 -C 18 alkylene- are each independently replaced with -OCH 2 CH 2 -; optionally substituted -C 1 -C 18 alkylene-C(O)-NH-R 5 -, wherein optionally up to 6 carbon atoms of said -C 1 -C 18 alkylene- are each independently replaced with -OCH 2 CH 2 -; -substituted; optionally substituted aryl; optionally substituted heteroaryl; and optionally substituted cycloalkyl; R 5 is selected from the group consisting of optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted cycloalkyl; and 【Chemistry 41-4】 but, 【Chemistry 41-5】 【Chemistry 41-6】 【Chemistry 41-7】 【Chemistry 41-8】 is selected from the group consisting of:

42. The spacer, 【Chemistry 42】 and n is 0 or 1; X is selected from the group consisting of optionally substituted -C 1 -C 18 alkylene-, wherein optionally up to 6 carbon atoms of said -C 1 -C 18 alkylene- are each independently replaced with -OCH 2 CH 2 -; optionally substituted aryl, optionally substituted heteroaryl, and optionally substituted cycloalkyl; and R 2 is as defined in claim 1 or 2; 42. A delivery system according to any one of claims 1, 2, 4 or 16 to 41.

43. The spacer, 【Chemistry 43】 and Where: R 2 is selected from the group consisting of -H, optionally substituted C 1 -C 12 alkyl, optionally substituted aryl, and optionally substituted heteroaryl; and W 1 , W 2 , W 3 and W 4 are each independently selected from the group consisting of -H, halogen, -C(O)OH, -C(O)O-C ​​1 -C 6 alkyl, -NO 2 , haloalkyl, -S(O) 2 -C 1 -C 6 alkyl, and -CN; 43. A delivery system according to any one of claims 1, 2, 4 or 16 to 42.

44. The delivery system of claim 43, wherein W 1 , W 2 , W 3 and W 4 are each independently selected from the group consisting of -H, -Cl, -Br, -I, -F, -C(O)OH, -NO 2 , -CF 3 , and -CN.

45. The delivery system of claim 44, wherein W 1 , W 2 , W 3 and W 4 are each independently selected from the group consisting of -H, -Cl, -F, -NO 2 and -CF 3 .

46. The spacer, 【Chemistry 46】 and Where: R 2 is selected from the group consisting of -H, optionally substituted C 1 -C 12 alkyl, optionally substituted aryl, or optionally substituted heteroaryl; and W 1 , W 2 , W 3 and W 4 are each independently selected from a phenoxy group, a primary, secondary or tertiary amine group, an ether group, a phenol group, an amide group, an ester group, an alkyl group, a substituted alkyl group, a phenyl group, and a vinyl group; 43. A delivery system according to any one of claims 1, 2, 4 or 16 to 42.

47. The spacer, 【Chemistry 47】 and Where: R 2 is selected from the group consisting of -H, optionally substituted C 1 -C 12 alkyl, optionally substituted aryl, or optionally substituted heteroaryl; and W 1 , W 2 , W 3 and W 4 are each independently selected from -OP(O)(OH) 2 , -P(O)(OH)OP(O)(OH) 2 , -OP(O)(OH)OP(O)(OH)OP(O)(OH) 2 , -OP(O)(OH)(NH 2 ), -P(O)(OH) 2 , -SO 3 H, and pharma- ceutically acceptable salts thereof; 43. A delivery system according to any one of claims 1, 2, 4 or 16 to 42.

48. The spacer, 【Chemistry 48】 and Where: R 2 is selected from the group consisting of -H, optionally substituted C 1 -C 12 alkyl, optionally substituted aryl, and optionally substituted heteroaryl; W 1 is selected from the group consisting of halogen, -C(O)OH, -C(O)O-C ​​1 -C 6 alkyl, -NO 2 , haloalkyl, -S(O) 2 -C 1 -C 6 alkyl, and -CN; and W 2 , W 3 and W 4 are each independently selected from the group consisting of -H, halogen, -C(O)OH, -C(O)O-C ​​1 -C 6 alkyl, -NO 2 , haloalkyl, -S(O) 2 -C 1 -C 6 alkyl, and -CN; 43. A delivery system according to any one of claims 1, 2, 4 or 16 to 42.

49. W 1 is selected from the group consisting of -Cl, -Br, -I, -F, -C(O)OH, -NO 2 , -CF 3 , and -CN; and 49. The delivery system of claim 48, wherein W 2 , W 3 and W 4 are each independently selected from the group consisting of -H, -Cl, -Br, -I, -F, -C(O)OH, -NO 2 , -CF 3 , and -CN.

50. The compound according to claim 50, wherein W 1 is selected from the group consisting of -Cl, -F, and -NO 2 , and 50. The delivery system of claim 49, wherein W 2 , W 3 and W 4 are each independently selected from the group consisting of -H, -Cl, -F, -NO 2 , and -CF 3 .

51. The spacer is 【Chemistry 51】 and R 2 is selected from the group consisting of -H, optionally substituted C 1 -C 12 alkyl, optionally substituted aryl, and optionally substituted heteroaryl; 43. The delivery system of claim 42.

52. The spacer, 【Chemistry 52】 52. The delivery system of claim 51 , wherein

53. The spacer, 【Chemistry 53】 and m is 1, 2, 3, 4, 5, or 6.

54. The spacer, 【Chemical 54】 54. The delivery system of claim 53, wherein 55. The delivery system of any one of claims 7 to 10 and 12 to 54, wherein X 1 , X 2 , X 3 , and X 4 are each independently selected from the group consisting of -H, -OH, -CH 3 , -F, -Cl, -Br, -I, and -N 3 .

56. A delivery system for providing controlled release of a therapeutic agent, wherein the delivery system comprises: 【Chemistry 56-1】 【Chemistry 56-2】 or a pharma- ceutically acceptable salt, hydrate, solvate, tautomer, E (entgegen) isomer, Z (zusammen) isomer, or stereoisomer thereof. [In the formula, SG= 【Chemistry 56-3】 and 【Chemistry 56-4】 does not exist or 【Chemistry 56-5】 is selected from the group consisting of R is 【Chemistry 56-6】 (wherein M 1 =Mg 2+ , 2Na + , 2K + , 2H + , 2NH 4 + , Na + , K + , NH 4 + , and / or H + ), or 【Chemistry 56-7】 (wherein M 2 =Na + , K + , H + , and / or NH 4 + ).

57. A delivery system for providing controlled release of a therapeutic agent, wherein the delivery system comprises: 【Chemistry 57-1】 【Chemistry 57-2】 【Chemistry 57-3】 【Chemistry 57-4】 【Chemistry 57-5】 【Chemistry 57-6】 【Chemistry 57-7】 【Chemistry 57-8】 【Chemistry 57-9】 or a pharma- ceutically acceptable salt, hydrate, solvate, tautomer, E (entgegen) isomer, Z (zusammen) isomer, or stereoisomer thereof.

58. A delivery system for providing controlled release of a therapeutic agent, wherein the delivery system comprises: 【Chemistry 58-1】 【Chemistry 58-2】 or a pharma- ceutically acceptable salt, hydrate, solvate, tautomer, E (entgegen) isomer, Z (zusammen) isomer, or stereoisomer thereof.

59. A delivery system for providing controlled release of a therapeutic agent, wherein the delivery system comprises: 【Chemistry 59-1】 or a pharma- ceutically acceptable salt, hydrate, solvate, tautomer, E (entgegen) isomer, Z (zusammen) isomer, or stereoisomer thereof.

Citation Information

Patent Citations

  • Method for producing an injectable medicament preparation

    US7387771B1